US5882330A
(en)
*
|
1984-05-25 |
1999-03-16 |
Lemelson; Jerome H. |
Drugs and methods for treating diseases
|
US5456663A
(en)
*
|
1984-05-25 |
1995-10-10 |
Lemelson; Jerome H. |
Drugs and methods for treating diseases
|
US5925375A
(en)
*
|
1987-05-22 |
1999-07-20 |
The Liposome Company, Inc. |
Therapeutic use of multilamellar liposomal prostaglandin formulations
|
JPH0720857B2
(en)
*
|
1988-08-11 |
1995-03-08 |
テルモ株式会社 |
Liposome and its manufacturing method
|
US6132763A
(en)
*
|
1988-10-20 |
2000-10-17 |
Polymasc Pharmaceuticals Plc |
Liposomes
|
GB8824593D0
(en)
*
|
1988-10-20 |
1988-11-23 |
Royal Free Hosp School Med |
Liposomes
|
US5153000A
(en)
*
|
1988-11-22 |
1992-10-06 |
Kao Corporation |
Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
|
US5843473A
(en)
*
|
1989-10-20 |
1998-12-01 |
Sequus Pharmaceuticals, Inc. |
Method of treatment of infected tissues
|
US5527528A
(en)
*
|
1989-10-20 |
1996-06-18 |
Sequus Pharmaceuticals, Inc. |
Solid-tumor treatment method
|
US20010051183A1
(en)
*
|
1989-10-20 |
2001-12-13 |
Alza Corporation |
Liposomes with enhanced circulation time and method of treatment
|
US5620689A
(en)
*
|
1989-10-20 |
1997-04-15 |
Sequus Pharmaceuuticals, Inc. |
Liposomes for treatment of B-cell and T-cell disorders
|
US5356633A
(en)
*
|
1989-10-20 |
1994-10-18 |
Liposome Technology, Inc. |
Method of treatment of inflamed tissues
|
US5013556A
(en)
*
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5656211A
(en)
*
|
1989-12-22 |
1997-08-12 |
Imarx Pharmaceutical Corp. |
Apparatus and method for making gas-filled vesicles of optimal size
|
US5441746A
(en)
*
|
1989-12-22 |
1995-08-15 |
Molecular Bioquest, Inc. |
Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production
|
US5352435A
(en)
*
|
1989-12-22 |
1994-10-04 |
Unger Evan C |
Ionophore containing liposomes for ultrasound imaging
|
US5580575A
(en)
*
|
1989-12-22 |
1996-12-03 |
Imarx Pharmaceutical Corp. |
Therapeutic drug delivery systems
|
US5776429A
(en)
*
|
1989-12-22 |
1998-07-07 |
Imarx Pharmaceutical Corp. |
Method of preparing gas-filled microspheres using a lyophilized lipids
|
US6001335A
(en)
*
|
1989-12-22 |
1999-12-14 |
Imarx Pharmaceutical Corp. |
Contrasting agents for ultrasonic imaging and methods for preparing the same
|
US5705187A
(en)
*
|
1989-12-22 |
1998-01-06 |
Imarx Pharmaceutical Corp. |
Compositions of lipids and stabilizing materials
|
US5922304A
(en)
*
|
1989-12-22 |
1999-07-13 |
Imarx Pharmaceutical Corp. |
Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
|
US6146657A
(en)
|
1989-12-22 |
2000-11-14 |
Imarx Pharmaceutical Corp. |
Gas-filled lipid spheres for use in diagnostic and therapeutic applications
|
US6088613A
(en)
|
1989-12-22 |
2000-07-11 |
Imarx Pharmaceutical Corp. |
Method of magnetic resonance focused surgical and therapeutic ultrasound
|
US6551576B1
(en)
|
1989-12-22 |
2003-04-22 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Container with multi-phase composition for use in diagnostic and therapeutic applications
|
US5305757A
(en)
*
|
1989-12-22 |
1994-04-26 |
Unger Evan C |
Gas filled liposomes and their use as ultrasonic contrast agents
|
US5542935A
(en)
*
|
1989-12-22 |
1996-08-06 |
Imarx Pharmaceutical Corp. |
Therapeutic delivery systems related applications
|
US5585112A
(en)
*
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
US5733572A
(en)
*
|
1989-12-22 |
1998-03-31 |
Imarx Pharmaceutical Corp. |
Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
|
US5469854A
(en)
*
|
1989-12-22 |
1995-11-28 |
Imarx Pharmaceutical Corp. |
Methods of preparing gas-filled liposomes
|
US5773024A
(en)
*
|
1989-12-22 |
1998-06-30 |
Imarx Pharmaceutical Corp. |
Container with multi-phase composition for use in diagnostic and therapeutic applications
|
US5882678A
(en)
*
|
1990-01-12 |
1999-03-16 |
The Liposome Co, Inc. |
Interdigitation-fusion liposomes containing arachidonic acid metabolites
|
US5162361A
(en)
*
|
1990-04-10 |
1992-11-10 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Method of treating diseases associated with elevated levels of interleukin 1
|
US6465188B1
(en)
*
|
1990-06-11 |
2002-10-15 |
Gilead Sciences, Inc. |
Nucleic acid ligand complexes
|
US20060084797A1
(en)
*
|
1990-06-11 |
2006-04-20 |
Gilead Sciences, Inc. |
High affinity TGFbeta nucleic acid ligands and inhibitors
|
US20030113369A1
(en)
*
|
1991-01-16 |
2003-06-19 |
Martin Francis J. |
Liposomes with enhanced circulation time and method of treatment
|
US5874062A
(en)
*
|
1991-04-05 |
1999-02-23 |
Imarx Pharmaceutical Corp. |
Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
|
US5205290A
(en)
|
1991-04-05 |
1993-04-27 |
Unger Evan C |
Low density microspheres and their use as contrast agents for computed tomography
|
JP3220180B2
(en)
*
|
1991-05-23 |
2001-10-22 |
三菱化学株式会社 |
Drug-containing protein-bound liposomes
|
GB9111611D0
(en)
*
|
1991-05-30 |
1991-07-24 |
Sandoz Ltd |
Liposomes
|
EP1236473A3
(en)
|
1992-04-03 |
2003-01-15 |
The Regents Of The University Of California |
Self-assembling polynucleotide delivery system
|
ZA933926B
(en)
*
|
1992-06-17 |
1994-01-03 |
Amgen Inc |
Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
|
EP0656368B2
(en)
*
|
1992-08-05 |
2003-06-04 |
Meito Sangyo Kabushiki Kaisha |
Small-diameter composite composed of water-soluble carboxypolysaccharide and magnetic iron oxide
|
NL9201722A
(en)
*
|
1992-10-05 |
1994-05-02 |
Stichting Tech Wetenschapp |
Pharmaceutical composition for the site-bound release of a clot dissolving protein and method for its preparation.
|
DE4236237A1
(en)
*
|
1992-10-27 |
1994-04-28 |
Behringwerke Ag |
Prodrugs, their preparation and use as medicines
|
US6764693B1
(en)
*
|
1992-12-11 |
2004-07-20 |
Amaox, Ltd. |
Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
|
JP3351476B2
(en)
*
|
1993-01-22 |
2002-11-25 |
三菱化学株式会社 |
Phospholipid derivatives and liposomes containing the same
|
US5395619A
(en)
*
|
1993-03-03 |
1995-03-07 |
Liposome Technology, Inc. |
Lipid-polymer conjugates and liposomes
|
AU6368394A
(en)
*
|
1993-03-23 |
1994-10-11 |
Liposome Technology, Inc. |
Polymer-polypeptide composition and method
|
US6326353B1
(en)
*
|
1993-03-23 |
2001-12-04 |
Sequus Pharmaceuticals, Inc. |
Enhanced circulation effector composition and method
|
US6180134B1
(en)
*
|
1993-03-23 |
2001-01-30 |
Sequus Pharmaceuticals, Inc. |
Enhanced ciruclation effector composition and method
|
WO1994026251A1
(en)
*
|
1993-05-07 |
1994-11-24 |
Sequus Pharmaceuticals, Inc. |
Subcutaneous liposome delivery method
|
US20050181976A1
(en)
*
|
1993-05-10 |
2005-08-18 |
Ekwuribe Nnochiri N. |
Amphiphilic oligomers
|
US5681811A
(en)
*
|
1993-05-10 |
1997-10-28 |
Protein Delivery, Inc. |
Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
|
US6191105B1
(en)
|
1993-05-10 |
2001-02-20 |
Protein Delivery, Inc. |
Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
|
US5359030A
(en)
*
|
1993-05-10 |
1994-10-25 |
Protein Delivery, Inc. |
Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
|
DE1118326T1
(en)
*
|
1993-05-21 |
2002-04-18 |
Liposome Co Inc |
Reduction of physiological counter-reactions induced by liposomes
|
US5744155A
(en)
*
|
1993-08-13 |
1998-04-28 |
Friedman; Doron |
Bioadhesive emulsion preparations for enhanced drug delivery
|
US5514670A
(en)
*
|
1993-08-13 |
1996-05-07 |
Pharmos Corporation |
Submicron emulsions for delivery of peptides
|
DE69424680T2
(en)
*
|
1993-10-25 |
2000-09-28 |
Liposome Co Inc |
LIPOSOMAL DEFENSINE
|
US5415869A
(en)
*
|
1993-11-12 |
1995-05-16 |
The Research Foundation Of State University Of New York |
Taxol formulation
|
US5468499A
(en)
*
|
1993-11-15 |
1995-11-21 |
Ohio State University |
Liposomes containing the salt of phosphoramide mustard and related compounds
|
US7083572B2
(en)
*
|
1993-11-30 |
2006-08-01 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Therapeutic delivery systems
|
WO1995016464A1
(en)
*
|
1993-12-14 |
1995-06-22 |
Johns Hopkins University School Of Medicine |
Controlled release of pharmaceutically active substances for immunotherapy
|
US6773719B2
(en)
|
1994-03-04 |
2004-08-10 |
Esperion Luv Development, Inc. |
Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
|
US6312719B1
(en)
*
|
1994-03-04 |
2001-11-06 |
The University Of British Columbia |
Liposome compositions and methods for the treatment of atherosclerosis
|
US20010055581A1
(en)
*
|
1994-03-18 |
2001-12-27 |
Lawrence Tamarkin |
Composition and method for delivery of biologically-active factors
|
US5736121A
(en)
*
|
1994-05-23 |
1998-04-07 |
Imarx Pharmaceutical Corp. |
Stabilized homogenous suspensions as computed tomography contrast agents
|
DE4423131A1
(en)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4
|
US5626862A
(en)
|
1994-08-02 |
1997-05-06 |
Massachusetts Institute Of Technology |
Controlled local delivery of chemotherapeutic agents for treating solid tumors
|
US5512294A
(en)
*
|
1994-08-05 |
1996-04-30 |
Li; King C. |
Targeted polymerized liposome contrast agents
|
US6132764A
(en)
*
|
1994-08-05 |
2000-10-17 |
Targesome, Inc. |
Targeted polymerized liposome diagnostic and treatment agents
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
US6001968A
(en)
*
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
US6124439A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockefeller University |
OB polypeptide antibodies and method of making
|
US6309853B1
(en)
|
1994-08-17 |
2001-10-30 |
The Rockfeller University |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
|
US6048837A
(en)
*
|
1994-08-17 |
2000-04-11 |
The Rockefeller University |
OB polypeptides as modulators of body weight
|
US6124448A
(en)
*
|
1994-08-17 |
2000-09-26 |
The Rockfeller University |
Nucleic acid primers and probes for the mammalian OB gene
|
DE69527206T2
(en)
*
|
1994-09-30 |
2003-02-27 |
Inex Pharmaceuticals Corp |
AGENT FOR INSERTING POLYANIONIC MATERIALS IN CELLS
|
DK0785773T3
(en)
*
|
1994-10-14 |
2001-01-29 |
Liposome Co Inc |
Etherlipid liposomes and their therapeutic use
|
CN1080575C
(en)
*
|
1994-10-14 |
2002-03-13 |
蛋白质传送股份有限公司 |
Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
|
US6214388B1
(en)
*
|
1994-11-09 |
2001-04-10 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
US6743779B1
(en)
|
1994-11-29 |
2004-06-01 |
Imarx Pharmaceutical Corp. |
Methods for delivering compounds into a cell
|
US5827531A
(en)
*
|
1994-12-02 |
1998-10-27 |
The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration |
Microcapsules and methods for making
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5830430A
(en)
*
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
IL112834A
(en)
*
|
1995-03-01 |
2000-12-06 |
Yeda Res & Dev |
Pharmaceutical compositions for controlled release of soluble receptors
|
US5658588A
(en)
*
|
1995-03-31 |
1997-08-19 |
University Of Cincinnati |
Fibrinogen-coated liposomes
|
GB9509016D0
(en)
*
|
1995-05-03 |
1995-06-21 |
Royal Free Hosp School Med |
Tissue entrapment
|
US8071737B2
(en)
*
|
1995-05-04 |
2011-12-06 |
Glead Sciences, Inc. |
Nucleic acid ligand complexes
|
US5997898A
(en)
*
|
1995-06-06 |
1999-12-07 |
Imarx Pharmaceutical Corp. |
Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US5981501A
(en)
*
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
US6521211B1
(en)
|
1995-06-07 |
2003-02-18 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Methods of imaging and treatment with targeted compositions
|
US6139819A
(en)
|
1995-06-07 |
2000-10-31 |
Imarx Pharmaceutical Corp. |
Targeted contrast agents for diagnostic and therapeutic use
|
EP1489184A1
(en)
*
|
1995-06-07 |
2004-12-22 |
Inex Pharmaceutical Corp. |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US6231834B1
(en)
|
1995-06-07 |
2001-05-15 |
Imarx Pharmaceutical Corp. |
Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
|
US6033645A
(en)
*
|
1996-06-19 |
2000-03-07 |
Unger; Evan C. |
Methods for diagnostic imaging by regulating the administration rate of a contrast agent
|
US6096720A
(en)
*
|
1995-08-01 |
2000-08-01 |
Novartis Ag |
Liposomal oligonucleotide compositions
|
US6107332A
(en)
|
1995-09-12 |
2000-08-22 |
The Liposome Company, Inc. |
Hydrolysis-promoting hydrophobic taxane derivatives
|
US6051600A
(en)
*
|
1995-09-12 |
2000-04-18 |
Mayhew; Eric |
Liposomal hydrolysis-promoting hydrophobic taxane derivatives
|
US5834025A
(en)
|
1995-09-29 |
1998-11-10 |
Nanosystems L.L.C. |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
US5858397A
(en)
*
|
1995-10-11 |
1999-01-12 |
University Of British Columbia |
Liposomal formulations of mitoxantrone
|
WO1997013501A1
(en)
*
|
1995-10-11 |
1997-04-17 |
Kevin Jon Williams |
Liposomal compositions and methods of using them
|
US6936439B2
(en)
*
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
US20030040467A1
(en)
*
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
US5626654A
(en)
|
1995-12-05 |
1997-05-06 |
Xerox Corporation |
Ink compositions containing liposomes
|
US5817856A
(en)
*
|
1995-12-11 |
1998-10-06 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Radiation-protective phospholipid and method
|
US6392069B2
(en)
|
1996-01-08 |
2002-05-21 |
Canji, Inc. |
Compositions for enhancing delivery of nucleic acids to cells
|
US20040014709A1
(en)
*
|
1996-01-08 |
2004-01-22 |
Canji, Inc. |
Methods and compositions for interferon therapy
|
US5789244A
(en)
*
|
1996-01-08 |
1998-08-04 |
Canji, Inc. |
Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
|
US7002027B1
(en)
|
1996-01-08 |
2006-02-21 |
Canji, Inc. |
Compositions and methods for therapeutic use
|
EP0885299B1
(en)
|
1996-01-08 |
2005-10-26 |
Genentech, Inc. |
Ob receptor and ligands
|
US6096336A
(en)
*
|
1996-01-30 |
2000-08-01 |
The Stehlin Foundation For Cancer Research |
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
US5908624A
(en)
*
|
1996-06-27 |
1999-06-01 |
Albany Medical College |
Antigenic modulation of cells
|
US6667053B1
(en)
|
1996-02-16 |
2003-12-23 |
Elan Pharmaceuticals, Inc. |
D and L etherlipid stereoisomers and liposomes
|
US6007839A
(en)
*
|
1996-02-16 |
1999-12-28 |
The Liposome Company, Inc. |
Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
|
US5965159A
(en)
|
1996-02-16 |
1999-10-12 |
The Liposome Company, Inc. |
Etherlipid-containing multiple lipid liposomes
|
US5942246A
(en)
*
|
1996-02-16 |
1999-08-24 |
The Liposome Company, Inc. |
Etherlipid containing multiple lipid liposomes
|
USRE39042E1
(en)
*
|
1996-02-16 |
2006-03-28 |
The Liposome Company, Inc. |
Etherlipid-containing multiple lipid liposomes
|
CA2250219C
(en)
|
1996-03-28 |
2008-10-07 |
Hayat Onyuksel |
Materials and methods for making improved liposome compositions
|
AU736301B2
(en)
|
1996-05-01 |
2001-07-26 |
Imarx Therapeutics, Inc. |
Methods for delivering compounds into a cell
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20070275921A1
(en)
*
|
1996-06-06 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric Compounds That Facilitate Risc Loading
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20050042647A1
(en)
*
|
1996-06-06 |
2005-02-24 |
Baker Brenda F. |
Phosphorous-linked oligomeric compounds and their use in gene modulation
|
US5919480A
(en)
|
1996-06-24 |
1999-07-06 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Liposomal influenza vaccine composition and method
|
US8007784B1
(en)
|
1996-06-27 |
2011-08-30 |
Albany Medical College |
Antigenic modulation of cells
|
US7368129B1
(en)
|
1996-08-14 |
2008-05-06 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
US6284267B1
(en)
|
1996-08-14 |
2001-09-04 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
DE69725747T2
(en)
*
|
1996-08-23 |
2004-07-29 |
Sequus Pharmaceuticals, Inc., Menlo Park |
LIPOSOME CONTAINING CISPLATIN
|
CA2264140A1
(en)
|
1996-08-26 |
1998-03-05 |
Transgene S.A. |
Cationic lipid-nucleic acid complexes
|
US6414139B1
(en)
|
1996-09-03 |
2002-07-02 |
Imarx Therapeutics, Inc. |
Silicon amphiphilic compounds and the use thereof
|
US5846517A
(en)
*
|
1996-09-11 |
1998-12-08 |
Imarx Pharmaceutical Corp. |
Methods for diagnostic imaging using a renal contrast agent and a vasodilator
|
ATE366588T1
(en)
*
|
1996-09-11 |
2007-08-15 |
Imarx Pharmaceutical Corp |
METHOD FOR DIAGNOSTIC IMAGING OF THE KIDNEY REGION USING A CONTRAST AGENT AND A VASODILATOR
|
US6224903B1
(en)
|
1996-10-11 |
2001-05-01 |
Sequus Pharmaceuticals, Inc. |
Polymer-lipid conjugate for fusion of target membranes
|
TW520297B
(en)
*
|
1996-10-11 |
2003-02-11 |
Sequus Pharm Inc |
Fusogenic liposome composition and method
|
JP2001503396A
(en)
|
1996-10-11 |
2001-03-13 |
アルザ コーポレイション |
Therapeutic liposome compositions and methods
|
US6056973A
(en)
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
US6339069B1
(en)
|
1996-10-15 |
2002-01-15 |
Elan Pharmaceuticalstechnologies, Inc. |
Peptide-lipid conjugates, liposomes and lipsomal drug delivery
|
IL130823A
(en)
*
|
1996-10-15 |
2005-12-18 |
Elan Pharm Inc |
Peptide-lipid conjugates, liposomes drug delivery
|
US6264917B1
(en)
*
|
1996-10-28 |
2001-07-24 |
Nycomed Imaging As |
Targeted ultrasound contrast agents
|
US20070036722A1
(en)
*
|
1996-10-28 |
2007-02-15 |
Pal Rongved |
Separation processes
|
US6261537B1
(en)
|
1996-10-28 |
2001-07-17 |
Nycomed Imaging As |
Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
|
US6331289B1
(en)
|
1996-10-28 |
2001-12-18 |
Nycomed Imaging As |
Targeted diagnostic/therapeutic agents having more than one different vectors
|
US5827533A
(en)
*
|
1997-02-06 |
1998-10-27 |
Duke University |
Liposomes containing active agents aggregated with lipid surfactants
|
US6207186B1
(en)
*
|
1997-02-14 |
2001-03-27 |
The Regents Of The University Of California |
Lamellar gels and methods for making and using
|
US6143276A
(en)
*
|
1997-03-21 |
2000-11-07 |
Imarx Pharmaceutical Corp. |
Methods for delivering bioactive agents to regions of elevated temperatures
|
US6537246B1
(en)
|
1997-06-18 |
2003-03-25 |
Imarx Therapeutics, Inc. |
Oxygen delivery agents and uses for the same
|
US6120751A
(en)
*
|
1997-03-21 |
2000-09-19 |
Imarx Pharmaceutical Corp. |
Charged lipids and uses for the same
|
US6090800A
(en)
|
1997-05-06 |
2000-07-18 |
Imarx Pharmaceutical Corp. |
Lipid soluble steroid prodrugs
|
AU741145B2
(en)
|
1997-04-03 |
2001-11-22 |
Eisai Inc. |
Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making and using the same
|
ES2361267T3
(en)
|
1997-04-07 |
2011-06-15 |
Genentech Inc. |
PROCEDURE FOR THE PRODUCTION OF HUMANIZED ANTIBODIES THROUGH RANDOM MUTAGENESIS.
|
JP3957765B2
(en)
|
1997-04-07 |
2007-08-15 |
ジェネンテク・インコーポレイテッド |
Anti-VEGF antibody
|
WO1998044910A1
(en)
|
1997-04-09 |
1998-10-15 |
Philipp Lang |
NEW TECHNIQUE TO MONITOR DRUG DELIVERY NONINVASIVELY $i(IN VIVO)
|
US20020039594A1
(en)
*
|
1997-05-13 |
2002-04-04 |
Evan C. Unger |
Solid porous matrices and methods of making and using the same
|
US6416740B1
(en)
|
1997-05-13 |
2002-07-09 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Acoustically active drug delivery systems
|
JP4656675B2
(en)
*
|
1997-05-14 |
2011-03-23 |
ユニバーシティー オブ ブリティッシュ コロンビア |
High rate encapsulation of charged therapeutic agents in lipid vesicles
|
DE19724796A1
(en)
*
|
1997-06-06 |
1998-12-10 |
Max Delbrueck Centrum |
Antitumor therapy agents
|
US6663899B2
(en)
*
|
1997-06-13 |
2003-12-16 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6113947A
(en)
*
|
1997-06-13 |
2000-09-05 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6217886B1
(en)
|
1997-07-14 |
2001-04-17 |
The Board Of Trustees Of The University Of Illinois |
Materials and methods for making improved micelle compositions
|
US6548047B1
(en)
|
1997-09-15 |
2003-04-15 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Thermal preactivation of gaseous precursor filled compositions
|
EP1014946B1
(en)
|
1997-09-18 |
2010-04-07 |
Pacira Pharmaceuticals, Inc. |
Sustained-release liposomal anesthetic compositions
|
US6083923A
(en)
*
|
1997-10-31 |
2000-07-04 |
Isis Pharmaceuticals Inc. |
Liposomal oligonucleotide compositions for modulating RAS gene expression
|
US7229841B2
(en)
*
|
2001-04-30 |
2007-06-12 |
Cytimmune Sciences, Inc. |
Colloidal metal compositions and methods
|
ES2384094T3
(en)
|
1997-11-14 |
2012-06-29 |
Pacira Pharmaceuticals, Inc. |
Production of multivesicular liposomes
|
DE69837897T2
(en)
|
1997-11-21 |
2008-03-06 |
Genentech Inc., San Francisco |
A33 related antigens and their pharmaceutical uses
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
JP2001524512A
(en)
*
|
1997-12-04 |
2001-12-04 |
イーサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム |
Combined chemoimmunotherapy with liposomal drugs and cytokines
|
US6787132B1
(en)
*
|
1997-12-04 |
2004-09-07 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Combined chemo-immunotherapy with liposomal drugs and cytokines
|
EP1947119A3
(en)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
|
US6123923A
(en)
|
1997-12-18 |
2000-09-26 |
Imarx Pharmaceutical Corp. |
Optoacoustic contrast agents and methods for their use
|
US20010003580A1
(en)
|
1998-01-14 |
2001-06-14 |
Poh K. Hui |
Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
|
EP1053009B1
(en)
|
1998-02-04 |
2004-09-22 |
Genentech, Inc. |
Use of heregulin as an epithelial cell growth factor
|
CA2319433C
(en)
*
|
1998-02-09 |
2008-04-22 |
Bracco Research S.A. |
Targeted delivery of biologically active media
|
US6312685B1
(en)
|
1998-03-13 |
2001-11-06 |
Timothy C. Fisher |
Red blood cells covalently bound with two different polyethylene glycol derivatives
|
US6942859B2
(en)
|
1998-03-13 |
2005-09-13 |
University Of Southern California |
Red blood cells covalently bound with polymers
|
ES2389387T3
(en)
|
1998-03-17 |
2012-10-25 |
Genentech, Inc. |
Homologous VEGF and BMP1 polypeptides
|
US6433012B1
(en)
*
|
1998-03-25 |
2002-08-13 |
Large Scale Biology Corp. |
Method for inhibiting inflammatory disease
|
KR20010042168A
(en)
*
|
1998-03-25 |
2001-05-25 |
바이오소스 테크놀로지스 인코포레이티드 |
Benzoates derivatives for inhibiting angiogenesis
|
US6858706B2
(en)
|
1998-04-07 |
2005-02-22 |
St. Jude Children's Research Hospital |
Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
|
CA2329768C
(en)
*
|
1998-04-27 |
2008-06-10 |
Opperbas Holding B.V. |
Pharmaceutical composition comprising factor viii and neutral liposomes
|
US6986902B1
(en)
*
|
1998-04-28 |
2006-01-17 |
Inex Pharmaceuticals Corporation |
Polyanionic polymers which enhance fusogenicity
|
US6448224B1
(en)
|
1998-05-06 |
2002-09-10 |
St. Jude Children's Research Hospital |
Antibiotics and methods of using the same
|
US6331407B1
(en)
|
1998-05-06 |
2001-12-18 |
St. Jude Children's Research Hospital |
Antibiotics and methods of using the same
|
US6169078B1
(en)
*
|
1998-05-12 |
2001-01-02 |
University Of Florida |
Materials and methods for the intracellular delivery of substances
|
EP1865061A3
(en)
|
1998-05-15 |
2007-12-19 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
EP3112468A1
(en)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17 homologous polypeptides and therapeutic uses thereof
|
DE69936382T3
(en)
|
1998-05-15 |
2011-07-07 |
Genentech, Inc., Calif. |
THERAPEUTIC USES OF IL-17 HOMOLOGOUS POLYPEPTIDE
|
AU4561199A
(en)
|
1998-06-12 |
1999-12-30 |
Genentech Inc. |
Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
|
US6200598B1
(en)
*
|
1998-06-18 |
2001-03-13 |
Duke University |
Temperature-sensitive liposomal formulation
|
US6726925B1
(en)
*
|
1998-06-18 |
2004-04-27 |
Duke University |
Temperature-sensitive liposomal formulation
|
US20040229363A1
(en)
*
|
1998-06-24 |
2004-11-18 |
Ed Nolan |
High efficiency transfection based on low electric field strength, long pulse length
|
US6693086B1
(en)
*
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
US20040247662A1
(en)
*
|
1998-06-25 |
2004-12-09 |
Dow Steven W. |
Systemic immune activation method using nucleic acid-lipid complexes
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
IL140899A0
(en)
|
1998-07-17 |
2002-02-10 |
Skyepharma Inc |
Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
US6703381B1
(en)
*
|
1998-08-14 |
2004-03-09 |
Nobex Corporation |
Methods for delivery therapeutic compounds across the blood-brain barrier
|
CA2346879A1
(en)
*
|
1998-09-16 |
2000-04-27 |
Alza Corporation |
Liposome-entrapped topoisomerase inhibitors
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6419709B1
(en)
|
1998-10-02 |
2002-07-16 |
Guilford Pharmaceuticals, Inc. |
Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
|
US6153212A
(en)
*
|
1998-10-02 |
2000-11-28 |
Guilford Pharmaceuticals Inc. |
Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
|
DE69934425T2
(en)
*
|
1998-10-23 |
2007-09-27 |
Amgen Inc., Thousand Oaks |
THROMBOPOIETIN SUBSTITUTE
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
EP1950300A3
(en)
|
1998-11-18 |
2011-03-23 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
AU1740900A
(en)
*
|
1998-11-20 |
2000-06-13 |
Genentech Inc. |
Method of inhibiting angiogenesis
|
US6773911B1
(en)
|
1998-11-23 |
2004-08-10 |
Amgen Canada Inc. |
Apoptosis-inducing factor
|
EP2075335A3
(en)
|
1998-12-22 |
2009-09-30 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
EP2016953A3
(en)
|
1998-12-22 |
2009-04-15 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists and uses thereof
|
US6350464B1
(en)
|
1999-01-11 |
2002-02-26 |
Guilford Pharmaceuticals, Inc. |
Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
|
US6818227B1
(en)
*
|
1999-02-08 |
2004-11-16 |
Alza Corporation |
Liposome composition and method for administration of a radiosensitizer
|
US6537585B1
(en)
|
1999-03-26 |
2003-03-25 |
Guilford Pharmaceuticals, Inc. |
Methods and compositions for treating solid tumors
|
US6379698B1
(en)
|
1999-04-06 |
2002-04-30 |
Isis Pharmaceuticals, Inc. |
Fusogenic lipids and vesicles
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US7112337B2
(en)
|
1999-04-23 |
2006-09-26 |
Alza Corporation |
Liposome composition for delivery of nucleic acid
|
WO2000066126A2
(en)
*
|
1999-04-29 |
2000-11-09 |
Alza Corporation |
Liposome compositions for improved drug retention
|
CA2270600A1
(en)
|
1999-05-03 |
2000-11-03 |
Infectio Recherche Inc. |
Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
|
EP1645290A1
(en)
|
1999-05-07 |
2006-04-12 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
WO2000067760A1
(en)
*
|
1999-05-11 |
2000-11-16 |
Sankyo Company, Limited |
Liposome preparation of fat-soluble antitumor drug
|
US20040229779A1
(en)
*
|
1999-05-14 |
2004-11-18 |
Ramesh Kekuda |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20040023874A1
(en)
*
|
2002-03-15 |
2004-02-05 |
Burgess Catherine E. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US6974684B2
(en)
*
|
2001-08-08 |
2005-12-13 |
Curagen Corporation |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20040067490A1
(en)
*
|
2001-09-07 |
2004-04-08 |
Mei Zhong |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
DE60043322D1
(en)
|
1999-06-15 |
2009-12-24 |
Genentech Inc |
Secreted and transmembrane polypeptides and nucleic acids for their coding
|
US6309633B1
(en)
|
1999-06-19 |
2001-10-30 |
Nobex Corporation |
Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
|
US7169889B1
(en)
|
1999-06-19 |
2007-01-30 |
Biocon Limited |
Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
|
AU780194B2
(en)
*
|
1999-06-24 |
2005-03-10 |
Kyowa Hakko Kirin Co., Ltd. |
Method of regulating leakage of drug encapsulated in liposomes
|
CN100340575C
(en)
|
1999-06-25 |
2007-10-03 |
杰南技术公司 |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US6352996B1
(en)
|
1999-08-03 |
2002-03-05 |
The Stehlin Foundation For Cancer Research |
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
GB9918670D0
(en)
|
1999-08-06 |
1999-10-13 |
Celltech Therapeutics Ltd |
Biological product
|
DE60042693D1
(en)
|
1999-08-27 |
2009-09-17 |
Genentech Inc |
DOSAGE FOR TREATMENT WITH ANTI ERBB2 ANTIBODIES
|
NZ523206A
(en)
*
|
1999-08-31 |
2004-12-24 |
Genentech Inc |
Antibodies that bind to tumor gene sequences
|
KR20010085996A
(en)
*
|
1999-09-03 |
2001-09-07 |
스티븐 엠. 오드레 |
Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
|
AU7868400A
(en)
*
|
1999-10-08 |
2001-04-23 |
Alza Corporation |
Neutral-cationic lipid for nucleic acid and drug delivery
|
IT1315253B1
(en)
*
|
1999-10-22 |
2003-02-03 |
Novuspharma Spa |
LIPOSOMIAL PREPARATION OF 6,9-BIS- (2-AMINOXYL) AMINO | BENZOG | ISOCHINOLIN-5,10-DIONE DIMALEATO
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US6511676B1
(en)
|
1999-11-05 |
2003-01-28 |
Teni Boulikas |
Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
|
ES2629683T3
(en)
|
1999-11-30 |
2017-08-14 |
Mayo Foundation For Medical Education And Research |
B7-H1, a new immunoregulatory molecule
|
CA2491610A1
(en)
|
1999-12-01 |
2001-06-07 |
Kevin P. Baker |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6593308B2
(en)
*
|
1999-12-03 |
2003-07-15 |
The Regents Of The University Of California |
Targeted drug delivery with a hyaluronan ligand
|
US20030147944A1
(en)
*
|
1999-12-10 |
2003-08-07 |
Mayer Lawrence D |
Lipid carrier compositions with protected surface reactive functions
|
DK1897944T3
(en)
|
1999-12-23 |
2011-10-24 |
Genentech Inc |
IL-17 homologous polypeptides and their therapeutic use
|
US20040009229A1
(en)
*
|
2000-01-05 |
2004-01-15 |
Unger Evan Charles |
Stabilized nanoparticle formulations of camptotheca derivatives
|
JP2003520210A
(en)
*
|
2000-01-05 |
2003-07-02 |
イマレックス セラピューティクス, インコーポレイテッド |
Pharmaceutical formulations for delivery of drugs with low water solubility
|
DE60137829D1
(en)
|
2000-01-13 |
2009-04-16 |
Genentech Inc |
HUMAN STRA6 POLYPEPTIDE
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
AU3467001A
(en)
*
|
2000-01-28 |
2001-08-07 |
Alza Corp |
Liposomes containing an entrapped compound in supersaturated solution
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
JP4922824B2
(en)
*
|
2000-04-03 |
2012-04-25 |
参天製薬株式会社 |
Delivery substance and drug delivery system using the same
|
ES2637801T3
(en)
|
2000-04-11 |
2017-10-17 |
Genentech, Inc. |
Multivalent antibodies and uses thereof
|
WO2001076644A2
(en)
*
|
2000-04-12 |
2001-10-18 |
Liplasome Pharma A/S |
Lipid-based systems for targeting diagnostic agents
|
WO2001081376A2
(en)
|
2000-04-21 |
2001-11-01 |
Amgen Inc. |
Apo-ai/aii peptide derivatives
|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
US7030219B2
(en)
*
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
AU2001258106A1
(en)
*
|
2000-05-11 |
2001-11-20 |
Celator Technologies Inc. |
Lipid carrier compositions for improved drug retention
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
AU6531101A
(en)
|
2000-06-02 |
2001-12-17 |
Genentech Inc |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
CA2410906C
(en)
|
2000-06-02 |
2012-10-02 |
Board Of Regents, The University Of Texas System |
Ethylenedicysteine (ec)-drug conjugates
|
US20030072794A1
(en)
*
|
2000-06-09 |
2003-04-17 |
Teni Boulikas |
Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
|
WO2001097858A2
(en)
|
2000-06-20 |
2001-12-27 |
Idec Pharmaceuticals Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
EP2275549A1
(en)
|
2000-06-23 |
2011-01-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
CA2648046A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
US20040023259A1
(en)
*
|
2000-07-26 |
2004-02-05 |
Luca Rastelli |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
ATE412009T1
(en)
|
2000-08-24 |
2008-11-15 |
Genentech Inc |
METHOD FOR INHIBITING IL-22 INDUCED PAP1
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20030133972A1
(en)
*
|
2000-10-11 |
2003-07-17 |
Targesome, Inc. |
Targeted multivalent macromolecules
|
US7045283B2
(en)
|
2000-10-18 |
2006-05-16 |
The Regents Of The University Of California |
Methods of high-throughput screening for internalizing antibodies
|
JP4198990B2
(en)
|
2000-10-18 |
2008-12-17 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
E-selectin / L-selectin ligand polypeptide of hematopoietic cells and use thereof
|
AU2002225878A1
(en)
*
|
2000-11-02 |
2002-05-15 |
Smith Kline Beecham Corporation |
Receptor antagonist-lipid conjugates and delivery vehicles containing same
|
DE10056136A1
(en)
*
|
2000-11-07 |
2002-05-16 |
Nemod New Modalities |
Inhibiting leukocyte or tumor cell adhesion to vascular endothelial cells e.g. for combating inflammation or metastasis, using e.g. pregnancy proteins or selectin binding liposomes containing calcium-binding compound
|
US20020132982A1
(en)
*
|
2000-11-30 |
2002-09-19 |
Balasubramanian Sathyamangalam V. |
AHF associated dispersion system and method for preparation
|
US7625584B2
(en)
*
|
2000-11-30 |
2009-12-01 |
The Research Foundation Of State University Of New York |
Method of complexing a protein by the use of a dispersed system and proteins thereof
|
WO2002061036A2
(en)
*
|
2000-11-30 |
2002-08-08 |
The Research Foundation Of State University Of New York |
Method of complexing a protein by the use of a dispersed system and proteins thereof
|
US8110218B2
(en)
*
|
2000-11-30 |
2012-02-07 |
The Research Foundation Of State University Of New York |
Compositions and methods for less immunogenic protein-lipid complexes
|
WO2002056829A2
(en)
*
|
2000-12-18 |
2002-07-25 |
Cubist Pharmaceuticals, Inc. |
Methods for preparing purified daptomycin
|
WO2002059145A1
(en)
*
|
2000-12-18 |
2002-08-01 |
Cubist Pharmaceuticals, Inc. |
Methods for preparing purified lipopeptides
|
US20060014674A1
(en)
|
2000-12-18 |
2006-01-19 |
Dennis Keith |
Methods for preparing purified lipopeptides
|
US20040077604A1
(en)
|
2001-12-19 |
2004-04-22 |
Lenard Lichtenberger |
Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
|
US6964849B2
(en)
|
2001-01-11 |
2005-11-15 |
Curagen Corporation |
Proteins and nucleic acids encoding same
|
US20040043928A1
(en)
*
|
2001-08-02 |
2004-03-04 |
Ramesh Kekuda |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
AR035779A1
(en)
|
2001-02-06 |
2004-07-14 |
Genetics Inst Llc |
FUSION POLYPEPTIDES DERIVED FROM GLICOPROTEIN IB PLATE ALFA AND METHODS OF USE OF THE SAME
|
US7060675B2
(en)
*
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
US6867183B2
(en)
*
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
AU2002245629A1
(en)
*
|
2001-03-08 |
2002-09-24 |
Targesome, Inc. |
Stabilized therapeutic and imaging agents
|
HUP0303616A3
(en)
*
|
2001-03-26 |
2006-07-28 |
Alza Corp Mountain View |
Liposome composition for improved intracellular delivery of a therapeutic agent
|
US20040126900A1
(en)
*
|
2001-04-13 |
2004-07-01 |
Barry Stephen E |
High affinity peptide- containing nanoparticles
|
WO2002087541A1
(en)
*
|
2001-04-30 |
2002-11-07 |
Protiva Biotherapeutics Inc. |
Lipid-based formulations for gene transfer
|
AU2002256398A2
(en)
*
|
2001-04-30 |
2002-11-11 |
Targeted Genetics Corporation |
Lipid-comprising drug delivery complexes and methods for their production
|
GB0111279D0
(en)
*
|
2001-05-10 |
2001-06-27 |
Nycomed Imaging As |
Radiolabelled liposomes
|
EE05294B1
(en)
|
2001-05-11 |
2010-04-15 |
Amgen Inc. |
TALL-1 binding agent composition
|
EP1389182A1
(en)
*
|
2001-05-15 |
2004-02-18 |
Transgene S.A. |
Complexes for transferring substances of interest into a cell
|
AU2002310046A1
(en)
*
|
2001-05-22 |
2002-12-03 |
Duke University |
Compositions and methods for inhibiting metastasis
|
US20020197253A1
(en)
*
|
2001-05-22 |
2002-12-26 |
Cheek Dennis J. |
Compositions and methods for promoting or inhibiting NDPK
|
EP2340849A1
(en)
|
2001-05-30 |
2011-07-06 |
Genentech, Inc. |
Anti-NGF antibodies for the treatment of various disorders
|
CA2447990C
(en)
*
|
2001-05-31 |
2012-01-31 |
Skyepharma Inc. |
Encapsulation of nanosuspensions in liposomes and microspheres
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6835802B2
(en)
*
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6858580B2
(en)
*
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828297B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7713932B2
(en)
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
JP2005501011A
(en)
*
|
2001-06-08 |
2005-01-13 |
ユタ ベンチャー ザ セカンド リミテッド パートナーシップ |
Tissue-specific inner membrane protein
|
KR100788092B1
(en)
|
2001-06-20 |
2007-12-21 |
제넨테크, 인크. |
Compositions and Methods for the Diagnosis and Treatment of Tumor
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA2790034A1
(en)
|
2001-06-21 |
2003-01-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
CN1827766B
(en)
|
2001-06-28 |
2010-08-25 |
徐荣祥 |
In vitro cell cultivation method
|
US20030087274A1
(en)
*
|
2001-07-05 |
2003-05-08 |
Anderson David W. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US20040029790A1
(en)
*
|
2001-07-05 |
2004-02-12 |
Meera Patturajan |
Novel human proteins, polynucleotides encoding them and methods of using the same
|
US20030134892A1
(en)
*
|
2001-07-19 |
2003-07-17 |
Wenbin Dang |
Compositions for treatment of head and neck cancers, and methods of making and using the same
|
WO2003007914A2
(en)
*
|
2001-07-19 |
2003-01-30 |
Guilford Pharmaceuticals, Inc. |
Biocompatible polymer containing composition for treatment of prostate cancers
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
CA2456092A1
(en)
*
|
2001-07-29 |
2003-02-13 |
Yissum Research Development Company Of The Hebrew University In Jerusalem |
Osteogenic growth oligopeptides as stimulants of hematopoiesis
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US20040030096A1
(en)
*
|
2001-08-02 |
2004-02-12 |
Linda Gorman |
Novel human proteins, polynucleotides encoding them and methods of using the same
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
US20030059375A1
(en)
*
|
2001-08-20 |
2003-03-27 |
Transave, Inc. |
Method for treating lung cancers
|
US20030211040A1
(en)
|
2001-08-31 |
2003-11-13 |
Paul Greengard |
Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
US7312192B2
(en)
*
|
2001-09-07 |
2007-12-25 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7196059B2
(en)
*
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US6913903B2
(en)
|
2001-09-07 |
2005-07-05 |
Nobex Corporation |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7166571B2
(en)
*
|
2001-09-07 |
2007-01-23 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7547673B2
(en)
*
|
2001-09-13 |
2009-06-16 |
The Johns Hopkins University |
Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
|
DE60238143D1
(en)
|
2001-09-18 |
2010-12-09 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF TUMORS
|
US7981863B2
(en)
|
2001-09-19 |
2011-07-19 |
Neuronova Ab |
Treatment of Parkinson's disease with PDGF
|
CN1635873A
(en)
*
|
2001-09-28 |
2005-07-06 |
埃斯佩里安医疗公司 |
Methods and apparatus for extrusion of vesicles at high pressure
|
DE10148065A1
(en)
*
|
2001-09-28 |
2003-04-17 |
Max Planck Gesellschaft |
(Ester) -lysolecithins in liposomes
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
NZ585001A
(en)
|
2001-10-09 |
2011-08-26 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US20030199442A1
(en)
*
|
2001-10-09 |
2003-10-23 |
Alsobrook John P. |
Therapeutic polypeptides, nucleic acids encoding same, and methods of use
|
US7332474B2
(en)
*
|
2001-10-11 |
2008-02-19 |
Amgen Inc. |
Peptides and related compounds having thrombopoietic activity
|
IL161733A0
(en)
|
2001-11-02 |
2005-11-20 |
Insert Therapeutics Inc |
Methods and compositions for therapeutic use of rna interference
|
AU2002340662B2
(en)
*
|
2001-11-07 |
2008-07-03 |
Tekmira Pharmaceuticals Corporation |
Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
|
US20040219201A1
(en)
*
|
2001-12-06 |
2004-11-04 |
Yechezkel Barenholz |
Tempamine compositions and methods of use
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
MXPA04006554A
(en)
|
2002-01-02 |
2005-03-31 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor.
|
WO2003057165A2
(en)
|
2002-01-04 |
2003-07-17 |
The Rockefeller University |
COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
|
US20040052928A1
(en)
*
|
2002-09-06 |
2004-03-18 |
Ehud Gazit |
Peptides and methods using same for diagnosing and treating amyloid-associated diseases
|
US7781396B2
(en)
*
|
2002-01-31 |
2010-08-24 |
Tel Aviv University Future Technology Development L.P. |
Peptides directed for diagnosis and treatment of amyloid-associated disease
|
EP1487273B1
(en)
*
|
2002-02-13 |
2009-01-21 |
Immunology Laboratories, Inc. |
Compositions and methods for treatment of microbial infections
|
JP2005535290A
(en)
|
2002-02-22 |
2005-11-24 |
ジェネンテック・インコーポレーテッド |
Compositions and methods for the treatment of immune related diseases
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
US20040009216A1
(en)
*
|
2002-04-05 |
2004-01-15 |
Rodrigueza Wendi V. |
Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
|
EP2011886A3
(en)
|
2002-04-16 |
2009-02-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AU2003233008B2
(en)
*
|
2002-04-22 |
2008-04-24 |
Recopharma Ab |
Fusion polypeptides and methods for inhibiting microbial adhesion
|
US20040009944A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Methylated immunostimulatory oligonucleotides and methods of using the same
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
WO2005056606A2
(en)
*
|
2003-12-03 |
2005-06-23 |
Xencor, Inc |
Optimized antibodies that target the epidermal growth factor receptor
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
AU2003236521A1
(en)
*
|
2002-06-13 |
2003-12-31 |
Nobex Corporation |
Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
|
EP2338478B1
(en)
|
2002-06-28 |
2014-07-23 |
Protiva Biotherapeutics Inc. |
Method for producing liposomes
|
DE60335469D1
(en)
*
|
2002-07-02 |
2011-02-03 |
Univ Texas |
RADIOACTIVELY MARKED COMPOUNDS AND LIPOSOME AND THEIR MANUFACTURING AND APPLICATION METHOD
|
US20040247661A1
(en)
*
|
2002-07-03 |
2004-12-09 |
Dov Michaeli |
Liposomal vaccine
|
US20050169979A1
(en)
*
|
2002-07-03 |
2005-08-04 |
Dov Michaeli |
Liposomal vaccine
|
AU2003267984A1
(en)
*
|
2002-07-03 |
2004-01-23 |
Receptor Biologix, Inc. |
Liposomal vaccine
|
WO2004004649A2
(en)
|
2002-07-08 |
2004-01-15 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
RU2338751C2
(en)
|
2002-07-15 |
2008-11-20 |
Дженентек, Инк. |
MEANS OF IDENTIFICATION OF TUMOURS, ACQUISITIVE TO TREATMENT BY ANTIBODIES AGAINST ErbB2
|
US7625563B2
(en)
*
|
2002-07-15 |
2009-12-01 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
|
ATE491725T1
(en)
*
|
2002-07-15 |
2011-01-15 |
Univ Texas |
ANTIBODIES BOUND TO ANIONIC PHOSPHOLIPIDES AND AMINOPHOSPHOLIPIDES AND THEIR USE IN THE TREATMENT OF VIRUS INFECTIONS
|
US7615223B2
(en)
*
|
2002-07-15 |
2009-11-10 |
Board Of Regents, The University Of Texas System |
Selected immunoconjugates for binding to aminophospholipids
|
US7622118B2
(en)
*
|
2002-07-15 |
2009-11-24 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using selected antibodies to aminophospholipids
|
US7714109B2
(en)
*
|
2002-07-15 |
2010-05-11 |
Board Of Regents, The University Of Texas System |
Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
|
US7572448B2
(en)
*
|
2002-07-15 |
2009-08-11 |
Board Of Regents, The University Of Texas System |
Combined cancer treatment methods using selected antibodies to aminophospholipids
|
US7678386B2
(en)
*
|
2002-07-15 |
2010-03-16 |
Board Of Regents The University Of Texas |
Liposomes coated with selected antibodies that bind to aminophospholipids
|
EP1546184A4
(en)
*
|
2002-07-16 |
2006-08-23 |
Univ South Florida |
Human immunosuppressive protein
|
US20040161423A1
(en)
*
|
2002-07-18 |
2004-08-19 |
Sanjeev Kumar (Mendiratta) |
Polymer modified anti-angiogenic serpins
|
US9186322B2
(en)
*
|
2002-08-02 |
2015-11-17 |
Insmed Incorporated |
Platinum aggregates and process for producing the same
|
MXPA05001312A
(en)
*
|
2002-08-02 |
2005-08-03 |
Transave Inc |
Platinum aggregates and process for producing the same.
|
CA2495251C
(en)
|
2002-08-14 |
2018-03-06 |
Macrogenics, Inc. |
Fc.gamma.riib-specific antibodies and methods of use thereof
|
EP1393720A1
(en)
*
|
2002-08-27 |
2004-03-03 |
Universiteit Utrecht |
Vesicle-encapsulated corticosteroids for treatment of cancer
|
PL376536A1
(en)
|
2002-08-28 |
2006-01-09 |
Immunex Corporation |
Compositions and methods for treating cardiovascular disease
|
AR036316A1
(en)
*
|
2002-08-29 |
2004-08-25 |
Monte Verde S A |
A PHARMACEUTICAL COMPOSITION OF SMALL SIZE LIPOSOMES AND PREPARATION METHOD
|
US20070231379A1
(en)
*
|
2002-08-29 |
2007-10-04 |
Slater James L |
Liposome-entrapped topoisomerase inhibitors
|
AU2003268531A1
(en)
|
2002-09-06 |
2004-03-29 |
University Of South Florida |
Materials and methods for treatment of allergic diseases
|
US20080214437A1
(en)
*
|
2002-09-06 |
2008-09-04 |
Mohapatra Shyam S |
Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
|
WO2004024072A2
(en)
|
2002-09-11 |
2004-03-25 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
WO2004024068A2
(en)
|
2002-09-11 |
2004-03-25 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
CA2498777C
(en)
*
|
2002-09-13 |
2015-01-13 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
US20050196382A1
(en)
*
|
2002-09-13 |
2005-09-08 |
Replicor, Inc. |
Antiviral oligonucleotides targeting viral families
|
JP2006515165A
(en)
|
2002-09-16 |
2006-05-25 |
ジェネンテック・インコーポレーテッド |
Novel compositions and methods for the treatment of immune related diseases
|
US6919426B2
(en)
|
2002-09-19 |
2005-07-19 |
Amgen Inc. |
Peptides and related molecules that modulate nerve growth factor activity
|
WO2004028479A2
(en)
|
2002-09-25 |
2004-04-08 |
Genentech, Inc. |
Nouvelles compositions et methodes de traitement du psoriasis
|
EP2272958A1
(en)
|
2002-09-26 |
2011-01-12 |
ISIS Pharmaceuticals, Inc. |
Modulation of forkhead box O1A expression
|
ES2562177T3
(en)
|
2002-09-27 |
2016-03-02 |
Xencor Inc. |
Optimized Fc variants and methods for their generation
|
US20040062748A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
EP1545615A4
(en)
*
|
2002-10-04 |
2006-03-01 |
Rinat Neuroscience Corp |
Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
|
UA80447C2
(en)
*
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
DK1556083T3
(en)
*
|
2002-10-08 |
2011-04-04 |
Rinat Neuroscience Corp |
Method of treating post-operative pain by administration of an antibody to nerve growth factor and composition containing the same
|
US7255860B2
(en)
|
2002-10-08 |
2007-08-14 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
|
KR20050071564A
(en)
*
|
2002-10-09 |
2005-07-07 |
리나트 뉴로사이언스 코퍼레이션 |
Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
|
EP1560597A4
(en)
*
|
2002-10-29 |
2007-06-27 |
Pharmacia Corp |
Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
|
JP2006517785A
(en)
|
2002-10-29 |
2006-08-03 |
ジェネンテック・インコーポレーテッド |
Novel compositions and methods for the treatment of immune related diseases
|
US8604183B2
(en)
|
2002-11-05 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
CA2504720C
(en)
|
2002-11-05 |
2013-12-24 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
AU2003295401B2
(en)
|
2002-11-08 |
2010-04-29 |
Genentech, Inc. |
Compositions and methods for the treatment of natural killer cell related diseases
|
US20040093198A1
(en)
*
|
2002-11-08 |
2004-05-13 |
Carbon Design Systems |
Hardware simulation with access restrictions
|
US20040152769A1
(en)
*
|
2002-11-09 |
2004-08-05 |
Ekwuribe Nnochiri Nkem |
Modified carbamate-containing prodrugs and methods of synthesizing same
|
CA2505801A1
(en)
|
2002-11-13 |
2004-05-27 |
Rosanne Crooke |
Antisense modulation of apolipoprotein b expression
|
SI1569695T1
(en)
|
2002-11-13 |
2013-08-30 |
Genzyme Corporation |
Antisense modulation of apolipoprotein b expression
|
US20050158375A1
(en)
*
|
2002-11-15 |
2005-07-21 |
Toshikiro Kimura |
Pharmaceutical composition containing liposomes for treating cancer
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
US7648962B2
(en)
*
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
AU2003297583B2
(en)
|
2002-11-26 |
2010-01-14 |
Biocon, Ltd |
Modified naturetic compounds, conjugates, and uses thereof
|
WO2004047728A2
(en)
|
2002-11-26 |
2004-06-10 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US7491699B2
(en)
|
2002-12-09 |
2009-02-17 |
Ramot At Tel Aviv University Ltd. |
Peptide nanostructures and methods of generating and using the same
|
WO2004056323A2
(en)
*
|
2002-12-19 |
2004-07-08 |
Alza Corporation |
Method of treating angiogenic tissue growth
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
CA2511598C
(en)
|
2002-12-24 |
2016-09-13 |
Rinat Neuroscience Corp. |
Anti-ngf antibodies and methods using same
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
US8980310B2
(en)
*
|
2002-12-31 |
2015-03-17 |
Bharat Serums and Vaccines, Ltd. |
Non-pegylated long-circulating liposomes
|
CA2511464C
(en)
|
2002-12-31 |
2011-08-23 |
Bharat Serums & Vaccines Ltd. |
Non-pegylated long-circulating liposomes
|
ATE426575T1
(en)
*
|
2003-01-07 |
2009-04-15 |
Univ Ramot |
PEPTIDE ANOSTRUCTURES CONTAINING FOREIGN MATERIAL AND METHOD FOR PRODUCING THE SAME
|
JPWO2004063216A1
(en)
*
|
2003-01-10 |
2006-06-15 |
アステラス製薬株式会社 |
Conjugates for blood retention and cancer tissue specific drug delivery
|
US7169892B2
(en)
|
2003-01-10 |
2007-01-30 |
Astellas Pharma Inc. |
Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems
|
EP1597366B1
(en)
|
2003-02-11 |
2012-11-21 |
Antisense Therapeutics Ltd |
Modulation of insulin like growth factor i receptor expression
|
CA2516454A1
(en)
|
2003-02-19 |
2004-09-02 |
Rinat Neuroscience Corp. |
Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US7968115B2
(en)
|
2004-03-05 |
2011-06-28 |
Board Of Regents, The University Of Texas System |
Liposomal curcumin for treatment of cancer
|
WO2004087097A2
(en)
*
|
2003-03-31 |
2004-10-14 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
MXPA05010499A
(en)
|
2003-03-31 |
2006-05-25 |
Johnson & Johnson |
Lipid particles having asymmetric lipid coating and method of preparing same.
|
JP4869064B2
(en)
|
2003-04-04 |
2012-02-01 |
ジェネンテック, インコーポレイテッド |
High concentration antibody and protein preparation
|
NZ587776A
(en)
|
2003-04-09 |
2012-03-30 |
Genentech Inc |
Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor using anti-CD20 antibody
|
PL1633440T3
(en)
*
|
2003-04-15 |
2008-12-31 |
Opperbas Holding Bv |
Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US20060246104A1
(en)
*
|
2003-04-16 |
2006-11-02 |
Massia Stephen P |
Stable rgd peptidomimetic composition
|
AU2004231740A1
(en)
*
|
2003-04-17 |
2004-11-04 |
The Trustees Of Columbia University In The City Ofnew York |
Desmoglein 4 is a novel gene involved in hair growth
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
CA2525464A1
(en)
|
2003-05-12 |
2004-11-25 |
Qun Yin |
Novel poly(ethylene glycol) modified compounds and uses thereof
|
EP2204193A3
(en)
|
2003-05-12 |
2010-08-18 |
Affymax, Inc. |
Novel spacer moiety for poly(ethylene glycol)-modified peptide-based compounds
|
RS20181002A1
(en)
|
2003-05-30 |
2018-12-31 |
Genentech Inc |
Treatment with anti-vegf antibodies
|
EP1629014A2
(en)
*
|
2003-05-30 |
2006-03-01 |
Genentech, Inc. |
Polypeptides that bind an anti-tissue factor antibody and uses thereof
|
EP2241572A3
(en)
|
2003-06-03 |
2011-04-06 |
Eli Lilly And Company |
Modulation of survivin expression
|
KR20060012661A
(en)
*
|
2003-06-04 |
2006-02-08 |
캔지, 인크. |
Methods and compositions for interferon therapy
|
DK1636593T5
(en)
|
2003-06-06 |
2009-07-27 |
Genentech Inc |
Modulating the interaction between HGF-beta chain and c-met
|
RU2403262C2
(en)
|
2003-06-11 |
2010-11-10 |
Уайт |
Isolated glycoprotein ib alpha polypeptide of human thrombocytes, fused protein, dna molecule (versions), expression vector (versions), cell (versions), polypeptide expression method, fused protein expression method, pharmaceutical composition (versions), method of inhibiting boding of blood cells to biological tissue in biological system, method of inhibiting bonding of protein to biological tissue in biological system and disorder treatment method
|
US7939058B2
(en)
*
|
2003-07-03 |
2011-05-10 |
University Of Southern California |
Uses of IL-12 in hematopoiesis
|
DE602004028837D1
(en)
|
2003-07-03 |
2010-10-07 |
Univ New Jersey Med |
GENES AS DIAGNOSTIC TOOLS FOR AUTISM
|
KR100945327B1
(en)
|
2003-07-08 |
2010-03-08 |
제넨테크, 인크. |
Il-17a/f heterologous polypeptides and therapeutic uses thereof
|
WO2005007196A2
(en)
*
|
2003-07-16 |
2005-01-27 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
CN100431525C
(en)
*
|
2003-07-17 |
2008-11-12 |
台湾东洋药品工业股份有限公司 |
Production method of liposome suspended liquid and products thereof
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
US20050058699A1
(en)
*
|
2003-07-31 |
2005-03-17 |
The Board Of Regents Of The University Of Texas System |
Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals and methods for making and using same
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
WO2005016348A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Icos Corporation |
Method of inhibiting immune responses stimulated by an endogenous factor
|
US20050054614A1
(en)
*
|
2003-08-14 |
2005-03-10 |
Diacovo Thomas G. |
Methods of inhibiting leukocyte accumulation
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
WO2005037911A2
(en)
*
|
2003-08-26 |
2005-04-28 |
Smithkline Beecham Corporation |
Heterofunctional copolymers of glycerol and polyethylene glycol, their conjugates and compositions
|
US8986731B2
(en)
*
|
2003-08-26 |
2015-03-24 |
Biolitec Pharma Marketing Ltd |
Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy
|
US8846079B1
(en)
|
2004-12-01 |
2014-09-30 |
Vgsk Technologies, Inc. |
Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
|
US11324698B2
(en)
|
2003-08-28 |
2022-05-10 |
Vgsk Technologies, Inc. |
Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
|
US20060115523A1
(en)
*
|
2004-12-01 |
2006-06-01 |
Konduri Kameswari S |
Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
|
KR20070019941A
(en)
*
|
2003-09-03 |
2007-02-16 |
교와 핫꼬 고교 가부시끼가이샤 |
Compound modified with glycerol derivative
|
US20050233435A1
(en)
*
|
2003-09-04 |
2005-10-20 |
Nyu Medical Center |
Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
|
US20070123480A1
(en)
*
|
2003-09-11 |
2007-05-31 |
Replicor Inc. |
Oligonucleotides targeting prion diseases
|
NZ581166A
(en)
*
|
2003-09-15 |
2011-06-30 |
Protiva Biotherapeutics Inc |
Polyethyleneglycol-modified lipid compounds and uses thereof
|
EP2256201A3
(en)
|
2003-09-18 |
2012-07-04 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E expression
|
CA2540407A1
(en)
*
|
2003-09-25 |
2005-03-31 |
Tel Aviv University Future Technology Development L.P. |
Compositions and methods using same for treating amyloid-associated diseases
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US7625707B2
(en)
*
|
2003-10-02 |
2009-12-01 |
Ramot At Tel Aviv University Ltd. |
Antibacterial agents and methods of identifying and utilizing same
|
DK1678194T3
(en)
|
2003-10-10 |
2013-10-07 |
Alchemia Oncology Pty Ltd |
MODULATING SYNTHESIS AND DEGRADING HYALURONANE IN THE TREATMENT OF DISEASE
|
JP2007509040A
(en)
*
|
2003-10-11 |
2007-04-12 |
イネックス ファーマシューティカルズ コーポレイション |
Methods and compositions for enhancing innate immunity and antibody-dependent cytotoxicity
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
WO2005041870A2
(en)
|
2003-10-24 |
2005-05-12 |
Ader Enterprises, Inc. |
Composition and method for the treatment of eye disease
|
EP1677765A1
(en)
*
|
2003-10-24 |
2006-07-12 |
Alza Corporation |
Preparation of lipid particles
|
WO2005040163A1
(en)
*
|
2003-10-28 |
2005-05-06 |
Dr. Reddy's Laboratories Ltd |
Heterocyclic compounds that block the effects of advanced glycation end products (age)
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
US7915227B2
(en)
*
|
2003-11-14 |
2011-03-29 |
Het Nederlands Kanker Instituut |
Pharmaceutical formulations employing short-chain sphingolipids and their use
|
US20050129753A1
(en)
*
|
2003-11-14 |
2005-06-16 |
Gabizon Alberto A. |
Method for drug loading in liposomes
|
EP2412725A3
(en)
|
2003-11-17 |
2012-04-25 |
Genentech, Inc. |
Antibodies against CD79b for the treatment of tumor of hematopoeitic origin
|
US7750123B2
(en)
*
|
2003-11-25 |
2010-07-06 |
Dana Farber Cancer Institute, Inc. |
Antibodies against SARS-CoV and methods of use thereof
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
US20050233960A1
(en)
|
2003-12-11 |
2005-10-20 |
Genentech, Inc. |
Methods and compositions for inhibiting c-met dimerization and activation
|
EP1700121A4
(en)
|
2003-12-23 |
2008-09-03 |
Rinat Neuroscience Corp |
Agonist anti-trkc antibodies and methods using same
|
EP3476861A1
(en)
|
2004-01-07 |
2019-05-01 |
Novartis Vaccines and Diagnostics, Inc. |
M-csf-specific monoclonal antibody and uses thereof
|
CA2553426A1
(en)
*
|
2004-01-15 |
2005-08-04 |
Alza Corporation |
Liposome composition for delivery of therapeutic agents
|
JP2007520222A
(en)
|
2004-01-20 |
2007-07-26 |
アイシス ファーマシューティカルズ インコーポレイテッド |
Regulation of glucocorticoid receptor expression
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
CA2559853A1
(en)
*
|
2004-02-17 |
2005-10-13 |
University Of South Florida |
Materials and methods for treatment of inflammatory and cell proliferation disorders
|
US20050181035A1
(en)
*
|
2004-02-17 |
2005-08-18 |
Dow Steven W. |
Systemic immune activation method using non CpG nucleic acids
|
AU2005214382B2
(en)
|
2004-02-19 |
2011-08-04 |
Genentech, Inc. |
CDR-repaired antibodies
|
US8784881B2
(en)
|
2004-03-05 |
2014-07-22 |
Board Of Regents, The University Of Texas System |
Liposomal curcumin for treatment of diseases
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP1735009A4
(en)
|
2004-03-12 |
2011-03-30 |
Alnylam Pharmaceuticals Inc |
iRNA AGENTS TARGETING VEGF
|
CN1679957B
(en)
*
|
2004-03-15 |
2010-06-09 |
尼普洛株式会社 |
A pharmaceutical composition containing liposomes for treating a cancer
|
WO2005089268A2
(en)
|
2004-03-15 |
2005-09-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of rna by rnase h
|
US20070065522A1
(en)
*
|
2004-03-18 |
2007-03-22 |
Transave, Inc. |
Administration of high potency platinum compound formulations by inhalation
|
CN1976711A
(en)
*
|
2004-03-18 |
2007-06-06 |
特兰萨维股份有限公司 |
Administration of cisplatin by inhalation
|
WO2005092388A1
(en)
*
|
2004-03-26 |
2005-10-06 |
Terumo Kabushiki Kaisha |
Liposome preparation
|
AU2005231692B2
(en)
*
|
2004-03-26 |
2011-01-27 |
Curis, Inc. |
RNA interference modulators of Hedgehog signaling and uses thereof
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
ES2338344T3
(en)
*
|
2004-04-07 |
2010-05-06 |
Rinat Neuroscience Corporation |
PROCESS OF BONE CANCER TREATMENT THROUGH THE ADMINISTRATION OF AN ANTAGONIST OF THE NEURONAL GROWTH FACTOR.
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
WO2005115453A2
(en)
*
|
2004-04-16 |
2005-12-08 |
Genentech, Inc. |
Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
|
ES2616047T3
(en)
|
2004-05-03 |
2017-06-09 |
Merrimack Pharmaceuticals, Inc. |
Liposomes useful for drug administration
|
US8658203B2
(en)
*
|
2004-05-03 |
2014-02-25 |
Merrimack Pharmaceuticals, Inc. |
Liposomes useful for drug delivery to the brain
|
ES2605792T3
(en)
|
2004-05-13 |
2017-03-16 |
Icos Corporation |
Quinazolinone used as a human phosphatidylinositol 3-kinase delta inhibitor
|
EP1750673B1
(en)
*
|
2004-05-17 |
2009-12-02 |
Tekmira Pharmaceuticals Corporation |
Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
|
AU2005250369A1
(en)
*
|
2004-05-18 |
2005-12-15 |
Genentech, Inc. |
M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein
|
US20050260260A1
(en)
*
|
2004-05-19 |
2005-11-24 |
Edward Kisak |
Liposome compositions for the delivery of macromolecules
|
CA2566174A1
(en)
*
|
2004-05-21 |
2005-12-01 |
Transave, Inc. |
Treatment of lung diseases and pre-lung disease conditions
|
JP2008500338A
(en)
*
|
2004-05-25 |
2008-01-10 |
イコス・コーポレイション |
Method for treating and / or preventing abnormal proliferation of hematopoietic cells
|
WO2005115384A2
(en)
*
|
2004-05-25 |
2005-12-08 |
Metabolex, Inc. |
Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
|
RU2006145872A
(en)
*
|
2004-05-25 |
2008-06-27 |
Метаболекс, Инк. (Us) |
SUBSTITUTED TRIAZOLES AS PPAR MODULATORS AND METHODS FOR PRODUCING THEM
|
ES2623362T3
(en)
*
|
2004-05-28 |
2017-07-11 |
Human Biomolecular Research Institute |
Metabolically stable pain relievers and pain medications
|
US20090048192A1
(en)
*
|
2004-06-03 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
EP1765416A4
(en)
*
|
2004-06-03 |
2010-03-24 |
Isis Pharmaceuticals Inc |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US20080261904A1
(en)
*
|
2004-06-03 |
2008-10-23 |
Balkrishen Bhat |
Chimeric Gapped Oligomeric Compounds
|
NZ604082A
(en)
|
2004-06-04 |
2014-09-26 |
Genentech Inc |
Method for treating multiple sclerosis
|
CA2569645C
(en)
|
2004-06-07 |
2014-10-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
WO2005121348A1
(en)
*
|
2004-06-07 |
2005-12-22 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
WO2006025920A2
(en)
*
|
2004-06-19 |
2006-03-09 |
Human Biomolecular Research Institute |
Modulators of central nervous system neurotransmitters
|
EP1766077B1
(en)
|
2004-06-21 |
2012-03-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
|
WO2006002538A1
(en)
|
2004-07-02 |
2006-01-12 |
Protiva Biotherapeutics, Inc. |
Immunostimulatory sirna molecules and uses therefor
|
US20060019893A1
(en)
*
|
2004-07-02 |
2006-01-26 |
Genentech, Inc. |
Factor VIIa variants
|
MX2007000216A
(en)
*
|
2004-07-08 |
2007-03-15 |
Amgen Inc |
Therapeutic peptides.
|
US20090156471A1
(en)
*
|
2004-07-15 |
2009-06-18 |
Ramot At Tel Aviv University Ltd. |
Use of anti-amyloid agents for treating and typing pathogen infections
|
EP2471813B1
(en)
|
2004-07-15 |
2014-12-31 |
Xencor, Inc. |
Optimized Fc variants
|
US20060051405A1
(en)
*
|
2004-07-19 |
2006-03-09 |
Protiva Biotherapeutics, Inc. |
Compositions for the delivery of therapeutic agents and uses thereof
|
RU2393168C2
(en)
*
|
2004-07-19 |
2010-06-27 |
Биокон Лимитед |
Insulin-oligomer conjugates, preparations and use thereof
|
AU2005269716B2
(en)
|
2004-07-20 |
2011-01-27 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
CA2570323C
(en)
|
2004-07-26 |
2014-08-26 |
Genentech, Inc. |
Methods and compositions for modulating hepatocyte growth factor activation
|
US7927594B2
(en)
*
|
2004-07-30 |
2011-04-19 |
Rinat Neuroscience Corp. |
Antibodies directed against amyloid-beta peptide
|
WO2006013552A2
(en)
|
2004-08-02 |
2006-02-09 |
Ramot At Tel Aviv University Ltd. |
Articles of peptide nanostructures and method of forming the same
|
US9132116B2
(en)
*
|
2004-08-02 |
2015-09-15 |
Willowcroft Pharm Inc. |
Mast cell stabilizers to prevent or treat laminitis
|
JP4934036B2
(en)
|
2004-08-17 |
2012-05-16 |
タイコ ヘルスケア グループ リミテッド パートナーシップ |
Anti-adhesion barrier
|
JP2006056807A
(en)
*
|
2004-08-18 |
2006-03-02 |
Konica Minolta Medical & Graphic Inc |
Preparation for use in photodynamic therapy
|
US7732479B2
(en)
|
2004-08-19 |
2010-06-08 |
Tel Aviv University Future Technology Development L.P. |
Compositions for treating amyloid associated diseases
|
JP4715133B2
(en)
*
|
2004-08-26 |
2011-07-06 |
コニカミノルタエムジー株式会社 |
Anti-tumor liposome preparation and production method thereof
|
JP2006069929A
(en)
*
|
2004-08-31 |
2006-03-16 |
Konica Minolta Medical & Graphic Inc |
Preparation for treating mycosis and method for producing the same
|
WO2006027780A2
(en)
*
|
2004-09-08 |
2006-03-16 |
Ramot At Tel Aviv University Ltd. |
Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
EP1793805A1
(en)
*
|
2004-09-09 |
2007-06-13 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Liposomal formulations comprising an amphipathic weak base like tempamine for treatment of neurodegenerative conditions
|
JP2008512445A
(en)
*
|
2004-09-09 |
2008-04-24 |
イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム |
Use of liposomal glucocorticoids for the treatment of inflammatory conditions
|
US6998028B1
(en)
*
|
2004-09-24 |
2006-02-14 |
Superpower, Inc. |
Methods for forming superconducting conductors
|
DK1797127T3
(en)
*
|
2004-09-24 |
2017-10-02 |
Amgen Inc |
Modified Fc molecules
|
CA2581896C
(en)
|
2004-09-29 |
2015-11-10 |
Mount Sinai School Of Medicine Of New York University |
Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
|
EP1812060A2
(en)
|
2004-10-05 |
2007-08-01 |
Genentech, Inc. |
Method for treating vasculitis
|
WO2006042112A2
(en)
|
2004-10-05 |
2006-04-20 |
California Institute Of Technology |
Aptamer regulated nucleic acids and uses thereof
|
CA2943949C
(en)
*
|
2004-10-06 |
2020-03-31 |
Mayo Foundation For Medical Education And Research |
B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
|
AU2005295072A1
(en)
*
|
2004-10-08 |
2006-04-20 |
Alza Corporation |
Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
|
TW200612993A
(en)
*
|
2004-10-08 |
2006-05-01 |
Alza Corp |
Lipopolymer conjugates
|
JO3000B1
(en)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
Antibody Formulations.
|
CN101119750B
(en)
*
|
2004-10-26 |
2013-03-06 |
法马马私人股份有限公司 |
Anti-cancer treatment
|
US20060110441A1
(en)
*
|
2004-10-28 |
2006-05-25 |
Harry Wong |
Lyophilized liposome formulations and method
|
DK1658848T3
(en)
|
2004-10-29 |
2007-11-26 |
Pharma Mar Sa |
Formulations comprising ecteinascidin and a disaccharide
|
JP4990786B2
(en)
|
2004-11-05 |
2012-08-01 |
イネックス ファーマシューティカルズ コーポレイション |
Compositions and methods for stabilizing drug liposome formulations
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
EP1811963A4
(en)
*
|
2004-11-08 |
2010-01-06 |
Transave Inc |
Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
|
CN101142234A
(en)
*
|
2004-11-11 |
2008-03-12 |
阿费麦克斯公司 |
Novel peptides that bind to the erythropoietin receptor
|
EP1817004A2
(en)
*
|
2004-11-15 |
2007-08-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Combination therapy associating preferably a ceramide with a cytotoxic drug
|
WO2006053430A1
(en)
*
|
2004-11-17 |
2006-05-26 |
Protiva Biotherapeutics, Inc. |
Sirna silencing of apolipoprotein b
|
EP1813288B1
(en)
*
|
2004-11-18 |
2018-07-18 |
Terumo Kabushiki Kaisha |
Medicinal composition, medicinal preparation, and combination preparation
|
US7361752B2
(en)
*
|
2004-12-14 |
2008-04-22 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of MLL-AF4 and uses thereof
|
JP2008526883A
(en)
|
2005-01-07 |
2008-07-24 |
ディアデクサス インコーポレーテッド |
Ovr110 antibody compositions and methods of use
|
WO2006076471A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Nobex Corporation |
Bnp conjugates and methods of use
|
CN101141981A
(en)
|
2005-01-21 |
2008-03-12 |
健泰科生物技术公司 |
Fixed dosing of her antibodies
|
JP5221126B2
(en)
*
|
2005-01-28 |
2013-06-26 |
協和発酵キリン株式会社 |
Method for producing fine particles surface-modified with water-soluble substances
|
EP1853289A4
(en)
|
2005-01-31 |
2008-04-09 |
Vaxinnate Corp |
Novel polypeptide ligands for toll-like receptor 2 (tlr2)
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
EP1855694B1
(en)
|
2005-02-09 |
2020-12-02 |
Sarepta Therapeutics, Inc. |
Antisense composition for treating muscle atrophy
|
JP5651285B2
(en)
|
2005-02-15 |
2015-01-07 |
デューク ユニバーシティ |
Anti-CD19 antibodies and use in oncology
|
EP1885356A2
(en)
*
|
2005-02-17 |
2008-02-13 |
Icos Corporation |
Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
|
US20090202619A1
(en)
*
|
2005-02-18 |
2009-08-13 |
The University Of Tokushima |
Polyoxyalkylene chain-containing lipid derivative and lipid film structure containing such derivative
|
US8329178B2
(en)
|
2005-02-18 |
2012-12-11 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against CXCR4 and methods of use thereof
|
DK1850874T3
(en)
|
2005-02-23 |
2013-11-11 |
Genentech Inc |
Extension of time to disease progression or survival for ovarian cancer using pertuzumab
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
WO2006096861A2
(en)
*
|
2005-03-08 |
2006-09-14 |
Genentech, Inc. |
METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
|
JP2008535796A
(en)
|
2005-03-10 |
2008-09-04 |
ジェネンテック・インコーポレーテッド |
Methods and compositions for regulating vascular integrity
|
JP2006248978A
(en)
*
|
2005-03-10 |
2006-09-21 |
Mebiopharm Co Ltd |
New liposome preparation
|
US20070065359A1
(en)
*
|
2005-03-14 |
2007-03-22 |
Shiladitya Sengupta |
Nanocells for diagnosis and treatment of diseases and disorders
|
JP2008538351A
(en)
|
2005-03-21 |
2008-10-23 |
メタボレックス インコーポレーティッド |
Method for avoiding edema in the treatment or prevention of PPARγ-responsive diseases including cancer
|
CN1840193B
(en)
*
|
2005-03-29 |
2010-05-12 |
中国科学院生物物理研究所 |
Nanometer capsule of anthracene nucleus anticancer antibiotic with polyethylene glycol-phospholipid
|
EP1866414B9
(en)
|
2005-03-31 |
2012-10-03 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
UY29504A1
(en)
*
|
2005-04-29 |
2006-10-31 |
Rinat Neuroscience Corp |
DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME.
|
AU2006244445B2
(en)
|
2005-05-05 |
2013-04-18 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
ES2561628T3
(en)
|
2005-05-06 |
2016-02-29 |
Zymogenetics, Inc. |
IL-31 monoclonal antibodies and methods of use
|
US8124084B2
(en)
|
2005-05-17 |
2012-02-28 |
University Of Connecticut |
Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7919461B2
(en)
*
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7550433B2
(en)
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
JP2008541781A
(en)
|
2005-06-06 |
2008-11-27 |
ジェネンテック・インコーポレーテッド |
Transgenic animals for different genes and their use for characterizing genes
|
WO2007005754A2
(en)
*
|
2005-07-01 |
2007-01-11 |
Alza Corporation |
Liposomal delivery vehicle for hydrophobic drugs
|
WO2007008943A2
(en)
|
2005-07-08 |
2007-01-18 |
Xencor, Inc. |
Optimized anti-ep-cam antibodies
|
CN101282994B
(en)
|
2005-07-22 |
2013-09-18 |
Y's治疗有限公司 |
Anti-CD26 antibodies and methods of use thereof
|
EP2277916A3
(en)
*
|
2005-07-28 |
2011-04-27 |
Novartis AG |
Use of antibody to M-CSF
|
WO2007016285A2
(en)
*
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
M-csf specific monoclonal antibody and uses thereof
|
US8998881B2
(en)
|
2005-08-10 |
2015-04-07 |
Alza Corporation |
Method for delivering drugs to tissue under microjet propulsion
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
JP2009504183A
(en)
|
2005-08-15 |
2009-02-05 |
ジェネンテック・インコーポレーテッド |
Gene disruption and related compositions and methods
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
US10004828B2
(en)
*
|
2005-10-11 |
2018-06-26 |
Romat at Tel-Aviv University Ltd. |
Self-assembled Fmoc-ff hydrogels
|
US7875602B2
(en)
*
|
2005-10-21 |
2011-01-25 |
Sutter West Bay Hospitals |
Camptothecin derivatives as chemoradiosensitizing agents
|
AR056142A1
(en)
|
2005-10-21 |
2007-09-19 |
Amgen Inc |
METHODS TO GENERATE THE MONOVALENT IGG ANTIBODY
|
SI2500360T1
(en)
|
2005-10-31 |
2015-11-30 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
GB0522082D0
(en)
|
2005-10-31 |
2005-12-07 |
Pharma Mar Sa |
Formulations
|
EP1951737A4
(en)
|
2005-11-01 |
2009-07-01 |
Alnylam Pharmaceuticals Inc |
Rnai inhibition of influenza virus replication
|
EP2395012B8
(en)
*
|
2005-11-02 |
2018-06-06 |
Arbutus Biopharma Corporation |
Modified siRNA molecules and uses thereof
|
US7879212B2
(en)
*
|
2005-11-03 |
2011-02-01 |
Ramot At Tel-Aviv University Ltd. |
Peptide nanostructure-coated electrodes
|
DE102005053066A1
(en)
*
|
2005-11-04 |
2007-05-10 |
Basf Ag |
Use of copolymers as solubilizers for sparingly water-soluble compounds
|
WO2007056236A2
(en)
*
|
2005-11-08 |
2007-05-18 |
Transave, Inc. |
Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
|
US20070190182A1
(en)
*
|
2005-11-08 |
2007-08-16 |
Pilkiewicz Frank G |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
WO2007056263A2
(en)
*
|
2005-11-08 |
2007-05-18 |
Transave, Inc. |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
|
US9107824B2
(en)
|
2005-11-08 |
2015-08-18 |
Insmed Incorporated |
Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
|
EP2564864B8
(en)
|
2005-11-12 |
2015-05-13 |
The Board of Trustees of The Leland Stanford Junior University |
FGF2-related methods for diagnosing and treating depression
|
PT2380592T
(en)
|
2005-11-14 |
2018-06-06 |
Teva Pharmaceuticals Int Gmbh |
Antagonist antibody directed against calcitonin gene-related peptide
|
PE20070684A1
(en)
|
2005-11-14 |
2007-08-06 |
Amgen Inc |
RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
CN101360826B
(en)
|
2005-11-18 |
2014-04-30 |
格兰马克药品股份有限公司 |
Anti-alpha2 integrin antibodies and their uses
|
CA2630432A1
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
WO2007062380A2
(en)
|
2005-11-21 |
2007-05-31 |
Isis Pharmaceuticals, Inc. |
Modulation of eif4e-bp2 expression
|
US20070122350A1
(en)
*
|
2005-11-30 |
2007-05-31 |
Transave, Inc. |
Safe and effective methods of administering therapeutic agents
|
KR101453570B1
(en)
|
2005-12-02 |
2014-10-22 |
제넨테크, 인크. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
|
EP1979379B1
(en)
|
2005-12-02 |
2013-09-18 |
Dana-Farber Cancer Institute |
Carbonic anhydrase ix (g250) antibodies and methods of use thereof
|
WO2007066335A2
(en)
*
|
2005-12-08 |
2007-06-14 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Methods for affecting liposome composition by ultrasound irradiation
|
WO2007065846A2
(en)
*
|
2005-12-09 |
2007-06-14 |
Basf Se |
Use of polyvinyl lactam-polyoxyalkylene block copolymers as solubilisers for poorly water-soluble compounds
|
WO2007070705A2
(en)
|
2005-12-15 |
2007-06-21 |
The Trustees Of The University Of Pennsylvania |
Cationic lipid-mediated vectors
|
EP2705854A1
(en)
|
2006-01-05 |
2014-03-12 |
Novartis AG |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
US20090215084A1
(en)
*
|
2006-01-05 |
2009-08-27 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
WO2007082144A2
(en)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and survivin in cancer
|
EP1973941A2
(en)
|
2006-01-26 |
2008-10-01 |
Recopharma AB |
Compositions and methods for inhibiting viral adhesion
|
EP3210633B1
(en)
|
2006-01-26 |
2019-06-19 |
Ionis Pharmaceuticals, Inc. |
Compositions and their uses directed to huntingtin
|
US7829097B2
(en)
*
|
2006-02-06 |
2010-11-09 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Use of HMGB1 for protection against ischemia reperfusion injury
|
WO2007114979A2
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
US8389688B2
(en)
|
2006-03-06 |
2013-03-05 |
Aeres Biomedical, Ltd. |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US20070218116A1
(en)
*
|
2006-03-14 |
2007-09-20 |
Schwendener Reto A |
Compositions and methods for the treatment of tumors and tumor metastases
|
US9119782B2
(en)
*
|
2006-03-20 |
2015-09-01 |
Mary P. McCourt |
Drug delivery means
|
PL1989231T3
(en)
|
2006-03-21 |
2015-10-30 |
Genentech Inc |
Combinatorial therapy involving alpha5beta1 antagonists
|
EP2004221A2
(en)
|
2006-03-23 |
2008-12-24 |
Novartis Pharma AG |
Anti-tumor cell antigen antibody therapeutics
|
WO2007115168A2
(en)
|
2006-03-31 |
2007-10-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 gene
|
AU2007243946B2
(en)
|
2006-04-05 |
2012-11-29 |
Curis, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
US20090288176A1
(en)
|
2006-04-19 |
2009-11-19 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
WO2007124361A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
Soluble b7-h1
|
WO2007121522A1
(en)
|
2006-04-21 |
2007-11-01 |
Minister for Primary Industries For And On Behalf Of The State Of New South Wales |
Pestivirus species
|
US7691824B2
(en)
|
2006-04-28 |
2010-04-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the JC virus
|
CA2656990A1
(en)
*
|
2006-04-28 |
2007-11-08 |
University Of South Florida |
Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
|
US8298818B2
(en)
*
|
2006-04-28 |
2012-10-30 |
University Of Florida Research Foundation, Inc. |
Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter
|
US8697120B2
(en)
*
|
2006-05-01 |
2014-04-15 |
Johns Hopkins University |
Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury
|
WO2007125173A2
(en)
*
|
2006-05-03 |
2007-11-08 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
US20070264322A1
(en)
*
|
2006-05-10 |
2007-11-15 |
Huang Ken S |
Method for making liposomes conjugated with temperature-sensitive ligands
|
JP5282031B2
(en)
*
|
2006-05-15 |
2013-09-04 |
ドミトリィ ビー カーポティン |
Magnetic fine particles containing organic matter
|
AU2007249160B2
(en)
|
2006-05-15 |
2013-09-12 |
I2 Pharmaceuticals, Inc. |
Neutralizing antibodies to influenza viruses
|
EP2029157A4
(en)
*
|
2006-05-19 |
2009-11-18 |
Georgia Tech Res Inst |
Abc transporter ligand
|
EP2023937B1
(en)
|
2006-05-19 |
2011-10-12 |
Alnylam Pharmaceuticals Inc. |
Rnai modulation of aha and therapeutic uses thereof
|
WO2007137220A2
(en)
|
2006-05-22 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
EP2023938A4
(en)
*
|
2006-05-23 |
2010-11-10 |
Isis Pharmaceuticals Inc |
Modulation of chrebp expression
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
US7915399B2
(en)
*
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
US7981425B2
(en)
*
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
WO2007149433A2
(en)
*
|
2006-06-19 |
2007-12-27 |
The Johns Hopkins University |
Tumor-specific delivery of therapeutic agents via liposomase
|
EP2452683A3
(en)
|
2006-06-26 |
2012-08-22 |
Amgen Inc. |
Methods for treating atherosclerosis
|
ES2599319T3
(en)
|
2006-06-26 |
2017-02-01 |
Macrogenics, Inc. |
Fc RIIB specific antibodies and their methods of use
|
JP5072275B2
(en)
*
|
2006-07-03 |
2012-11-14 |
テルモ株式会社 |
Method for separating closed vesicles, method for producing preparation and evaluation method
|
CN101511181B
(en)
|
2006-07-11 |
2013-08-21 |
新泽西医科和牙科大学 |
Proteins, nucleic acids encoding the same and associated methods of use
|
US8343539B2
(en)
|
2006-07-14 |
2013-01-01 |
Regents Of The University Of Minnesota |
Compounds that bind α5β1 integrin and methods of use
|
US8324158B2
(en)
*
|
2006-07-14 |
2012-12-04 |
Georgia Tech Research Corporation |
Methods for inhibiting CLC-2 channel with GATX2
|
ES2612383T3
(en)
|
2006-07-19 |
2017-05-16 |
The Trustees Of The University Of Pennsylvania |
WSX-1 / IL-27 as a target for anti-inflammatory responses
|
WO2008011473A2
(en)
|
2006-07-19 |
2008-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hbxip
|
JP4936312B2
(en)
*
|
2006-07-20 |
2012-05-23 |
株式会社島津製作所 |
Novel amphiphile, drug delivery system and molecular imaging system using the same
|
WO2008013918A2
(en)
*
|
2006-07-26 |
2008-01-31 |
Myelin Repair Foundation, Inc. |
Cell cycle regulation and differentiation
|
JP5406027B2
(en)
|
2006-08-04 |
2014-02-05 |
ノバルティス アーゲー |
EphB3-specific antibodies and uses thereof
|
CA2660286A1
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
ME01786B
(en)
|
2006-08-14 |
2014-09-20 |
Xencor Inc |
Optimized antibodies that target cd19
|
AR062435A1
(en)
|
2006-08-18 |
2008-11-05 |
Xoma Technology Ltd |
PRLR SPECIFIC ANTIBODY (PROLACTIN RECEPTOR) AND ITS USES
|
EP2061900A2
(en)
|
2006-08-25 |
2009-05-27 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
EP2064243A2
(en)
|
2006-08-28 |
2009-06-03 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistic human light-specific human monoclonal antibodies
|
BRPI0716143A2
(en)
|
2006-08-29 |
2013-11-26 |
Genentech Inc |
USE OF TENECTEPLASE TO TREAT ACUTE ISCHEMICAL SPILL
|
SI2594586T1
(en)
|
2006-09-01 |
2014-11-28 |
Zymogenetics, Inc. |
IL-31 monoclonal antibodies and methods of use
|
CA2600220C
(en)
*
|
2006-09-07 |
2014-12-09 |
Canadian Blood Services |
Surface cross-linked lipidic particles, methods of production and uses therefor
|
PL2066694T3
(en)
|
2006-09-29 |
2016-04-29 |
Oncomed Pharm Inc |
Compositions and methods for diagnosing and treating cancer
|
US9505821B2
(en)
|
2006-10-03 |
2016-11-29 |
Rutgers, The State University Of New Jersey |
ATAP peptides, nucleic acids encoding the same and associated methods of use
|
US10925977B2
(en)
*
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
AR063384A1
(en)
*
|
2006-10-25 |
2009-01-28 |
Amgen Inc |
THERAPEUTIC AGENTS BASED ON PEPTIDES DERIVED FROM TOXINS
|
CN101687031B
(en)
|
2006-10-27 |
2014-05-14 |
勒帕斯公司 |
Compositions and methods for treating ocular diseases and conditions
|
JP5795833B2
(en)
*
|
2006-10-27 |
2015-10-14 |
エルパス・インコーポレイテッドLpath, Inc. |
Compositions and methods for binding sphingosine-1-phosphate
|
WO2008058291A2
(en)
*
|
2006-11-09 |
2008-05-15 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
AU2007317203B2
(en)
|
2006-11-10 |
2010-12-16 |
Dimerix Bioscience Pty Ltd |
Detection system and uses therefor
|
EP2097422A4
(en)
*
|
2006-11-13 |
2010-04-14 |
Lilly Co Eli |
Thienopyrimidinones for treatment of inflammatory disorders and cancers
|
WO2008067283A2
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
MX2009006034A
(en)
|
2006-12-07 |
2009-10-12 |
Novartis Ag |
Antagonist antibodies against ephb3.
|
EP1932517A3
(en)
*
|
2006-12-11 |
2008-07-16 |
Universiteit Utrecht Holding B.V. |
Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof
|
US20100203110A1
(en)
*
|
2006-12-18 |
2010-08-12 |
The Johns Hopkins University |
Therapeutics for Cancer Using 3-Bromopyruvate and Other Selective Inhibitors of ATP Production
|
WO2008079973A2
(en)
*
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Egfr binding peptides and uses thereof
|
WO2008079982A2
(en)
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Liposome composition for targeting egfr receptor
|
WO2008079976A2
(en)
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Dimeric high affinity egfr constructs and uses thereof
|
WO2008094370A2
(en)
|
2006-12-22 |
2008-08-07 |
University Of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
WO2008083169A2
(en)
*
|
2006-12-26 |
2008-07-10 |
The Johns Hopkins University |
Compositions and methods for the treatment of immunologic disorders
|
JP5481199B2
(en)
|
2006-12-27 |
2014-04-23 |
ザ ジョンズ ホプキンス ユニバーシティー |
Compositions and methods for treating inflammation and autoimmune diseases
|
US20090142342A1
(en)
*
|
2006-12-27 |
2009-06-04 |
Johns Hopkins University |
B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
US8048998B2
(en)
*
|
2007-01-19 |
2011-11-01 |
Exiqon A/S |
Mediated cellular delivery of LNA oligonucleotides
|
US20100329664A1
(en)
*
|
2007-01-23 |
2010-12-30 |
Lim Dae-Soon |
Shutter device for camera
|
US20100093836A1
(en)
|
2007-01-29 |
2010-04-15 |
Isis Pharmaceuticals, Inc |
Compounds and methods for modulating protein expression
|
WO2008094275A1
(en)
|
2007-01-30 |
2008-08-07 |
New York University |
Peptides for treatment of conditions associated with nitric oxide
|
CA2676790A1
(en)
|
2007-02-22 |
2008-08-28 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
EP2132573B1
(en)
|
2007-03-02 |
2014-04-23 |
Genentech, Inc. |
Predicting response to a her dimerisation inhbitor based on low her3 expression
|
EP2146692A1
(en)
*
|
2007-03-19 |
2010-01-27 |
Fresenius Kabi Oncology Limited |
Proliposomal and liposomal compositions
|
JP4510842B2
(en)
*
|
2007-03-26 |
2010-07-28 |
キヤノン株式会社 |
Polyhydroxyalkanoate-coated liposome
|
WO2008121604A2
(en)
|
2007-03-29 |
2008-10-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the ebola
|
ES2540807T3
(en)
|
2007-05-04 |
2015-07-13 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa |
Variable domains of rabbit antibodies modified by genetic engineering and uses thereof
|
KR20100017514A
(en)
|
2007-05-07 |
2010-02-16 |
메디뮨 엘엘씨 |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US20090175784A1
(en)
|
2007-05-11 |
2009-07-09 |
Joshua Goldstein |
Anti-Alpha V Immunoliposome Composition, Methods, and Uses
|
US20090196913A1
(en)
*
|
2007-05-11 |
2009-08-06 |
Ken Shi Kun Huang |
Anti-Alpha-V Immunoliposome Composition, Methods, and Uses
|
US20090163698A1
(en)
*
|
2007-05-11 |
2009-06-25 |
John Joseph Grigsby |
Method for Preparing Antibody Conjugates
|
WO2009101479A2
(en)
|
2007-05-14 |
2009-08-20 |
Novimmune Sa |
Fc receptor-binding polypeptides with modified effector functions
|
EP2160200B1
(en)
|
2007-05-14 |
2013-07-10 |
The University of Chicago |
Antibody-LIGHT fusion products as cancer therapeutics
|
EP2162540A2
(en)
|
2007-05-22 |
2010-03-17 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
WO2008148023A2
(en)
*
|
2007-05-23 |
2008-12-04 |
Medical College Of Georgia Research Institute, Inc. |
Compositions and methods for treating neurological disorders
|
AU2008256644B2
(en)
|
2007-05-24 |
2014-07-03 |
The United States Government As Represented By The Department Of Veterans Affairs |
Intranuclear protein transduction through a nucleoside salvage pathway
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
WO2008150841A1
(en)
|
2007-05-30 |
2008-12-11 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
EP2176298B1
(en)
|
2007-05-30 |
2017-11-15 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
AR066984A1
(en)
*
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
INHIBITION OF THE EXPRESSION OF THE ALFA SUBUNITY OF THE SODIUM EPITELIAL CHANNEL (ENAC) THROUGH ARNI (INTERFERENCE RNA)
|
TW200916094A
(en)
*
|
2007-06-27 |
2009-04-16 |
Poniard Pharmaceuticals Inc |
Stabilized picoplatin dosage form
|
EP2514762B1
(en)
|
2007-07-13 |
2015-04-08 |
The Johns Hopkins University |
B7-DC variants
|
US20090082217A1
(en)
*
|
2007-07-16 |
2009-03-26 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
EP2641618A3
(en)
|
2007-07-16 |
2013-10-23 |
Genentech, Inc. |
Humanized anti-CD79B antibodies and immunoconjugates and methods of use
|
SG183023A1
(en)
|
2007-07-16 |
2012-08-30 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
US8183381B2
(en)
*
|
2007-07-19 |
2012-05-22 |
Metabolex Inc. |
N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
|
SI2489731T1
(en)
|
2007-07-26 |
2014-12-31 |
Amgen Inc. Patent Operations, M/S 28-2-C |
Modified lecithin-cholesterol acyltransferase enzymes
|
US20100204425A1
(en)
*
|
2007-07-26 |
2010-08-12 |
Basf Se |
Process for preparing copolymers obtained by graft polymerization in solution and based on polyethers in solid form
|
US7666973B2
(en)
|
2007-07-30 |
2010-02-23 |
Tyco Healthcare Group Lp |
Carbonate copolymers
|
US8679485B2
(en)
|
2007-08-02 |
2014-03-25 |
Gilead Biologics, Inc. |
Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
|
US20110269942A1
(en)
*
|
2007-08-09 |
2011-11-03 |
Daiichi Sankyo Company, Limited |
Antibodies modified with hydrophobic molecule
|
US8268958B2
(en)
|
2007-08-15 |
2012-09-18 |
Tyco Healthcare Group Ip |
Phospholipid copolymers
|
US20090048423A1
(en)
*
|
2007-08-15 |
2009-02-19 |
Tyco Healthcare Group Lp |
Phospholipid Copolymers
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
EP2197890A1
(en)
*
|
2007-09-07 |
2010-06-23 |
Gencia Corporation |
Mitochondrial compositions and uses thereof
|
US8865667B2
(en)
*
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
US20110014118A1
(en)
*
|
2007-09-21 |
2011-01-20 |
Lawrence Tamarkin |
Nanotherapeutic colloidal metal compositions and methods
|
EP2200932A4
(en)
*
|
2007-09-21 |
2014-09-10 |
Cytimmune Sciences Inc |
Nanotherapeutic colloidal metal compositions and methods
|
CN106310293A
(en)
|
2007-09-27 |
2017-01-11 |
免疫疫苗技术有限公司 |
Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
|
WO2009040426A1
(en)
|
2007-09-28 |
2009-04-02 |
Universitätsspital Basel |
Immunoliposomes for treatment of cancer
|
CA2700953A1
(en)
|
2007-10-02 |
2009-04-09 |
Amgen Inc. |
Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
|
US20100209452A1
(en)
*
|
2007-10-03 |
2010-08-19 |
Immunovaccine Technologies, Inc |
Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
|
MX2010003979A
(en)
*
|
2007-10-16 |
2010-06-02 |
Biocon Ltd |
An orally administerable solid pharmaceutical composition and a process thereof.
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
WO2009060124A2
(en)
*
|
2007-11-05 |
2009-05-14 |
Baltic Technology Development, Ltd. |
Use of oligonucleotides with modified bases in hybridization of nucleic acids
|
ES2557352T3
(en)
|
2007-11-05 |
2016-01-25 |
Medimmune, Llc |
Methods of treatment of scleroderma
|
PT2514436T
(en)
|
2007-11-07 |
2018-03-21 |
Genentech Inc |
Il-22 for use in treating microbial disorders
|
WO2010135521A2
(en)
|
2009-05-20 |
2010-11-25 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
DK2220116T3
(en)
|
2007-11-12 |
2012-11-26 |
Theraclone Sciences Inc |
COMPOSITIONS AND PROCEDURES FOR THE THERAPY AND DIAGNOSTICATION OF INFLUENZA
|
US8598165B2
(en)
*
|
2007-11-26 |
2013-12-03 |
University Of Kansas |
Morpholines as selective inhibitors of cytochrome P450 2A13
|
EP3524619A1
(en)
|
2007-12-06 |
2019-08-14 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against influenza virus and methods of use thereof
|
KR101603109B1
(en)
|
2007-12-07 |
2016-03-25 |
지모제넥틱스, 인코포레이티드 |
Humanized antibody molecules specific for il-31
|
EP2245159A2
(en)
|
2007-12-10 |
2010-11-03 |
Alnylam Pharmaceuticals Inc. |
Compositions and methods for inhibiting expression of factor vii gene
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
US8591898B2
(en)
|
2007-12-17 |
2013-11-26 |
Pfizer Limited |
Treatment of interstitial cystitis
|
US8962806B2
(en)
|
2007-12-28 |
2015-02-24 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
EP3100718B1
(en)
|
2008-01-02 |
2019-11-27 |
Arbutus Biopharma Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
US20090181094A1
(en)
*
|
2008-01-15 |
2009-07-16 |
Eric Yueh-Lang Sheu |
Molecular Cage for Sustained Release Control of Pharmaceutical and Cosmetic Agents
|
AR070141A1
(en)
*
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
SPECIFIC HUMANIZED ANTIBODIES FOR VON WILLEBRAND FACTOR
|
TWI472339B
(en)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
|
IL295449A
(en)
|
2008-01-31 |
2022-10-01 |
Genentech Inc |
Cycteine engineering anti-cd79b antibodies and antibody-drug conjugates
|
WO2009111315A2
(en)
*
|
2008-02-29 |
2009-09-11 |
Mayo Foundation For Medical Education And Research |
Methods for reducing granulomatous inflammation
|
WO2009111658A2
(en)
*
|
2008-03-05 |
2009-09-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 and vegf genes
|
AU2009223688B2
(en)
*
|
2008-03-10 |
2014-12-11 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
|
EP2105145A1
(en)
*
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Method for muscle-specific delivery lipid-conjugated oligonucleotides
|
AU2009228058A1
(en)
|
2008-03-28 |
2009-10-01 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to viral antigens
|
MX2010010562A
(en)
*
|
2008-03-31 |
2010-12-07 |
Metabolex Inc |
Oxymethylene aryl compounds and uses thereof.
|
BRPI0911332A2
(en)
|
2008-04-04 |
2019-09-24 |
Calando Pharmaceuticals Inc |
compositions and use of epas1 inhibitors
|
HUE036780T2
(en)
|
2008-04-09 |
2018-07-30 |
Genentech Inc |
Novel compositions and methods for the treatment of immune related diseases
|
AU2009234389B2
(en)
|
2008-04-10 |
2014-08-21 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting EGFR mutations in cancer
|
PL2279254T3
(en)
|
2008-04-15 |
2017-11-30 |
Protiva Biotherapeutics Inc. |
Novel lipid formulations for nucleic acid delivery
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
EP2280995A2
(en)
*
|
2008-04-29 |
2011-02-09 |
Wyeth LLC |
Methods for treating inflammation
|
US20090280134A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Recopharma Ab |
Compositions and methods for inhibiting toxin a from clostridium difficile
|
CA2722127A1
(en)
*
|
2008-05-09 |
2009-11-12 |
Recopharma Ab |
Compositions and methods for inhibiting shiga toxin and shiga-like toxin
|
EP2279004B1
(en)
|
2008-05-16 |
2015-01-14 |
F. Hoffmann-La Roche AG |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
CN102036658A
(en)
*
|
2008-05-23 |
2011-04-27 |
香港大学 |
Combination therapy for the treatment of influenza
|
JP5531332B2
(en)
|
2008-06-05 |
2014-06-25 |
株式会社島津製作所 |
Novel molecular assembly, molecular probe for molecular imaging and molecular probe for drug delivery system using the same, molecular imaging system and drug delivery system
|
AU2009253780B2
(en)
*
|
2008-06-05 |
2014-08-14 |
Immunovaccine Technologies Inc. |
Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
WO2009155431A1
(en)
*
|
2008-06-18 |
2009-12-23 |
University Of Louisville Research Foundation, Inc. |
Methods for targeted cancer treatment and detection
|
US20100003315A1
(en)
*
|
2008-07-02 |
2010-01-07 |
Willeford Kenneth L |
Method and Composition for the Treatment of Skin Conditions
|
WO2010005567A2
(en)
|
2008-07-08 |
2010-01-14 |
Oncomed Pharmaceuticals, Inc. |
Notch1 receptor binding agents and methods of use thereof
|
KR101647334B1
(en)
*
|
2008-07-10 |
2016-08-10 |
세리나 쎄라퓨틱스, 인코포레이티드 |
Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
|
US20100008900A1
(en)
*
|
2008-07-14 |
2010-01-14 |
The University Of Hong Kong |
Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
EP2323667A4
(en)
*
|
2008-08-07 |
2012-07-25 |
Isis Pharmaceuticals Inc |
Modulation of transthyretin expression for the treatment of cns related disorders
|
WO2010019702A2
(en)
|
2008-08-12 |
2010-02-18 |
Oncomed Pharmaceuticals, Inc. |
Ddr1-binding agents and methods of use thereof
|
EP2484666A1
(en)
|
2008-08-15 |
2012-08-08 |
Georgetown University |
Fluorescent regulators of RASSF1A expression and human cancer cell proliferation
|
DK2331092T3
(en)
*
|
2008-08-21 |
2014-05-19 |
Univ Johns Hopkins |
Methods and compositions for administering 3-halopyruvate and associated compounds for the treatment of cancer
|
DK2367812T3
(en)
|
2008-08-22 |
2015-12-21 |
Sanofi Sa |
[4- (5-aminomethyl-2-fluoro-phenyl) -piperidin-1-yl] - [7-fluoro-1- (2-methoxyethyl) -4-trifluoromethoxy-1H-indol-3-yl] methanone as an inhibitor of mast cell tryptase
|
EP3081648A1
(en)
|
2008-08-25 |
2016-10-19 |
Excaliard Pharmaceuticals, Inc. |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
AU2009288289B2
(en)
*
|
2008-08-25 |
2012-11-08 |
Amplimmune, Inc. |
PD-1 antagonists and methods of use thereof
|
CA2736799A1
(en)
|
2008-08-25 |
2010-03-11 |
Burnham Institute For Medical Research |
Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
|
PE20110435A1
(en)
|
2008-08-25 |
2011-07-20 |
Amplimmune Inc |
ANTAGONIST COMPOSITIONS OF PD-1
|
US8318693B2
(en)
|
2008-09-02 |
2012-11-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mutant EGFR gene
|
WO2010030813A2
(en)
|
2008-09-10 |
2010-03-18 |
Genentech, Inc. |
Methods for inhibiting ocular angiogenesis
|
TWI445716B
(en)
|
2008-09-12 |
2014-07-21 |
Rinat Neuroscience Corp |
Pcsk9 antagonists
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
US8796443B2
(en)
|
2008-09-22 |
2014-08-05 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
EP3109321B1
(en)
|
2008-09-25 |
2019-05-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
US9139554B2
(en)
|
2008-10-09 |
2015-09-22 |
Tekmira Pharmaceuticals Corporation |
Amino lipids and methods for the delivery of nucleic acids
|
US9173840B2
(en)
|
2008-10-09 |
2015-11-03 |
Northeastern University |
Multifunctional self-assembling polymeric nanosystems
|
NO2937418T3
(en)
|
2008-10-20 |
2018-03-17 |
|
|
US8147847B2
(en)
*
|
2008-10-21 |
2012-04-03 |
International Vaccine Institute |
Shigella protein antigens and methods
|
MX2011004125A
(en)
|
2008-10-21 |
2011-05-19 |
Metabolex Inc |
Aryl gpr120 receptor agonists and uses thereof.
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
AU2009312532B2
(en)
*
|
2008-11-06 |
2013-05-16 |
Ichnos Sciences SA |
Treatment with anti-alpha2 integrin antibodies
|
EP4241767A3
(en)
|
2008-11-10 |
2023-11-01 |
Arbutus Biopharma Corporation |
Novel lipids and compositions for the delivery of therapeutics
|
NZ592880A
(en)
|
2008-11-13 |
2013-06-28 |
Gilead Calistoga Llc |
Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
KR101807319B1
(en)
|
2008-11-22 |
2017-12-11 |
제넨테크, 인크. |
Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
|
WO2010068414A2
(en)
*
|
2008-11-25 |
2010-06-17 |
Bowen Richard L |
Methods for treating obesity related disease
|
US20110160222A1
(en)
*
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
EP2370580B1
(en)
|
2008-12-04 |
2019-09-11 |
CuRNA, Inc. |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
|
RU2746478C2
(en)
|
2008-12-04 |
2021-04-14 |
КьюРНА, Инк. |
Treatment of tumors of diseases related to the genom-suppressor by therapy of natural transcript inhibition in anti-significant orientation regarding this gene
|
CN102317458B
(en)
|
2008-12-04 |
2018-01-02 |
库尔纳公司 |
Pass through treatment of the suppression of erythropoietin(EPO) (EPO) natural antisense transcript to EPO relevant diseases
|
CA2746514C
(en)
|
2008-12-10 |
2018-11-27 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
WO2010068680A1
(en)
|
2008-12-10 |
2010-06-17 |
Mount Sinai School Of Medicine Of New York University |
Thelper cell type 17 lineage-specific adjuvants, compositions and methods
|
TW201034675A
(en)
|
2008-12-18 |
2010-10-01 |
Sanofi Aventis |
Method for treating macular degeneration
|
AR074760A1
(en)
*
|
2008-12-18 |
2011-02-09 |
Metabolex Inc |
GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME.
|
EP2381964B1
(en)
*
|
2008-12-22 |
2014-06-25 |
Creabilis S.a. |
Synthesis of polymer conjugates of indolocarbazole compounds
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
CA2748034A1
(en)
*
|
2008-12-23 |
2010-07-01 |
Pharmasset, Inc. |
Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections
|
PA8855601A1
(en)
|
2008-12-23 |
2010-07-27 |
|
NUCLEOSID FORFORMIDATES
|
CN102325783A
(en)
|
2008-12-23 |
2012-01-18 |
法莫赛特股份有限公司 |
Synthesis of purine nucleosides
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
EP3243504A1
(en)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
PT2396038E
(en)
|
2009-02-12 |
2016-02-19 |
Curna Inc |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
CN102439149B
(en)
|
2009-02-12 |
2018-01-02 |
库尔纳公司 |
By suppressing to treat the related diseases of GDNF for the natural antisense transcript of the glial derived neurotrophic factor (GDNF)
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
EP2403863B1
(en)
|
2009-03-02 |
2013-08-28 |
Alnylam Pharmaceuticals Inc. |
Nucleic acid chemical modifications
|
CA2754749C
(en)
|
2009-03-04 |
2019-04-30 |
Opko Curna, Llc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
|
NZ594995A
(en)
|
2009-03-12 |
2013-06-28 |
Alnylam Pharmaceuticals Inc |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
|
EP2228059A1
(en)
|
2009-03-12 |
2010-09-15 |
Universitätsspital Basel |
Chemotherapeutic composition for the treatment of cancer
|
ES2656290T3
(en)
|
2009-03-16 |
2018-02-26 |
Curna, Inc. |
Treatment of diseases related to nuclear factor (derived from erythroid 2) similar to 2 (NRF2) by inhibition of natural antisense transcript to NRF2
|
EP2408920B1
(en)
|
2009-03-17 |
2017-03-08 |
CuRNA, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
SI3260136T1
(en)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv) -neutralizing antibodies
|
CA2756347A1
(en)
|
2009-03-24 |
2010-09-30 |
Gilead Calistoga Llc |
Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
|
SG10201609416XA
(en)
|
2009-03-25 |
2016-12-29 |
Genentech Inc |
NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF
|
PE20120878A1
(en)
|
2009-04-01 |
2012-08-06 |
Genentech Inc |
ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES
|
KR101766927B1
(en)
|
2009-04-01 |
2017-08-09 |
제넨테크, 인크. |
Treatment of insulin-resistant disorders
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
WO2010123931A1
(en)
*
|
2009-04-20 |
2010-10-28 |
Calistoga Pharmaceuticals Inc. |
Methods of treatment for solid tumors
|
EP3248618A1
(en)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Innate immune suppression enables repeated delivery of long rna molecules
|
SG175305A1
(en)
|
2009-04-23 |
2011-11-28 |
Theraclone Sciences Inc |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
CN102459346B
(en)
|
2009-04-27 |
2016-10-26 |
昂考梅德药品有限公司 |
The method manufacturing heteromultimers molecule
|
EP2248903A1
(en)
|
2009-04-29 |
2010-11-10 |
Universitat Autònoma De Barcelona |
Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
|
US8524783B2
(en)
|
2009-04-30 |
2013-09-03 |
Intezyne Technologies, Incorporated |
Polymer micelles containing anthracylines for the treatment of cancer
|
US8524784B2
(en)
|
2009-04-30 |
2013-09-03 |
Intezyne Technologies, Incorporated |
Polymer micelles containing anthracylines for the treatment of cancer
|
CA2760589C
(en)
|
2009-05-01 |
2019-08-20 |
Joseph Collard |
Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
|
NZ621981A
(en)
|
2009-05-05 |
2015-09-25 |
Tekmira Pharmaceuticals Corp |
Lipid compositions
|
EP2427203B1
(en)
|
2009-05-05 |
2018-10-17 |
Novimmune S.A. |
Anti-il-17f antibodies and use thereof
|
CA3045126A1
(en)
|
2009-05-05 |
2010-11-11 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
KR101722541B1
(en)
|
2009-05-06 |
2017-04-04 |
큐알엔에이, 인크. |
Treatment of tristetraproline(ttp) related diseases by inhibition of natural antisense transcript to ttp
|
CN103223177B
(en)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
|
CA2762369C
(en)
|
2009-05-18 |
2021-12-28 |
Joseph Collard |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
TWI576352B
(en)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
Nucleoside phosphoramidates
|
WO2011019423A2
(en)
|
2009-05-20 |
2011-02-17 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
EP2432882B1
(en)
|
2009-05-22 |
2019-12-25 |
CuRNA, Inc. |
TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
|
CA2764683A1
(en)
|
2009-05-28 |
2010-12-02 |
Joseph Collard |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
HUE056773T2
(en)
|
2009-06-10 |
2022-03-28 |
Arbutus Biopharma Corp |
Improved lipid formulation
|
US20120100206A1
(en)
|
2009-06-11 |
2012-04-26 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Targeted liposomes comprising n-containing bisphosphonates and uses thereof
|
EP2443237B1
(en)
|
2009-06-16 |
2017-02-22 |
CuRNA, Inc. |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
JP6128846B2
(en)
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
Treatment of PON1 gene-related diseases by suppression of natural antisense transcripts against paraoxonase (PON1)
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
CN102597238B
(en)
|
2009-06-24 |
2016-06-29 |
库尔纳公司 |
The relevant disease of TNFR2 is treated by suppressing for the natural antisense transcript of tumor necrosis factor receptor 2 (TNFR2)
|
CN102482672B
(en)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
By suppressing the natural antisense transcript treatment Down syndrome gene-associated diseases of Down syndrome gene
|
AU2010265949B2
(en)
|
2009-06-26 |
2016-05-05 |
I2 Pharmaceuticals, Inc. |
Expression of surrogate light chains
|
WO2011000384A1
(en)
|
2009-06-30 |
2011-01-06 |
Общество С Ограниченной Ответсвенностью "Онкомакс" |
Method for suppressing tumor growth by blocking fibroblast growth factor receptor, and method for diagnosing malignant neoplasms
|
EP2449114B9
(en)
|
2009-07-01 |
2017-04-19 |
Protiva Biotherapeutics Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
US9018187B2
(en)
|
2009-07-01 |
2015-04-28 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
US8569256B2
(en)
|
2009-07-01 |
2013-10-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods for the delivery of therapeutic agents
|
CN102471381A
(en)
|
2009-07-07 |
2012-05-23 |
霍夫曼-拉罗奇有限公司 |
Diagnosis and treatment of autoimmune demyelinating diseases
|
US8920775B2
(en)
|
2009-07-17 |
2014-12-30 |
Technical University Of Denmark |
Loading technique for preparing radionuclide containing nanoparticles
|
JP2013500257A
(en)
|
2009-07-21 |
2013-01-07 |
ギリアード カリストガ エルエルシー |
Treatment of liver damage with PI3K inhibitors
|
WO2011017297A2
(en)
|
2009-08-03 |
2011-02-10 |
The University Of North Carolina At Chapel Hill |
Biodegradable delivery system complexes for the delivery of bioactive compounds
|
CN102762731B
(en)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
By inhibiting to treat insulin gene (INS) relevant disease for the natural antisense transcript of insulin gene (INS)
|
AP3574A
(en)
|
2009-08-14 |
2016-02-08 |
Alnylam Pharmaceuticals Inc |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
JP6088246B2
(en)
|
2009-08-15 |
2017-03-01 |
ジェネンテック, インコーポレイテッド |
Anti-angiogenic therapy for the treatment of previously treated breast cancer
|
FR2955324A1
(en)
|
2010-01-15 |
2011-07-22 |
Sanofi Aventis |
DISUBSTITUTED 4- (5-AMINOMETHYL-PHENYL) -PIPERIDIN-1-YL] -1H-INDOL-3-YL] -METHANONES
|
JP5964232B2
(en)
|
2009-08-25 |
2016-08-03 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of IQGAP-related diseases by inhibition of natural antisense transcripts against 'IQ motif-containing GTPase-activating protein' (IQGAP)
|
IN2012DN02753A
(en)
|
2009-08-31 |
2015-09-18 |
Amplimmune Inc |
|
US20110059111A1
(en)
|
2009-09-01 |
2011-03-10 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
|
JP5887270B2
(en)
|
2009-09-02 |
2016-03-16 |
ジェネンテック, インコーポレイテッド |
Mutant SMOOTHENED AND METHOD OF USING THE SAME
|
ES2497566T3
(en)
|
2009-10-01 |
2014-09-23 |
Cymabay Therapeutics, Inc. |
Tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
|
EP3252068A3
(en)
|
2009-10-12 |
2018-03-14 |
Larry J. Smith |
Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
|
MX368790B
(en)
*
|
2009-10-15 |
2019-10-16 |
Genentech Inc |
Chimeric fibroblast growth factors with altered receptor specificity.
|
ES2895226T3
(en)
|
2009-10-16 |
2022-02-18 |
Mereo Biopharma 5 Inc |
Therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
RU2539772C2
(en)
|
2009-10-22 |
2015-01-27 |
Дженентек, Инк. |
Methods and compositions for hepsin modulation of macrophage-stimulating protein
|
LT2496567T
(en)
|
2009-11-05 |
2017-11-27 |
Rhizen Pharmaceuticals S.A. |
Novel benzopyran kinase modulators
|
US20120244169A1
(en)
|
2009-11-06 |
2012-09-27 |
Fibrogen, Inc. |
Treatment for Radiation-Induced Disorders
|
WO2011062997A2
(en)
|
2009-11-17 |
2011-05-26 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
CN103755809B
(en)
|
2009-11-30 |
2016-06-01 |
霍夫曼-拉罗奇有限公司 |
The antibody of the tumour of SLC34A2 (TAT211=SEQID2) is expressed in treatment and diagnosis
|
CA2783372C
(en)
|
2009-12-07 |
2019-07-16 |
Muthiah Manoharan |
Compositions for nucleic acid delivery
|
US20120269830A1
(en)
|
2009-12-07 |
2012-10-25 |
Lawrence Horowitz |
Conjugates with improved pharmacokinetic properties
|
AU2010329847A1
(en)
|
2009-12-11 |
2012-07-26 |
Genecode As |
Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
|
WO2011081904A1
(en)
|
2009-12-14 |
2011-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Delivery of transthyretin across the blood-brain barrier as a treatment for alzheimer's disease
|
KR101823702B1
(en)
|
2009-12-16 |
2018-01-30 |
큐알엔에이, 인크. |
Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
|
US8691227B2
(en)
|
2009-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
|
ES2749426T3
(en)
|
2009-12-18 |
2020-03-20 |
Univ British Columbia |
Nucleic Acid Administration Methods and Compositions
|
CA2785439A1
(en)
|
2009-12-23 |
2011-06-30 |
Sanofi |
[4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
|
HUE028629T2
(en)
|
2009-12-23 |
2016-12-28 |
Synimmune Gmbh |
Anti-flt3 antibodies and methods of using the same
|
JP6031356B2
(en)
|
2009-12-23 |
2016-11-24 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of uncoupling protein 2 (UCP2) -related diseases by inhibition of natural antisense transcripts against UCP2.
|
CN102791702A
(en)
|
2009-12-23 |
2012-11-21 |
赛诺菲 |
Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1H-pyrrolo-pyridin-yl)-methanones and synthesis thereof
|
US8940708B2
(en)
|
2009-12-23 |
2015-01-27 |
Curna, Inc. |
Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
|
EP3450459B1
(en)
|
2009-12-28 |
2021-05-26 |
OncoTherapy Science, Inc. |
Anti-cdh3 antibodies and uses thereof
|
CA2785177C
(en)
|
2009-12-29 |
2019-09-24 |
Curna, Inc. |
Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
|
CN102782134B
(en)
|
2009-12-29 |
2017-11-24 |
库尔纳公司 |
NRF1 relevant diseases are treated by suppressing the natural antisense transcript of the core breathing factor 1 (NRF1)
|
WO2011082187A1
(en)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Methods for modulating a pdgf-aa mediated biological response
|
WO2011082409A2
(en)
|
2010-01-04 |
2011-07-07 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
|
WO2011085066A2
(en)
|
2010-01-06 |
2011-07-14 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
EP2522366B1
(en)
*
|
2010-01-08 |
2018-10-31 |
FUJIFILM Corporation |
Targeting agent for tumor site
|
EP2524039B1
(en)
|
2010-01-11 |
2017-11-29 |
CuRNA, Inc. |
Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
|
TWI535445B
(en)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt antagonists and methods of treatment and screening
|
WO2011088215A2
(en)
|
2010-01-13 |
2011-07-21 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
WO2011090971A2
(en)
|
2010-01-19 |
2011-07-28 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
WO2011089211A1
(en)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anti-cd133 antibodies and methods of using the same
|
RU2611192C2
(en)
|
2010-01-25 |
2017-02-21 |
Курна, Инк. |
TREATMENT OF RNase H1 RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNase H1
|
US8198337B2
(en)
*
|
2010-01-27 |
2012-06-12 |
Momentive Performance Materials Inc. |
Demulsifier compositions and methods for separating emulsions using the same
|
EP2531175A2
(en)
|
2010-02-01 |
2012-12-12 |
Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. |
Liposomes comprising amphipathic drugs and method for their preparation
|
US8962586B2
(en)
|
2010-02-22 |
2015-02-24 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
|
EP2539367A2
(en)
|
2010-02-23 |
2013-01-02 |
F. Hoffmann-La Roche AG |
Anti-angiogenesis therapy for the treatment of ovarian cancer
|
RU2545401C2
(en)
|
2010-02-23 |
2015-03-27 |
Санофи |
Anti-integrin alpha-2 antibodies and using them
|
AR080243A1
(en)
|
2010-02-23 |
2012-03-21 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT
|
AR080291A1
(en)
|
2010-02-24 |
2012-03-28 |
Rinat Neuroscience Corp |
ANTI-BODIES ANTAGONISTS ANTI RECEIVER OF IL-7 AND PROCEDURES
|
US8889193B2
(en)
|
2010-02-25 |
2014-11-18 |
The Johns Hopkins University |
Sustained delivery of therapeutic agents to an eye compartment
|
KR20120138241A
(en)
|
2010-03-11 |
2012-12-24 |
화이자 인코포레이티드 |
Antibodies with ph dependent antigen binding
|
MX354867B
(en)
|
2010-03-22 |
2018-03-23 |
Genentech Inc Star |
Compositions and methods useful for stabilizing protein-containing formulations.
|
US9080171B2
(en)
|
2010-03-24 |
2015-07-14 |
RXi Parmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
CA2793959C
(en)
|
2010-03-25 |
2019-06-04 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
CA2794708C
(en)
|
2010-03-29 |
2021-11-16 |
Zymeworks Inc. |
Antibodies with enhanced or suppressed effector function
|
AU2011235276B2
(en)
|
2010-03-29 |
2015-09-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
|
PT3178851T
(en)
|
2010-03-31 |
2020-07-17 |
Boehringer Ingelheim Int |
Anti-cd40 antibodies
|
TW201136945A
(en)
|
2010-03-31 |
2011-11-01 |
Pharmasset Inc |
Purine nucleoside phosphoramidate
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
SG184323A1
(en)
|
2010-03-31 |
2012-11-29 |
Gilead Pharmasett Llc |
Stereoselective synthesis of phosphorus containing actives
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
WO2011125015A2
(en)
|
2010-04-05 |
2011-10-13 |
Bar-Ilan University |
Protease-activatable pore-forming polypeptides
|
TWI644675B
(en)
|
2010-04-09 |
2018-12-21 |
可娜公司 |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
WO2011133868A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
US10913767B2
(en)
|
2010-04-22 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
EP3085387A1
(en)
|
2010-04-26 |
2016-10-26 |
Abraxis BioScience, LLC |
Sparc binding antibodies and uses thereof
|
WO2011135905A1
(en)
*
|
2010-04-28 |
2011-11-03 |
国立大学法人北海道大学 |
Lipid membrane structure
|
BR112012027547B1
(en)
|
2010-04-29 |
2022-06-14 |
Ionis Pharmaceuticals, Inc |
SINGLE STRIP MODIFIED OLIGONUCLEOTIDE, COMPOSITION, AND ITS USES TO TREAT TRANSTHIRRETIN AYLOIDOSIS, REDUCE ITS SYMPTOMS, AND TO REDUCE TRANSTHIRRETIN MRNA OR PROTEIN EXPRESSION
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
ES2552954T3
(en)
|
2010-04-30 |
2015-12-03 |
Alexion Pharmaceuticals, Inc. |
Anti-C5a antibodies and methods for the use of antibodies
|
KR101915115B1
(en)
|
2010-05-03 |
2018-11-05 |
큐알엔에이, 인크. |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
WO2011139718A1
(en)
|
2010-05-03 |
2011-11-10 |
Genentech, Inc. |
Compositions and methods useful for reducing the viscosity of protein-containing formulations
|
SG185027A1
(en)
|
2010-05-03 |
2012-11-29 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
JP5866106B2
(en)
|
2010-05-12 |
2016-02-17 |
コロンビア ユニヴァーシティ |
Method for producing enteroendocrine cells that produce and secrete insulin
|
TWI531370B
(en)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
|
CN103068824B
(en)
|
2010-05-17 |
2017-09-08 |
印蔻真治疗公司 |
It is used as new 3,5 2 substitution 3H imidazos [4,5 B] pyridine and 3,5 2 substitution 3H [1,2,3] triazol [4,5 B] pyridine compounds of protein kinase modulators
|
JP6267510B2
(en)
|
2010-05-18 |
2018-01-24 |
ニューメディシンズ,インコーポレーテッド |
IL-12 formulation for enhancing hematopoiesis
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
US8895528B2
(en)
|
2010-05-26 |
2014-11-25 |
Curna, Inc. |
Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
EP3957653A1
(en)
|
2010-06-02 |
2022-02-23 |
Dana Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
EP2576579B1
(en)
|
2010-06-02 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
IL300109A
(en)
|
2010-06-03 |
2023-03-01 |
Alnylam Pharmaceuticals Inc |
Biodegradable lipids for the delivery of active agents
|
US8299117B2
(en)
|
2010-06-16 |
2012-10-30 |
Metabolex Inc. |
GPR120 receptor agonists and uses thereof
|
WO2011159297A1
(en)
|
2010-06-16 |
2011-12-22 |
Metabolex, Inc. |
Gpr120 receptor agonists and uses thereof
|
US9566238B2
(en)
|
2010-06-19 |
2017-02-14 |
Western University Of Health Sciences |
Formulation of PEGylated-liposome encapsulated glycopeptide antibiotics
|
EP2585048B1
(en)
|
2010-06-23 |
2018-04-11 |
CymaBay Therapeutics, Inc. |
Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
AU2011270828B2
(en)
|
2010-06-24 |
2015-09-24 |
Genentech, Inc. |
Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
|
CN102309448B
(en)
*
|
2010-06-29 |
2014-07-09 |
中国人民解放军军事医学科学院毒物药物研究所 |
Pulmonary delivery ciprofloxacin pharmaceutical composition and preparation method thereof
|
WO2012000104A1
(en)
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
LT3243526T
(en)
|
2010-07-06 |
2020-02-10 |
Glaxosmithkline Biologicals S.A. |
Delivery of rna to trigger multiple immune pathways
|
BR112013000244A2
(en)
|
2010-07-06 |
2016-05-17 |
Novartis Ag |
lipid liposomes having advantageous pka for administration of rna
|
PL2590676T3
(en)
|
2010-07-06 |
2017-02-28 |
Glaxosmithkline Biologicals Sa |
Virion-like delivery particles for self-replicating rna molecules
|
JP5940064B2
(en)
|
2010-07-06 |
2016-06-29 |
ノバルティス アーゲー |
Immunization of large mammals with low doses of RNA
|
US20120208855A1
(en)
|
2010-07-12 |
2012-08-16 |
Sanofi |
Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
|
MX2013000491A
(en)
|
2010-07-12 |
2013-02-26 |
Covx Technologies Ireland Ltd |
Multifunctional antibody conjugates.
|
US8980860B2
(en)
|
2010-07-14 |
2015-03-17 |
Curna, Inc. |
Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
|
JP2013538191A
(en)
|
2010-07-23 |
2013-10-10 |
トラスティーズ オブ ボストン ユニバーシティ |
Anti-DEsupR inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US20130323269A1
(en)
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
WO2012019093A1
(en)
|
2010-08-05 |
2012-02-09 |
Human Biomolecular Research Institute |
Synthetic compounds and methods to decrease nicotine self-administration
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
AU2011289275A1
(en)
|
2010-08-12 |
2013-02-21 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
EP4066819B1
(en)
|
2010-08-31 |
2023-03-01 |
GlaxoSmithKline Biologicals SA |
Small liposomes for delivery of immunogen-encoding rna
|
WO2012030904A2
(en)
|
2010-08-31 |
2012-03-08 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
SI2611461T1
(en)
|
2010-08-31 |
2022-08-31 |
Glaxosmithkline Biologicals Sa |
Pegylated liposomes for delivery of immunogen-encoding rna
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
EP2625197B1
(en)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN103210086B
(en)
|
2010-10-06 |
2017-06-09 |
库尔纳公司 |
NEU4 relevant diseases are treated by suppressing the natural antisense transcript of sialidase 4 (NEU4)
|
AU2011316707A1
(en)
|
2010-10-11 |
2013-05-09 |
Novartis Ag |
Antigen delivery platforms
|
EP2630241B1
(en)
|
2010-10-22 |
2018-10-17 |
CuRNA, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
EP2633317A1
(en)
|
2010-10-25 |
2013-09-04 |
Genentech, Inc. |
Treatment of gastrointestinal inflammation and psoriasis a
|
JP6073795B2
(en)
|
2010-10-27 |
2017-02-01 |
カッパーアールエヌエー,インコーポレイテッド |
Treatment of IFRD1-related diseases by inhibition of natural antisense transcripts to interferon-related developmental regulator 1 (IFRD1)
|
EP3456740A1
(en)
|
2010-11-04 |
2019-03-20 |
Boehringer Ingelheim International GmbH |
Anti-il-23 antibodies
|
WO2012061811A2
(en)
|
2010-11-05 |
2012-05-10 |
Fibrogen, Inc. |
Treatment method for lung remodeling diseases
|
CN110123830A
(en)
|
2010-11-09 |
2019-08-16 |
阿尔尼拉姆医药品有限公司 |
Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare
|
WO2012065044A2
(en)
|
2010-11-12 |
2012-05-18 |
Purdue Research Foundation |
Treating bladder tumor cells using fibronectin attachment protein as a target
|
EP2640831A1
(en)
|
2010-11-17 |
2013-09-25 |
Sea Lane Biotechnologies,llc. |
Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
|
RU2018102375A
(en)
|
2010-11-18 |
2019-02-21 |
Зе Дженерал Хоспитал Корпорейшен |
NEW COMPOSITIONS AND APPLICATIONS OF ANTIHYPERTENSIVE MEDICINES FOR CANCER THERAPY
|
KR102010598B1
(en)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog
|
CA2818853A1
(en)
|
2010-11-30 |
2012-06-07 |
Gilead Pharmasset Llc |
2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
EP2649182A4
(en)
|
2010-12-10 |
2015-05-06 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for increasing erythropoietin (epo) production
|
JP5947807B2
(en)
|
2010-12-14 |
2016-07-06 |
テクニカル ユニバーシティ オブ デンマークTechnical University Of Denmark |
Encapsulation of radionuclides in nanoparticle compositions
|
EP2468259A1
(en)
*
|
2010-12-23 |
2012-06-27 |
Traslational Cancer Drugs Pharma, S.L. |
Pharmaceutical compositions of pyridinium and quinolinium derivatives
|
CA2834968C
(en)
|
2011-01-05 |
2018-01-09 |
Livon Laboratories |
Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
|
WO2012099755A1
(en)
|
2011-01-11 |
2012-07-26 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
AU2012206945B2
(en)
|
2011-01-11 |
2015-02-19 |
Dimerix Bioscience Pty Ltd |
Combination therapy
|
KR101697396B1
(en)
|
2011-02-02 |
2017-01-17 |
엑스칼리아드 파마슈티컬즈, 인코포레이티드 |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
|
RU2440142C1
(en)
|
2011-02-07 |
2012-01-20 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Antibody, stopping or retarding tumour growth (versions), method of suppressing tumour growth, method of diagnosing malignant lesions
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
AU2012217867A1
(en)
|
2011-02-14 |
2013-09-05 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
PL226015B1
(en)
*
|
2011-03-03 |
2017-06-30 |
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną |
Liposome preparation containing anticancer active substance, process for the preparation thereof and pharmaceutical compositions containing thereof
|
KR101938343B1
(en)
|
2011-03-09 |
2019-01-14 |
셀 시그널링 테크놀러지, 인크. |
Methods and reagents for creating monoclonal antibodies
|
MX2013010367A
(en)
|
2011-03-15 |
2014-04-14 |
Theraclone Sciences Inc |
Compositions and methods for the therapy and diagnosis of influenza.
|
EP2686340A2
(en)
|
2011-03-16 |
2014-01-22 |
Amgen Inc. |
Potent and selective inhibitors of nav1.3 and nav1.7
|
US10184942B2
(en)
|
2011-03-17 |
2019-01-22 |
University Of South Florida |
Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
|
WO2012134975A1
(en)
|
2011-03-28 |
2012-10-04 |
St. Jude Children's Research Hospital |
Methods and compositions employing immunogenic fusion proteins
|
MX360349B
(en)
|
2011-03-29 |
2018-10-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of tmprss6 gene.
|
EP3412309A1
(en)
|
2011-03-31 |
2018-12-12 |
F. Hoffmann-La Roche AG |
Methods of administering beta7 integrin antagonists
|
EP2508176A1
(en)
|
2011-04-08 |
2012-10-10 |
Lipotarg Gmbh |
Novel combination treatment of cancer
|
CA2832972C
(en)
|
2011-04-13 |
2019-04-30 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
RU2625034C2
(en)
|
2011-04-20 |
2017-07-11 |
МЕДИММЬЮН, ЭлЭлСи |
Antibodies and other molecules binding b7-h1 and pd-1
|
KR101589135B1
(en)
|
2011-04-20 |
2016-01-29 |
주식회사 셀앤바이오 |
Humanized anti-EMAPII antibodies and uses thereof
|
RS58326B1
(en)
|
2011-05-04 |
2019-03-29 |
Rhizen Pharmaceuticals S A |
Novel compounds as modulators of protein kinases
|
CN103842383B
(en)
|
2011-05-16 |
2017-11-03 |
健能隆医药技术(上海)有限公司 |
Polyspecific FAB fusion proteins and its application method
|
SG195252A1
(en)
|
2011-06-02 |
2013-12-30 |
Harvard College |
Methods and uses for ex vivo tissue culture systems
|
CA2838588C
(en)
|
2011-06-09 |
2021-09-14 |
Curna, Inc. |
Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
|
AU2012267786B2
(en)
|
2011-06-10 |
2017-08-03 |
Oregon Health & Science University |
CMV glycoproteins and recombinant vectors
|
CN103597074A
(en)
|
2011-06-16 |
2014-02-19 |
Isis制药公司 |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
EP2723351B1
(en)
|
2011-06-21 |
2018-02-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
AU2012272908A1
(en)
|
2011-06-21 |
2013-12-19 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
EP2723756B1
(en)
|
2011-06-21 |
2020-03-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
|
EP2537532A1
(en)
|
2011-06-22 |
2012-12-26 |
J. Stefan Institute |
Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
|
US20140235693A1
(en)
|
2011-06-23 |
2014-08-21 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
CN103765212A
(en)
|
2011-06-27 |
2014-04-30 |
杰克逊实验室 |
Methods and compositions for treatment of cancer and autoimmune disease
|
WO2013003652A1
(en)
|
2011-06-28 |
2013-01-03 |
Sea Lane Biotechnologies, Llc |
Multispecific stacked variable domain binding proteins
|
ES2656050T3
(en)
|
2011-07-06 |
2018-02-22 |
Glaxosmithkline Biologicals Sa |
Immunogenic combination compositions and uses thereof
|
DK2731591T3
(en)
|
2011-07-13 |
2020-09-21 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
LIPOSOMES WHICH ENCAPLATE A BISPHOSPHONATE AND AN AMFIFILATE
|
EP2731623A1
(en)
|
2011-07-14 |
2014-05-21 |
Pfizer Inc |
Treatment with anti-pcsk9 antibodies
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US20140328811A1
(en)
|
2011-08-01 |
2014-11-06 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
AU2012296613B2
(en)
|
2011-08-15 |
2016-05-12 |
Amplimmune, Inc. |
Anti-B7-H4 antibodies and their uses
|
FR2979239A1
(en)
*
|
2011-08-25 |
2013-03-01 |
Trophos |
LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
CA2847057C
(en)
|
2011-08-31 |
2019-06-11 |
St. Jude Children's Research Hospital |
Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
|
MY170725A
(en)
|
2011-09-09 |
2019-08-27 |
Univ Osaka |
Dengue-virus serotype neutralizing antibodies
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
AU2012312654B2
(en)
|
2011-09-19 |
2017-04-13 |
Gencia Corporation |
Modified creatine compounds
|
EP2758533B1
(en)
|
2011-09-20 |
2018-04-11 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of gcgr expression
|
PE20141537A1
(en)
|
2011-09-23 |
2014-11-17 |
Oncomed Pharm Inc |
AGENTS OF LINKING THE VASCULAR ENDOTHELIAL GROWTH FACTOR / LIGANDO 4 SIMILAR TO DELTA (VEGF / DLL4) AND USES OF THE SAME
|
JP2014533929A
(en)
|
2011-09-23 |
2014-12-18 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハー |
Bispecific binding molecules for 5T4 and CD3
|
EP2758434A2
(en)
|
2011-09-23 |
2014-07-30 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA |
Anti-tumor necrosis factor-alpha agents and uses thereof
|
WO2013049328A1
(en)
|
2011-09-27 |
2013-04-04 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
JP6368645B2
(en)
|
2011-09-29 |
2018-08-01 |
ピーエルエックス オプコ インコーポレーテッド |
PH-dependent carriers for targeted release of drugs along the gastrointestinal tract, compositions thereby, and their manufacture and use
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
SG11201401177WA
(en)
|
2011-10-06 |
2014-04-28 |
Immunovaccine Technologies Inc |
Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
|
KR102102862B1
(en)
|
2011-10-14 |
2020-04-22 |
제넨테크, 인크. |
ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
|
US8883989B2
(en)
|
2011-10-18 |
2014-11-11 |
Regents Of The University Of Minnesota |
Fractalkine binding polynucleotides and methods of use
|
CA2853373A1
(en)
|
2011-10-25 |
2013-05-02 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of gccr expression
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
KR20140097205A
(en)
|
2011-10-28 |
2014-08-06 |
제넨테크, 인크. |
Therapeutic combinations and methods of treating melanoma
|
EP3091029B1
(en)
|
2011-10-31 |
2022-12-28 |
F. Hoffmann-La Roche AG |
Anti-il13 antibody formulations
|
JP6205095B2
(en)
*
|
2011-11-03 |
2017-09-27 |
タイワン リポサム カンパニー、エルティーディー. |
Pharmaceutical composition of hydrophobic camptothecin derivative
|
US10980798B2
(en)
|
2011-11-03 |
2021-04-20 |
Taiwan Liposome Company, Ltd. |
Pharmaceutical compositions of hydrophobic camptothecin derivatives
|
BR112014011331A2
(en)
|
2011-11-11 |
2017-04-25 |
Rinat Neuroscience Corp |
trop-2 specific antibodies and their uses
|
TWI679212B
(en)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
Binding molecules for e3 of bcma and cd3
|
EP3536710A1
(en)
|
2011-11-16 |
2019-09-11 |
Boehringer Ingelheim International GmbH |
Anti il-36r antibodies
|
US9493532B2
(en)
|
2011-12-15 |
2016-11-15 |
The University Of Chicago |
Compositions for cancer therapy using mutant light molecules with increased affinity to receptors
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
EP2794659A1
(en)
|
2011-12-22 |
2014-10-29 |
Rinat Neuroscience Corp. |
Human growth hormone receptor antagonist antibodies and methods of use thereof
|
US11147852B2
(en)
|
2011-12-23 |
2021-10-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
CA2863216C
(en)
|
2012-01-09 |
2020-06-02 |
Covx Technologies Ireland Limited |
Mutant antibodies and conjugation thereof
|
EP2804620A4
(en)
|
2012-01-18 |
2016-04-13 |
Neumedicines Inc |
Il-12 for radiation protection and radiation-induced toxicity mitigation
|
EP2804631B1
(en)
|
2012-01-20 |
2021-03-17 |
i2 Pharmaceuticals, Inc. |
Surrobody conjugates
|
US20150004219A1
(en)
|
2012-02-02 |
2015-01-01 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Stable liposomes for drug delivery
|
EA034778B1
(en)
|
2012-02-06 |
2020-03-19 |
Инхибркс, Инк. |
Cd47 antibodies and methods of use thereof
|
CA2864469C
(en)
*
|
2012-02-17 |
2020-07-07 |
Celsion Corporation |
Thermosensitive nanoparticle formulations and method of making the same
|
US9138492B2
(en)
*
|
2012-02-23 |
2015-09-22 |
Canon Kabushiki Kaisha |
Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle
|
WO2013128027A1
(en)
|
2012-03-01 |
2013-09-06 |
Amgen Research (Munich) Gmbh |
Long life polypeptide binding molecules
|
AP2014007875A0
(en)
|
2012-03-05 |
2014-08-31 |
Gilead Calistoga Llc |
Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
|
KR20140136488A
(en)
|
2012-03-15 |
2014-11-28 |
큐알엔에이, 인크. |
Treatment of brain derived neurotrophic factor(bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
US9453076B2
(en)
|
2012-03-29 |
2016-09-27 |
Novimmune S.A. |
Anti-TLR4 antibodies and uses thereof
|
MX359888B
(en)
|
2012-03-30 |
2018-10-15 |
Rhizen Pharmaceuticals Sa |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases.
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
AU2013252909B2
(en)
|
2012-04-24 |
2017-09-28 |
University Of Miami |
Perforin 2 defense against invasive and multidrug resistant pathogens
|
US11078265B2
(en)
|
2012-05-03 |
2021-08-03 |
Boehringer Ingelheim International Gmbh |
Anti-IL-23 antibodies
|
US9441045B2
(en)
|
2012-05-04 |
2016-09-13 |
Dana-Farber Cancer Institute, Inc. |
Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
|
AU2013256008B2
(en)
|
2012-05-04 |
2016-02-25 |
The Johns Hopkins University |
Lipid-based drug carriers for rapid penetration through mucus linings
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
US9789193B2
(en)
|
2012-06-15 |
2017-10-17 |
The Brigham And Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
WO2013192546A1
(en)
|
2012-06-22 |
2013-12-27 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and mehtods of using the same
|
EP2679596B1
(en)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 env glycoprotein variant
|
AU2013292647B2
(en)
|
2012-07-18 |
2018-03-15 |
Onyx Therapeutics, Inc. |
Liposomal compositions of epoxyketone-based proteasome inhibitors
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
CN103565745A
(en)
|
2012-08-10 |
2014-02-12 |
德克萨斯州大学系统董事会 |
Neuroprotective liposome compositions and methods for treatment of stroke
|
WO2014027959A1
(en)
|
2012-08-14 |
2014-02-20 |
Nanyang Technological University |
Angiopoietin-like 4 antibody and a method of its use in cancer treatment
|
DK2892524T3
(en)
|
2012-09-04 |
2021-01-25 |
Eleison Pharmaceuticals LLC |
PREVENTION OF PULMONAL CANCER RECYCLING WITH LIPID-COMPLEXED CISPLATIN
|
US20160136159A1
(en)
|
2012-09-17 |
2016-05-19 |
Chemedest Ltd. |
Method for Treating Peripheral Neuropathy
|
CN107892719B
(en)
|
2012-10-04 |
2022-01-14 |
达纳-法伯癌症研究所公司 |
Human monoclonal anti-PD-L1 antibodies and methods of use
|
WO2014055824A1
(en)
|
2012-10-05 |
2014-04-10 |
Genentech, Inc. |
Methods for diagnosing and treating inflammatory bowel disease
|
CA2887711A1
(en)
|
2012-10-23 |
2014-05-01 |
Oncomed Pharmaceuticals, Inc. |
Methods of treating neuroendocrine tumors using wnt pathway-binding agents
|
EP2914961A4
(en)
|
2012-10-31 |
2016-04-20 |
Oncomed Pharm Inc |
Methods and monitoring of treatment with a dll4 antagonist
|
RU2019118257A
(en)
|
2012-12-03 |
2019-06-24 |
Новиммун С.А. |
ANTI-CD47 ANTIBODIES AND METHODS OF THEIR APPLICATION
|
WO2014092858A1
(en)
|
2012-12-12 |
2014-06-19 |
Temple University - Of The Commonwealth System Of Higher Education |
Compositions and methods for treatment of cancer
|
WO2014100439A2
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
ES2764090T3
(en)
|
2012-12-19 |
2020-06-02 |
Univ New York State Res Found |
Compositions and Procedure for Light Activated Release of Nanovesicle Materials
|
GB201223053D0
(en)
|
2012-12-20 |
2013-02-06 |
Medical Res Council |
Receptor
|
EP2935311B1
(en)
|
2012-12-20 |
2021-03-31 |
Amgen Inc. |
Apj receptor agonists and uses thereof
|
BR112015014621A2
(en)
|
2012-12-21 |
2017-10-03 |
Amplimmune Inc |
ANTI-H7CR ANTIBODIES
|
US9566325B2
(en)
|
2013-01-07 |
2017-02-14 |
Biomedical Research Models, Inc. |
Therapeutic vaccines for treating herpes simplex virus type-2 infections
|
US9920121B2
(en)
|
2013-01-25 |
2018-03-20 |
Amgen Inc. |
Antibodies targeting CDH19 for melanoma
|
JO3519B1
(en)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
Antibody constructs for CDH19 and CD3
|
US10568975B2
(en)
|
2013-02-05 |
2020-02-25 |
The Johns Hopkins University |
Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
|
ES2944477T3
(en)
|
2013-02-06 |
2023-06-21 |
Inhibrx Inc |
Non-Platelet Reducing and Non-Red Cell Reducing CD47 Antibodies and Methods of Using Them
|
EP2956169B1
(en)
|
2013-02-12 |
2018-04-11 |
THE UNITED STATES OF AMERICA, represented by the S |
Monoclonal antibodies that neutralize norovirus
|
US10344060B2
(en)
|
2013-03-12 |
2019-07-09 |
Amgen Inc. |
Potent and selective inhibitors of Nav1.7
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
AU2014236559B2
(en)
|
2013-03-14 |
2020-03-12 |
Julie HUGHES |
Cholestosome vesicles for incorporation of molecules into chylomicrons
|
US9707244B2
(en)
|
2013-03-15 |
2017-07-18 |
Gencia Corporation |
Compositions and methods for treating conditions that affect epidermis
|
MX367668B
(en)
|
2013-03-15 |
2019-08-30 |
Dana Farber Cancer Inst Inc |
Flavivirus neutralizing antibodies and methods of use thereof.
|
AU2014240045A1
(en)
|
2013-03-15 |
2015-09-10 |
Dyax Corp. |
Anti-plasma kallikrein antibodies
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
EP2970446A1
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Research (Munich) GmbH |
Antibody constructs for influenza m2 and cd3
|
AR095374A1
(en)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
UNION MOLECULES FOR BCMA AND CD3
|
US11156608B2
(en)
|
2013-03-15 |
2021-10-26 |
The Trustees Of The University Of Pennsylvania |
Method for the site-specific covalent cross-linking of antibodies to surfaces
|
CA2907175C
(en)
*
|
2013-03-15 |
2022-11-08 |
M. Alphabet 3, L.L.C. |
Methods and compositions for enhancing oxygen levels in tissues
|
WO2014140358A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Single chain binding molecules comprising n-terminal abp
|
US10052364B2
(en)
|
2013-03-15 |
2018-08-21 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
EP3495814A3
(en)
|
2013-03-27 |
2019-07-17 |
F. Hoffmann-La Roche AG |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
CA2918194C
(en)
|
2013-03-27 |
2022-12-06 |
The General Hospital Corporation |
Methods and agents for treating alzheimer's disease
|
KR20220044380A
(en)
|
2013-04-12 |
2022-04-07 |
이칸 스쿨 오브 메디슨 엣 마운트 시나이 |
Method for treating post-traumatic stress disorder
|
JP2016518140A
(en)
|
2013-05-03 |
2016-06-23 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Method for inducing cyclic dinucleotide of type I interferon
|
AR096203A1
(en)
|
2013-05-06 |
2015-12-16 |
Alnylam Pharmaceuticals Inc |
DOSAGES AND METHODS FOR MANAGING NUCLEIC ACID MOLECULES FORMULATED IN LIPIDS
|
PL2981822T3
(en)
|
2013-05-06 |
2021-07-12 |
Scholar Rock, Inc. |
Compositions and methods for growth factor modulation
|
SG11201508264UA
(en)
|
2013-05-07 |
2015-11-27 |
Rinat Neuroscience Corp |
Anti-glucagon receptor antibodies and methods of use thereof
|
EP2994163B1
(en)
|
2013-05-09 |
2019-08-28 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
|
WO2014190356A2
(en)
|
2013-05-24 |
2014-11-27 |
Amplimmune, Inc. |
Anti-b7-h5 antibodies and their uses
|
SG11201509839TA
(en)
|
2013-05-31 |
2016-01-28 |
Genentech Inc |
Anti-wall teichoic antibodies and conjugates
|
CA2913011A1
(en)
|
2013-05-31 |
2014-12-04 |
Genentech, Inc. |
Anti-wall teichoic antibodies and conjugates
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
WO2014197938A1
(en)
|
2013-06-13 |
2014-12-18 |
Antisense Therapeutics Ltd |
Combination therapy
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
ES2683268T3
(en)
|
2013-07-25 |
2018-09-25 |
Cytomx Therapeutics, Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods for using them
|
US20160193148A1
(en)
*
|
2013-08-01 |
2016-07-07 |
University Of Georgia Research Foundation, Inc. |
Liposomal formulations for the treatment of bacterial infections
|
MX371455B
(en)
|
2013-08-02 |
2020-01-28 |
Pfizer |
Anti-cxcr4 antibodies and antibody-drug conjugates.
|
JP6463359B2
(en)
|
2013-08-12 |
2019-01-30 |
ジェネンテック, インコーポレイテッド |
Compositions and methods for treating complement related conditions
|
CA2921398C
(en)
|
2013-08-14 |
2021-12-14 |
The Governing Council Of The University Of Toronto |
Antibodies for inhibiting frizzled receptors and pharmaceutical compositions containing antibodies for inhibiting frizzled receptors
|
EP3038600B1
(en)
*
|
2013-08-27 |
2020-06-03 |
Northeastern University |
Nanoparticle drug delivery system and method of treating cancer and neurotrauma
|
CA2930859C
(en)
|
2013-09-04 |
2022-05-03 |
Cold Spring Harbor Laboratory |
Reducing nonsense-mediated mrna decay
|
EP2848937A1
(en)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Methods of identifying novel HIV-1 immunogens
|
WO2015035231A1
(en)
|
2013-09-05 |
2015-03-12 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
TWI688401B
(en)
|
2013-09-13 |
2020-03-21 |
美商安進公司 |
Combination of epigenetic factors and bispecific compounds targeting cd33 and cd3 in the treatment of myeloid leukemia
|
US20160228364A1
(en)
*
|
2013-09-16 |
2016-08-11 |
Glycomine, Inc. |
Pharmaceutical preparation of carbohydrates for therapeutic use
|
DE102013015334A1
(en)
*
|
2013-09-17 |
2015-03-19 |
Fresenius Medical Care Deutschland Gmbh |
Magnesium-liposome complexes
|
US10036020B2
(en)
|
2013-09-19 |
2018-07-31 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for inhibiting JC virus (JCV)
|
NZ756892A
(en)
|
2013-09-25 |
2022-05-27 |
Cytomx Therapeutics Inc |
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
|
WO2015050663A1
(en)
|
2013-10-01 |
2015-04-09 |
Mayo Foundation For Medical Education And Research |
Methods for treating cancer in patients with elevated levels of bim
|
EP3052626A1
(en)
|
2013-10-02 |
2016-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
PE20161130A1
(en)
|
2013-10-04 |
2016-11-25 |
Icahn School Med Mount Sinai |
COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF THE ALAS1 GENE
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP3070167A4
(en)
|
2013-11-06 |
2017-06-07 |
Osaka University |
Antibody having broad neutralizing activity in group 1 influenza a virus
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
EP3080611B1
(en)
|
2013-12-13 |
2018-11-14 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
US9708327B2
(en)
|
2013-12-20 |
2017-07-18 |
Gilead Calistoga Llc |
Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
|
MX2016008259A
(en)
|
2013-12-20 |
2016-10-13 |
Gilead Calistoga Llc |
Process methods for phosphatidylinositol 3-kinase inhibitors.
|
EP3094317B1
(en)
|
2014-01-14 |
2019-10-02 |
The Johns Hopkins University |
Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof
|
EP3099715B1
(en)
|
2014-01-31 |
2020-11-18 |
Boehringer Ingelheim International GmbH |
Novel anti-baff antibodies
|
CN106459153B
(en)
|
2014-01-31 |
2021-12-21 |
西托姆克斯治疗公司 |
Substrates and other cleavable moieties for proteolytic enzymes and U-type plasminogen activators and methods of use thereof
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP3450571B1
(en)
|
2014-02-24 |
2023-04-05 |
Celgene Corporation |
Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
EP4043489A1
(en)
|
2014-03-19 |
2022-08-17 |
Dana-Farber Cancer Institute, Inc. |
Immunogenetic restriction on elicitation of antibodies
|
US9896502B2
(en)
|
2014-03-21 |
2018-02-20 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
AR099856A1
(en)
|
2014-03-27 |
2016-08-24 |
Genentech Inc |
METHODS TO DIAGNOSE AND TREAT INFLAMMED INTESTINE DISEASE
|
CA2944401A1
(en)
|
2014-04-03 |
2015-10-08 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
KR20160145813A
(en)
|
2014-04-25 |
2016-12-20 |
다나-파버 캔서 인스티튜트 인크. |
Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
|
RS61516B1
(en)
|
2014-04-30 |
2021-03-31 |
Pfizer |
Anti-ptk7 antibody-drug conjugates
|
WO2015168474A1
(en)
|
2014-04-30 |
2015-11-05 |
President And Fellows Of Harvard College |
Fusion proteins for treating cancer and related methods
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
ES2936810T3
(en)
|
2014-05-16 |
2023-03-22 |
Pfizer |
Bispecific antibodies with engineered CH1-CL interfaces
|
WO2015179654A1
(en)
|
2014-05-22 |
2015-11-26 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti b7-h1 antibodies
|
EA028614B1
(en)
|
2014-05-22 |
2017-12-29 |
Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" |
Selective inhibitors interfering with fibroblast growth factor receptor and frs2 interaction for the prevention and treatment of cancer
|
PT3148581T
(en)
|
2014-05-30 |
2020-01-06 |
Henlix Biotech Co Ltd |
Anti-epidermal growth factor receptor (egfr) antibodies
|
WO2015191781A2
(en)
|
2014-06-10 |
2015-12-17 |
Amgen Inc. |
Apelin polypeptides
|
EA201692202A1
(en)
|
2014-06-11 |
2017-06-30 |
Джилид Сайэнс, Инк. |
METHODS OF TREATING CARDIOVASCULAR DISEASES
|
MX2016016530A
(en)
|
2014-06-13 |
2017-03-27 |
Gilead Sciences Inc |
Phosphatidylinositol 3-kinase inhibitors.
|
TWI695011B
(en)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
Monoclonal antibodies against her2 epitope and methods of use thereof
|
US10562946B2
(en)
|
2014-06-20 |
2020-02-18 |
Genentech, Inc. |
Chagasin-based scaffold compositions, methods, and uses
|
US10487314B2
(en)
|
2014-06-26 |
2019-11-26 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
|
US10517875B2
(en)
|
2014-07-23 |
2019-12-31 |
Mayo Foundation for Medical Engineering and Research |
Targeting DNA-PKcs and B7-H1 to treat cancer
|
US10669337B2
(en)
|
2014-07-25 |
2020-06-02 |
Cytomx Therapeutics, Inc. |
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
|
CA2956471A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
UY36245A
(en)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
|
US20170224816A1
(en)
|
2014-08-06 |
2017-08-10 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
WO2016034968A1
(en)
|
2014-09-02 |
2016-03-10 |
Pfizer Inc. |
Therapeutic antibody
|
WO2016046684A1
(en)
|
2014-09-23 |
2016-03-31 |
Pfizer Inc. |
Treatment with anti-pcsk9 antibodies
|
WO2016054638A1
(en)
|
2014-10-03 |
2016-04-07 |
Dana-Farber Cancer Institute, Inc. |
Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
|
GB201417589D0
(en)
|
2014-10-06 |
2014-11-19 |
Cantab Biopharmaceuticals Patents Ltd |
Pharmaceutical Formulations
|
AU2015328273B2
(en)
|
2014-10-06 |
2020-09-17 |
Dana-Farber Cancer Institute, Inc. |
Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
|
ES2808153T3
(en)
|
2014-10-31 |
2021-02-25 |
Mereo Biopharma 5 Inc |
Combination therapy for disease treatment
|
US20170306046A1
(en)
|
2014-11-12 |
2017-10-26 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
WO2016077566A1
(en)
|
2014-11-12 |
2016-05-19 |
Research Institute At Nationwide Children's Hospital |
Modulation of alternative mdm2 splicing
|
JP7175608B2
(en)
|
2014-11-19 |
2022-11-21 |
ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク |
Osteocalcin as a treatment for age-related frailty
|
WO2016090038A1
(en)
|
2014-12-03 |
2016-06-09 |
Genentech, Inc. |
Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
|
MX2017007231A
(en)
|
2014-12-03 |
2017-11-08 |
Genentech Inc |
Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof.
|
US10072070B2
(en)
|
2014-12-05 |
2018-09-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Potent anti-influenza A neuraminidase subtype N1 antibody
|
TWI595006B
(en)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
Anti-pd-1 antibodies and methods of use thereof
|
KR20170087500A
(en)
|
2014-12-11 |
2017-07-28 |
피에르 파브르 메디카먼트 |
Anti-C10ORF54 antibodies and uses thereof
|
TW201702218A
(en)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease
|
SG10201903210WA
(en)
|
2014-12-15 |
2019-05-30 |
Univ Johns Hopkins |
Sunitinib Formulations and Methods for Use Thereof in Treatment of Ocular Disorders
|
CA2970795A1
(en)
|
2014-12-18 |
2016-06-23 |
Alnylam Pharmaceuticals, Inc. |
Reversir compounds
|
WO2016118476A1
(en)
|
2015-01-20 |
2016-07-28 |
The Children's Medical Center Corporation |
Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
|
MA41374A
(en)
|
2015-01-20 |
2017-11-28 |
Cytomx Therapeutics Inc |
MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF
|
US10485757B2
(en)
|
2015-01-27 |
2019-11-26 |
The Johns Hopkins University |
Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
|
WO2016123329A2
(en)
|
2015-01-28 |
2016-08-04 |
Genentech, Inc. |
Gene expression markers and treatment of multiple sclerosis
|
EP3250588A1
(en)
|
2015-01-29 |
2017-12-06 |
Board of Trustees of Michigan State University |
Cryptic polypeptides and uses thereof
|
WO2016134066A1
(en)
*
|
2015-02-17 |
2016-08-25 |
Mallinckrodt Llc |
Modified docetaxel liposome formulations and uses thereof
|
US10550173B2
(en)
|
2015-02-19 |
2020-02-04 |
Compugen, Ltd. |
PVRIG polypeptides and methods of treatment
|
HUE049791T2
(en)
|
2015-02-19 |
2020-10-28 |
Compugen Ltd |
Anti-pvrig antibodies and methods of use
|
MX2017010336A
(en)
|
2015-02-26 |
2017-12-20 |
Genentech Inc |
Integrin beta7 antagonists and methods of treating crohn's disease.
|
EP3265059A4
(en)
|
2015-03-03 |
2018-08-29 |
Cureport Inc. |
Combination liposomal pharmaceutical formulations
|
FI3265123T3
(en)
|
2015-03-03 |
2023-01-31 |
|
Antibodies, uses & methods
|
EP3265063A4
(en)
*
|
2015-03-03 |
2018-11-07 |
Cureport, Inc. |
Dual loaded liposomal pharmaceutical formulations
|
MX2017011644A
(en)
|
2015-03-13 |
2017-12-04 |
Cytomx Therapeutics Inc |
Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof.
|
EP3270898B1
(en)
|
2015-03-17 |
2021-05-05 |
Lipomedix Pharmaceuticals Ltd. |
Methods for the treatment of bladder cancer
|
MA41795A
(en)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
US9758575B2
(en)
|
2015-04-06 |
2017-09-12 |
Yung Shin Pharmaceutical Industrial Co. Ltd. |
Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
|
CA2981969C
(en)
|
2015-04-08 |
2023-12-05 |
Dana-Farber Cancer Institute, Inc. |
Humanized influenza monoclonal antibodies and methods of use thereof
|
BR112017019785B1
(en)
|
2015-04-13 |
2022-11-16 |
Pfizer Inc |
BISPECIFIC ANTIBODY, ITS USE AND PHARMACEUTICAL COMPOSITION
|
SG10201909308XA
(en)
|
2015-04-17 |
2019-11-28 |
Amgen Res Munich Gmbh |
Bispecific antibody constructs for cdh3 and cd3
|
EP3288977B1
(en)
|
2015-05-01 |
2021-11-17 |
Dana-Farber Cancer Institute, Inc. |
Methods of mediating cytokine expression with anti ccr4 antibodies
|
CA2984945A1
(en)
|
2015-05-04 |
2016-11-10 |
Cytomx Therapeutics, Inc. |
Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
|
BR112017023868A2
(en)
|
2015-05-04 |
2018-07-24 |
Cytomx Therapeutics Inc |
anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
|
DK3292150T3
(en)
|
2015-05-04 |
2020-04-27 |
Cytomx Therapeutics Inc |
ACTIVABLE ANTI-CD166 ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
EP3736287A1
(en)
|
2015-05-11 |
2020-11-11 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
US20180117076A1
(en)
|
2015-05-14 |
2018-05-03 |
Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic) |
MiRNA compositions for the treatment of mature B-cell neoplasms
|
US11318131B2
(en)
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
EP3763827A1
(en)
|
2015-05-29 |
2021-01-13 |
F. Hoffmann-La Roche AG |
Pd-l1 promoter methylation in cancer
|
EP3851531A1
(en)
|
2015-06-01 |
2021-07-21 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon exclusion in type vii collagen
|
CA2989115C
(en)
|
2015-06-10 |
2024-01-02 |
Elysium Health, Inc. |
Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
|
MX2018000016A
(en)
|
2015-07-02 |
2019-01-31 |
Otsuka Pharma Co Ltd |
Lyophilized pharmaceutical compositions.
|
AU2016291846B2
(en)
|
2015-07-13 |
2022-05-26 |
Compugen Ltd. |
HIDE1 Compositions and Methods
|
WO2017011580A2
(en)
|
2015-07-13 |
2017-01-19 |
Cytomx Therapeutics, Inc. |
Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
|
US11053495B2
(en)
|
2015-07-17 |
2021-07-06 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
BR112018001202A2
(en)
|
2015-07-21 |
2018-09-25 |
Dyax Corp |
monoclonal antibody, nucleic acid, vector, host cell, pharmaceutical composition and method
|
CN107849126B
(en)
|
2015-07-29 |
2022-04-08 |
阿勒根公司 |
Heavy chain-only anti-ANG-2 antibodies
|
TWI829617B
(en)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for flt3 and cd3
|
TWI717375B
(en)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for cd70 and cd3
|
TWI744242B
(en)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for egfrviii and cd3
|
TW202346349A
(en)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for dll3 and cd3
|
TWI796283B
(en)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for msln and cd3
|
JP2018523673A
(en)
|
2015-08-14 |
2018-08-23 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
Heavy chain only antibody against PDGF
|
MX2018001659A
(en)
|
2015-08-20 |
2018-05-28 |
Ipsen Biopharm Ltd |
Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment.
|
CN108495629A
(en)
|
2015-08-21 |
2018-09-04 |
益普生生物制药有限公司 |
Use the method comprising liposome Irinotecan and the combination therapy to treat metastatic cancer of pancreas of oxaliplatin
|
HUE063528T2
(en)
|
2015-09-01 |
2024-01-28 |
Boehringer Ingelheim Int |
Use of anti-cd40 antibodies for treatment of lupus nephritis
|
TW201718857A
(en)
|
2015-09-14 |
2017-06-01 |
艾爾妮蘭製藥公司 |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
TWI799366B
(en)
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
Cystine knot scaffold platform
|
PT3350220T
(en)
|
2015-09-15 |
2021-08-06 |
Scholar Rock Inc |
Anti-pro/latent-myostatin antibodies and uses thereof
|
EP3353204B1
(en)
|
2015-09-23 |
2023-10-18 |
Mereo BioPharma 5, Inc. |
Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
|
WO2017058881A1
(en)
|
2015-09-28 |
2017-04-06 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
WO2017055966A1
(en)
|
2015-10-01 |
2017-04-06 |
Pfizer Inc. |
Low viscosity antibody compositions
|
IL293708A
(en)
|
2015-10-06 |
2022-08-01 |
Genentech Inc |
Method for treating multiple sclerosis
|
WO2017062835A2
(en)
|
2015-10-09 |
2017-04-13 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
GB201518172D0
(en)
|
2015-10-14 |
2015-11-25 |
Cantab Biopharmaceuticals Patents Ltd |
Colloidal particles for use in medicine
|
GB201518171D0
(en)
|
2015-10-14 |
2015-11-25 |
Cantab Biopharmaceuticals Patents Ltd |
Colloidal particles for topical administration with therapeutic agent
|
GB201518170D0
(en)
|
2015-10-14 |
2015-11-25 |
Cantab Biopharmaceuticals Patents Ltd |
Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
|
US10456360B2
(en)
|
2015-10-16 |
2019-10-29 |
Ipsen Biopharm Ltd. |
Stabilizing camptothecin pharmaceutical compositions
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
WO2017075037A1
(en)
|
2015-10-27 |
2017-05-04 |
Scholar Rock, Inc. |
Primed growth factors and uses thereof
|
IL295097A
(en)
|
2015-10-30 |
2022-09-01 |
Genentech Inc |
Anti-htra1 antibodies and methods of use thereof
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
AU2016349954B2
(en)
|
2015-11-05 |
2022-08-25 |
Antisense Therapeutics Ltd |
Mobilizing leukemia cells
|
EP3370712A4
(en)
|
2015-11-06 |
2019-10-09 |
The Johns Hopkins University |
Methods of treating liver fibrosis by administering 3-bromopyruvate
|
PL3373910T3
(en)
|
2015-11-10 |
2023-10-09 |
Children's Research Institute, Children's National Medical Center |
Echinomycin formulation, method of making and method of use thereof
|
JP2018533596A
(en)
|
2015-11-12 |
2018-11-15 |
グレイバグ ビジョン インコーポレイテッド |
Aggregated microparticles for medical therapy
|
CN116217729A
(en)
|
2015-11-12 |
2023-06-06 |
思进公司 |
Glycan interaction compounds and methods of use
|
CA2949033A1
(en)
|
2015-11-30 |
2017-05-30 |
Pfizer Inc. |
Antibodies and antibody fragments for site-specific conjugation
|
TWI726942B
(en)
|
2015-11-30 |
2021-05-11 |
美商輝瑞股份有限公司 |
Site specific her2 antibody drug conjugates
|
KR20180100122A
(en)
|
2015-12-02 |
2018-09-07 |
주식회사 에스티사이언스 |
Antibodies specific for glycated BTLA (B- and T-lymphocyte weakening factor)
|
ES2861449T3
(en)
|
2015-12-02 |
2021-10-06 |
Stcube & Co Inc |
Antibodies and Molecules that Immunospecifically Bind to BTN1A1 and Their Therapeutic Uses
|
WO2017100562A1
(en)
|
2015-12-09 |
2017-06-15 |
Alexion Pharmaceuticals, Inc, |
Modified mrna encoding a uridine diphopsphate glucuronosyl transferase and uses thereof
|
US10548844B2
(en)
|
2015-12-14 |
2020-02-04 |
Massachusetts Institute Of Technology |
pH-responsive mucoadhesive polymeric encapsulated microorganisms
|
WO2017106630A1
(en)
|
2015-12-18 |
2017-06-22 |
The General Hospital Corporation |
Polyacetal polymers, conjugates, particles and uses thereof
|
EP3395370B1
(en)
|
2015-12-21 |
2021-01-20 |
FUJIFILM Corporation |
Liposome and liposome composition
|
WO2017117218A1
(en)
|
2015-12-30 |
2017-07-06 |
Momenta Pharmaceuticals, Inc. |
Methods related to biologics
|
SG11201805709RA
(en)
|
2016-01-08 |
2018-07-30 |
Scholar Rock Inc |
Anti-pro/latent myostatin antibodies and methods of use thereof
|
WO2017127750A1
(en)
|
2016-01-22 |
2017-07-27 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
TWI797073B
(en)
|
2016-01-25 |
2023-04-01 |
德商安美基研究(慕尼黑)公司 |
Pharmaceutical composition comprising bispecific antibody constructs
|
BR112018015715A2
(en)
|
2016-02-03 |
2019-02-05 |
Amgen Inc |
bispecific bcma and cd3 t cell coupling antibody constructs
|
EA039859B1
(en)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Bispecific antibody constructs binding egfrviii and cd3
|
EP3411404B1
(en)
|
2016-02-03 |
2022-11-09 |
Amgen Research (Munich) GmbH |
Psma and cd3 bispecific t cell engaging antibody constructs
|
JP2019509721A
(en)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
Mutant smoothened and method of using the same
|
CN109071669A
(en)
|
2016-03-07 |
2018-12-21 |
查尔斯顿制药有限责任公司 |
Anti- paranuclein antibody
|
EP3426306A1
(en)
*
|
2016-03-07 |
2019-01-16 |
Memorial Sloan Kettering Cancer Center |
Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
|
ES2951648T3
(en)
|
2016-03-11 |
2023-10-24 |
Scholar Rock Inc |
Tgfbeta1-binding immunoglobulins and their use
|
CN109476756B
(en)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
Multi-specificity Fab fusion protein and application thereof
|
AU2017254106A1
(en)
|
2016-04-18 |
2018-11-01 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
WO2017181379A1
(en)
|
2016-04-21 |
2017-10-26 |
Versitech Limited |
Compositions and methods for lightening skin and reducing hyperpigmentation
|
ES2963807T3
(en)
|
2016-06-08 |
2024-04-02 |
Xencor Inc |
Treatment of IgG4-related diseases with anti-CD19 antibodies cross-linking to CD32B
|
ITUA20164630A1
(en)
|
2016-06-23 |
2017-12-23 |
Paolo Blasi |
PHARMACOLOGICAL ADIUVANTS FOR TUMOR THERMAL WELDING
|
ES2887573T3
(en)
|
2016-06-27 |
2021-12-23 |
Alexion Pharma Inc |
Methods for treating hypophosphatasia in children and adolescents
|
WO2018005657A1
(en)
|
2016-06-28 |
2018-01-04 |
Verily Life Sciences Llc |
Serial filtration to generate small cholesterol-containing liposomes
|
IL296127A
(en)
|
2016-07-22 |
2022-11-01 |
Dana Farber Cancer Inst Inc |
Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
|
KR20190035752A
(en)
|
2016-08-03 |
2019-04-03 |
사이머베이 쎄라퓨틱스, 인코퍼레이티드 |
An oxymethylene aryl compound for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
|
TWI754659B
(en)
|
2016-08-08 |
2022-02-11 |
台灣微脂體股份有限公司 |
Delivery vehicle, method and kit for preparing a liposomal composition containing mild acidic agent
|
AU2017321973A1
(en)
|
2016-09-02 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
EP3509633A1
(en)
|
2016-09-06 |
2019-07-17 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating or preventing zika virus infection
|
EP3509616A1
(en)
|
2016-09-09 |
2019-07-17 |
H. Hoffnabb-La Roche Ag |
Selective peptide inhibitors of frizzled
|
TW201825674A
(en)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
Oncolytic virus expressing bispecific engager molecules
|
EP3512564B1
(en)
|
2016-09-14 |
2024-01-17 |
The Trustees of The University of Pennsylvania |
Proximity-based sortase-mediated protein purification and ligation
|
RU2752832C2
(en)
|
2016-09-16 |
2021-08-09 |
Шанхай Хенлиус Байотек, Инк. |
Anti-pd-1 antibodies
|
JP6937368B2
(en)
|
2016-09-23 |
2021-09-22 |
テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー |
How to treat intractable migraine
|
AU2017331592A1
(en)
|
2016-09-23 |
2019-04-11 |
Teva Pharmaceuticals International Gmbh |
Treating cluster headache
|
EP3532070A1
(en)
|
2016-10-26 |
2019-09-04 |
Modernatx, Inc. |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
CA3040395A1
(en)
|
2016-11-02 |
2018-05-11 |
Ipsen Biopharm Ltd. |
Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
AU2017353936A1
(en)
|
2016-11-04 |
2019-05-02 |
Novimmune Sa |
Anti-CD19 antibodies and methods of use thereof
|
JP2020500020A
(en)
|
2016-11-14 |
2020-01-09 |
ノバルティス アーゲー |
Compositions, methods, and therapeutic uses related to the fusogenic protein MINION
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
Glycan-interacting compounds and methods of use
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
DK3555064T5
(en)
|
2016-12-16 |
2023-05-01 |
Pfizer |
GLP-1 receptor agonists and uses thereof
|
US10772926B2
(en)
|
2016-12-16 |
2020-09-15 |
Nutragen Health Innovations, Inc. |
Natural drugs for the treatment of inflammation and melanoma
|
WO2018129395A1
(en)
|
2017-01-06 |
2018-07-12 |
Scholar Rock, Inc. |
Methods for treating metabolic diseases by inhibiting myostatin activation
|
US20180207267A1
(en)
|
2017-01-06 |
2018-07-26 |
Scholar Rock, Inc. |
Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
|
US11155611B2
(en)
|
2017-01-06 |
2021-10-26 |
Scholar Rock, Inc. |
Compositions and methods for making and using anti-myostatin antibodies
|
CN117224710A
(en)
|
2017-02-01 |
2023-12-15 |
莫得纳特斯公司 |
Immunomodulatory therapeutic MRNA compositions encoding mutant peptides that activate oncogenes
|
JOP20190189A1
(en)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
Low ph pharmaceutical composition comprising t cell engaging antibody constructs
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
EP3589319A4
(en)
|
2017-03-03 |
2021-07-14 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
EP3589657A1
(en)
|
2017-03-03 |
2020-01-08 |
Rinat Neuroscience Corp. |
Anti-gitr antibodies and methods of use thereof
|
US20180303952A1
(en)
|
2017-03-09 |
2018-10-25 |
Cytomx Therapeutics, Inc. |
Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
|
US20180273627A1
(en)
|
2017-03-27 |
2018-09-27 |
Boehringer Ingelheim International Gmbh |
Anti il-36r antibodies combination therapy
|
US11359200B2
(en)
|
2017-04-09 |
2022-06-14 |
The Cleveland Clinic Foundation |
Cancer treatment by MALAT1 inhibition
|
CA3059542A1
(en)
|
2017-04-12 |
2018-10-18 |
Pfizer Inc. |
Antibodies having conditional affinity and methods of use thereof
|
EP3610010A4
(en)
|
2017-04-14 |
2021-02-24 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
AU2018255244A1
(en)
|
2017-04-21 |
2019-10-31 |
Mellitus, Llc |
Methods and antibodies for diabetes-related applications
|
EP3615569A1
(en)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
US11318190B2
(en)
|
2017-05-05 |
2022-05-03 |
United States Government As Represented By The Department Of Veterans Affairs |
Methods and compositions for treating liver disease
|
AU2018261951A1
(en)
|
2017-05-05 |
2019-10-31 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
JP2020519585A
(en)
|
2017-05-10 |
2020-07-02 |
グレイバグ ビジョン インコーポレイテッド |
Extended release microparticles and suspensions thereof for medical therapy
|
WO2018209288A1
(en)
|
2017-05-12 |
2018-11-15 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded rna complexes and uses related thereto
|
CN110662760A
(en)
|
2017-05-12 |
2020-01-07 |
奥古斯塔大学研究所公司 |
Human alpha-fetoprotein specific T cell receptor and uses thereof
|
AU2018272311A1
(en)
|
2017-05-26 |
2019-12-19 |
Novimmune Sa |
Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
|
WO2018222685A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
US20200148768A1
(en)
|
2017-05-31 |
2020-05-14 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
AU2018278327B2
(en)
|
2017-06-01 |
2023-03-16 |
Cytomx Therapeutics, Inc. |
Activatable anti-pdl1 antibodies and methods of use thereof
|
KR20200026209A
(en)
|
2017-06-06 |
2020-03-10 |
주식회사 에스티큐브앤컴퍼니 |
How to treat cancer using antibodies and molecules that bind BTN1A1 or BTN1A1-ligand
|
GB201710838D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
Bispecific antibodies
|
BR112019023650A2
(en)
|
2017-07-06 |
2020-06-02 |
Arrowhead Pharmaceuticals, Inc. |
RNAI AGENTS TO INHIBIT ALFA-ENAC EXPRESSION AND METHODS OF USE
|
CN110997002A
(en)
|
2017-07-13 |
2020-04-10 |
麻省理工学院 |
Targeting HDAC2-SP3 complexes to enhance synaptic function
|
US11220544B2
(en)
|
2017-07-14 |
2022-01-11 |
Cytomx Therapeutics, Inc. |
Anti-CD166 antibodies and uses thereof
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
EP3655779A1
(en)
|
2017-07-20 |
2020-05-27 |
CytomX Therapeutics, Inc. |
Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof
|
WO2019016784A1
(en)
|
2017-07-21 |
2019-01-24 |
Universidade De Coimbra |
Anti-nucleolin antibody
|
WO2019018765A1
(en)
|
2017-07-21 |
2019-01-24 |
Modernatx, Inc. |
Modified mrna encoding a propionyl-coa carboxylase and uses thereof
|
EP3658672A1
(en)
|
2017-07-24 |
2020-06-03 |
Modernatx, Inc. |
Modified mrna encoding a glucose-6-phosphatase and uses thereof
|
CN116271012A
(en)
|
2017-07-27 |
2023-06-23 |
瑞颂医药公司 |
High concentration anti-C5 antibody formulations
|
MA49690A
(en)
|
2017-07-28 |
2021-05-19 |
Scholar Rock Inc |
SPECIFIC INHIBITORS OF THE TGF-BETA 1 LTBP COMPLEX AND THEIR USES
|
KR20200035438A
(en)
|
2017-08-03 |
2020-04-03 |
오쓰까 세이야꾸 가부시키가이샤 |
Drug compound and purification method thereof
|
US11135187B2
(en)
|
2017-08-22 |
2021-10-05 |
National Institutes Of Health (Nih) |
Compositions and methods for treating diabetic retinopathy
|
KR20200058406A
(en)
|
2017-08-30 |
2020-05-27 |
싸이톰스 테라퓨틱스, 인크. |
Activatable anti-CD166 antibodies and methods of use
|
CN111133005A
(en)
|
2017-09-07 |
2020-05-08 |
奥古斯塔大学研究所公司 |
Programmed cell death protein 1 antibodies
|
US11364303B2
(en)
|
2017-09-29 |
2022-06-21 |
Pfizer Inc. |
Cysteine engineered antibody drug conjugates
|
AU2018347521A1
(en)
|
2017-10-12 |
2020-05-07 |
Immunowake Inc. |
VEGFR-antibody light chain fusion protein
|
AU2018347607A1
(en)
|
2017-10-14 |
2020-03-26 |
Cytomx Therapeutics, Inc. |
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
|
BR112020007586A2
(en)
|
2017-10-17 |
2020-09-24 |
Rhizen Pharmaceuticals Sa |
crac channel modulators to treat esophageal cancer
|
JP7394753B2
(en)
|
2017-10-18 |
2023-12-08 |
サレプタ セラピューティクス, インコーポレイテッド |
antisense oligomer compounds
|
WO2019082124A1
(en)
|
2017-10-26 |
2019-05-02 |
Rhizen Pharmaceuticals Sa |
Composition and method for treating diffuse large b-cell lymphoma
|
CA3205442A1
(en)
|
2017-10-27 |
2019-05-02 |
Pfizer, Inc. |
Antibodies and antibody-drug conjugates specific for cd123 and uses thereof
|
SG11202003437PA
(en)
|
2017-10-30 |
2020-05-28 |
Rhizen Pharmaceuticals Sa |
Calcium release-activated calcium channel modulators for treating hematological and solid cancers
|
WO2019086626A1
(en)
|
2017-11-03 |
2019-05-09 |
Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) |
MIRNAs AND COMBINATIONS THEREOF FOR USE IN THE TREATMENT OF HUMAN B CELL NEOPLASIAS
|
US20200289520A1
(en)
|
2017-12-06 |
2020-09-17 |
Rhizen Pharmaceuticals Sa |
Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma
|
US11946094B2
(en)
|
2017-12-10 |
2024-04-02 |
Augusta University Research Institute, Inc. |
Combination therapies and methods of use thereof
|
US20210163592A1
(en)
|
2017-12-11 |
2021-06-03 |
Amgen Inc |
Continuous manufacturing process for bispecific antibody products
|
UY38041A
(en)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3
|
WO2019165101A1
(en)
|
2018-02-22 |
2019-08-29 |
Verily Life Sciences Llc |
Combining orthogonal chemistries for preparation of multiplexed nanoparticles
|
WO2019166946A1
(en)
|
2018-02-28 |
2019-09-06 |
Pfizer Inc. |
Il-15 variants and uses thereof
|
WO2019173771A1
(en)
|
2018-03-09 |
2019-09-12 |
Cytomx Therapeutics, Inc. |
Activatable cd147 antibodies and methods of making and use thereof
|
CN112166123B
(en)
|
2018-03-14 |
2022-09-30 |
北京轩义医药科技有限公司 |
Anti-claudin 18.2 antibodies
|
AU2019235523A1
(en)
|
2018-03-14 |
2020-10-29 |
Novimmune Sa |
Anti-CD3 epsilon antibodies and methods of use thereof
|
EP3768306A1
(en)
|
2018-03-21 |
2021-01-27 |
Colorado State University Research Foundation |
Cancer vaccine compositions and methods of use thereof
|
US10722528B2
(en)
|
2018-03-28 |
2020-07-28 |
Augusta University Research Institute, Inc. |
Compositions and methods for inhibiting metastasis
|
CN112334485A
(en)
|
2018-04-06 |
2021-02-05 |
百进生物科技公司 |
Anti-tetraspanin 33agents and compositions thereof and methods of making and using
|
EP3772928A4
(en)
|
2018-04-06 |
2021-12-29 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
EP3774925A1
(en)
|
2018-04-13 |
2021-02-17 |
Institut national de la santé et de la recherche médicale (INSERM) |
Fc-engineered anti-human ige antibodies and methods of use
|
EP3788071A1
(en)
|
2018-05-02 |
2021-03-10 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
TWI816396B
(en)
|
2018-05-23 |
2023-09-21 |
美商輝瑞大藥廠 |
Antibodies specific for gucy2c and uses thereof
|
MX2020012539A
(en)
|
2018-05-23 |
2021-02-16 |
Pfizer |
Antibodies specific for cd3 and uses thereof.
|
WO2019234680A1
(en)
|
2018-06-08 |
2019-12-12 |
Pfizer Inc. |
Methods of treating iron metabolic disease with a neutralizing antibody binding erhythroferrone
|
US10934279B2
(en)
|
2018-06-13 |
2021-03-02 |
Pfizer Inc. |
GLP-1 receptor agonists and uses thereof
|
WO2019239371A1
(en)
|
2018-06-15 |
2019-12-19 |
Pfizer Inc. |
Glp-1 receptor agonists and uses thereof
|
WO2019245817A1
(en)
|
2018-06-19 |
2019-12-26 |
Armo Biosciences, Inc. |
Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
|
BR112020025824A2
(en)
|
2018-06-28 |
2021-03-23 |
Crispr Therapeutics Ag |
compositions and methods for genome editing by inserting donor polynucleotides
|
WO2020006347A1
(en)
|
2018-06-29 |
2020-01-02 |
Boehringer Ingelheim International Gmbh |
Anti-cd40 antibodies for use in treating autoimmune disease
|
CA3105161C
(en)
|
2018-07-06 |
2022-11-15 |
Pfizer Inc. |
Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof
|
US20210122814A1
(en)
|
2018-07-11 |
2021-04-29 |
Scholar Rock, Inc. |
HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
|
TW202019957A
(en)
|
2018-07-11 |
2020-06-01 |
美商供石公司 |
Tgfβ1 inhibitors and use thereof
|
SI3677278T1
(en)
|
2018-07-11 |
2022-01-31 |
Scholar Rock, Inc. |
Isoform selective tgfbeta1 inhibitors and use thereof
|
EP3824287A1
(en)
|
2018-07-20 |
2021-05-26 |
Pierre Fabre Médicament |
Receptor for vista
|
US20210348162A1
(en)
|
2018-08-16 |
2021-11-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
EP3849515A1
(en)
*
|
2018-09-11 |
2021-07-21 |
Memorial Sloan Kettering Cancer Center |
Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use
|
EP3856343A1
(en)
|
2018-09-25 |
2021-08-04 |
Biolegend, Inc. |
Anti-tlr9 agents and compositions and methods for making and using the same
|
SG11202103025PA
(en)
|
2018-09-27 |
2021-04-29 |
Phosphogam Inc |
Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
|
AU2019349874A1
(en)
|
2018-09-28 |
2021-04-29 |
Lyvgen Biopharma Holdings Limited |
Anti-CD40 binding molecules having engineered Fc domains and therapeutic uses thereof
|
EP3864127A1
(en)
|
2018-10-10 |
2021-08-18 |
Boehringer Ingelheim International GmbH |
Method for membrane gas transfer in high density bioreactor culture
|
AU2019356564A1
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
WO2020079652A1
(en)
|
2018-10-17 |
2020-04-23 |
Insilico Medicine Hong Kong Limited |
Kinase inhibitors
|
EP3870286A1
(en)
|
2018-10-23 |
2021-09-01 |
Scholar Rock, Inc. |
Rgmc-selective inhibitors and use thereof
|
US20210379545A1
(en)
*
|
2018-10-26 |
2021-12-09 |
University Of Connecticut |
A Continuous Processing System And Methods For Internal And External Modifications To Nanoparticles
|
CA3118445A1
(en)
|
2018-11-02 |
2020-05-07 |
Cytomx Therapeutics, Inc. |
Activatable anti-cd166 antibodies and methods of use thereof
|
WO2020103815A1
(en)
|
2018-11-22 |
2020-05-28 |
Qilu Regor Therapeutics Inc. |
Glp-1r agonists and uses thereof
|
JP2022513159A
(en)
|
2018-11-29 |
2022-02-07 |
フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド |
How to regulate RNA
|
CN113271956A
(en)
|
2018-12-06 |
2021-08-17 |
西托姆克斯治疗公司 |
Matrix metalloprotease cleavable and serine or cysteine protease cleavable substrates and methods of use thereof
|
BR112021012172A2
(en)
|
2018-12-12 |
2021-08-31 |
Kite Pharma, Inc. |
CHIMERIC AND T-CELL ANTIGEN RECEPTORS AND METHODS OF USE
|
MX2021008800A
(en)
|
2019-01-22 |
2021-11-12 |
Massachusetts Inst Technology |
In vitro human blood brain barrier.
|
JP2020117502A
(en)
|
2019-01-28 |
2020-08-06 |
ファイザー・インク |
Method of treating signs and symptoms of osteoarthritis
|
EA202192130A1
(en)
|
2019-01-30 |
2021-12-28 |
Сколар Рок, Инк. |
LTBP-SPECIFIC TGF INHIBITORS AND THEIR APPLICATIONS
|
US20220144846A1
(en)
|
2019-02-15 |
2022-05-12 |
Pfizer Inc. |
Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
|
JP2020143045A
(en)
|
2019-02-18 |
2020-09-10 |
ファイザー・インク |
Method of treatment of chronic low back pain
|
CN113874394B
(en)
|
2019-02-20 |
2024-01-19 |
和铂抗体有限公司 |
Antibodies to
|
US11739078B2
(en)
|
2019-02-22 |
2023-08-29 |
Insilico Medicine Ip Limited |
Methods of inhibiting kinases
|
WO2020176672A1
(en)
|
2019-02-26 |
2020-09-03 |
Cytomx Therapeutics, Inc. |
Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
|
US20200283796A1
(en)
|
2019-03-05 |
2020-09-10 |
Massachusetts Institute Of Technology |
Dna launched rna replicon system (drep) and uses thereof
|
WO2020185293A1
(en)
|
2019-03-08 |
2020-09-17 |
Massachusetts Institute Of Technology |
Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
|
AU2020248645A1
(en)
|
2019-03-27 |
2021-10-28 |
Tigatx, Inc. |
Engineered IgA antibodies and methods of use
|
TW202102266A
(en)
|
2019-04-01 |
2021-01-16 |
美商建南德克公司 |
Compositions and methods for stabilizing protein-containing formulations
|
JP7284830B2
(en)
|
2019-04-02 |
2023-05-31 |
アレイ バイオファーマ インコーポレイテッド |
protein tyrosine phosphatase inhibitor
|
TW202115086A
(en)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk inhibitors
|
CA3144848C
(en)
|
2019-06-28 |
2023-11-21 |
Pfizer Inc. |
5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases
|
LT6699B
(en)
|
2019-07-15 |
2020-02-10 |
UAB "Valentis" |
Method for production of proliposomes by using up to 5% ethanol and the use thereof for encapsulation of lipophilic substances
|
CN112300279A
(en)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
Methods and compositions directed to anti-CD 73 antibodies and variants
|
US10758329B1
(en)
|
2019-08-20 |
2020-09-01 |
Raymond L. Wright, III |
Hydrating mouth guard
|
US20220290152A1
(en)
|
2019-09-03 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
CN114650844A
(en)
|
2019-09-23 |
2022-06-21 |
西托姆克斯治疗公司 |
anti-CD 47 antibodies, activatable anti-CD 47 antibodies, and methods of use thereof
|
WO2021062096A1
(en)
|
2019-09-26 |
2021-04-01 |
Massachusetts Institute Of Technology |
Microrna-based logic gates and uses thereof
|
EP4041767A1
(en)
|
2019-09-26 |
2022-08-17 |
StCube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
WO2021062092A1
(en)
|
2019-09-26 |
2021-04-01 |
Massachusetts Institute Of Technology |
Trans-activated functional rna by strand displacement and uses thereof
|
WO2021067526A1
(en)
|
2019-10-02 |
2021-04-08 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
TWI771766B
(en)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
Diacylglycerol acyltransferase 2 inhibitor
|
WO2021067747A1
(en)
|
2019-10-04 |
2021-04-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
US20240050529A1
(en)
|
2019-10-07 |
2024-02-15 |
University Of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
JP2022552282A
(en)
|
2019-10-09 |
2022-12-15 |
エスティーキューブ アンド カンパニー |
Antibodies specific for glycosylated LAG3 and methods of use thereof
|
EP4041312A4
(en)
|
2019-10-10 |
2023-12-20 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
WO2021072244A1
(en)
|
2019-10-11 |
2021-04-15 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn antibodies and uses thereof
|
CA3155215A1
(en)
|
2019-10-21 |
2021-04-29 |
Srikant Viswanadha |
Compositions comprising a dhodh inhibitor for the treatment of acute myeloid leukemia
|
US20230040920A1
(en)
|
2019-11-01 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
CN115175893A
(en)
|
2019-12-10 |
2022-10-11 |
辉瑞公司 |
Solid forms of 2- ((4- ((S) -2- (5-chloropyridin-2-yl) -2-methylbenzo [ d ] [1,3] dioxol-4-yl) piperidin-1-yl) methyl) -1- (((S) -oxetan-2-yl) methyl) -1H-benzo [ d ] imidazole-6-carboxylic acid, 1, 3-dihydroxy-2- (hydroxymethyl) propan-2-amine salt
|
US20230050148A1
(en)
|
2020-01-11 |
2023-02-16 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
BR112022013733A2
(en)
|
2020-01-11 |
2022-11-01 |
Scholar Rock Inc |
TGFBETA INHIBITORS AND THEIR USE
|
JP2023511274A
(en)
|
2020-01-14 |
2023-03-17 |
シンセカイン インコーポレイテッド |
IL2 orthologs and usage
|
CN115427447A
(en)
|
2020-01-17 |
2022-12-02 |
百进生物科技公司 |
anti-TLR 7 agents and compositions and methods of making and using the same
|
EP4093426A1
(en)
|
2020-01-24 |
2022-11-30 |
University of Virginia Patent Foundation |
Modulating lymphatic vessels in neurological disease
|
IL295445A
(en)
|
2020-02-10 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for silencing vegf-a expression
|
JP2022058085A
(en)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
Combination of inhibitors of diacylglycerol acyltransferase 2 and inhibitors of acetyl-coa carboxylase
|
WO2021178877A1
(en)
|
2020-03-06 |
2021-09-10 |
The Colorado State University Research Foundation |
Production of vaccines comprising inactivated sars-cov-2 viral particles
|
WO2021181233A2
(en)
|
2020-03-09 |
2021-09-16 |
Pfizer Inc. |
Fusion proteins and uses thereof
|
GB202003632D0
(en)
|
2020-03-12 |
2020-04-29 |
Harbour Antibodies Bv |
SARS-Cov-2 (SARS2, COVID-19) antibodies
|
WO2021188096A1
(en)
|
2020-03-17 |
2021-09-23 |
Dst Pharma, Inc. |
Methods and compositions for treating viral infections
|
AU2021244695A1
(en)
|
2020-03-26 |
2022-11-10 |
Plx Opco Inc. |
Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same
|
JP2021155415A
(en)
|
2020-03-27 |
2021-10-07 |
ファイザー・インク |
Treatment of type 2 diabetes or obesity or overweight using 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or pharmaceutical salt thereof
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
CA3179411A1
(en)
|
2020-04-06 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
MX2022012561A
(en)
|
2020-04-07 |
2022-11-07 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for silencing scn9a expression.
|
AU2021252213A1
(en)
|
2020-04-08 |
2022-11-03 |
Pfizer Inc. |
Crystalline forms of 3-cyano-1-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo(1,5-a)pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutaneacetonitrile, and use thereof
|
KR20230005268A
(en)
|
2020-04-24 |
2023-01-09 |
밀레니엄 파머슈티컬스 인코퍼레이티드 |
Anti-CD19 Antibodies and Uses Thereof
|
WO2021224850A1
(en)
|
2020-05-06 |
2021-11-11 |
Crispr Therapeutics Ag |
Mask peptides and masked anti-ptk7 antibodies comprising such
|
WO2021229502A1
(en)
|
2020-05-15 |
2021-11-18 |
Crispr Therapeutics Ag |
Messenger rna encoding cas9 for use in genome-editing systems
|
EP4153746A1
(en)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
CA3179890A1
(en)
|
2020-05-27 |
2021-12-02 |
Qilu Regor Therapeutics Inc. |
Salt and crystal forms of glp-1r agonists and uses thereof
|
EP4161927A1
(en)
|
2020-06-09 |
2023-04-12 |
Pfizer Inc. |
Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
|
MX2022016590A
(en)
|
2020-06-26 |
2023-02-01 |
Pfizer |
Methods of treating inflammatory bowel disease with tl1a antibodies.
|
WO2022006562A1
(en)
|
2020-07-03 |
2022-01-06 |
Dana-Farber Cancer Institute, Inc. |
Multispecific coronavirus antibodies
|
CA3189590A1
(en)
|
2020-07-17 |
2022-01-20 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
EP4185274A1
(en)
|
2020-07-24 |
2023-05-31 |
Strand Therapeutics Inc. |
Lipidnanoparticle comprising modified nucleotides
|
CA3187393A1
(en)
|
2020-07-28 |
2022-02-03 |
Andrew BELFIELD |
Chiral synthesis of fused bicyclic raf inhibitors
|
US11858930B2
(en)
|
2020-07-28 |
2024-01-02 |
Jazz Pharmaceuticals Ireland Limited |
Fused bicyclic RAF inhibitors and methods for use thereof
|
MX2023001491A
(en)
|
2020-08-05 |
2023-03-08 |
Synthekine Inc |
Gp130 binding molecules and methods of use.
|
CA3190415A1
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il2rb/il2rg synthetic cytokines
|
JP2023536654A
(en)
|
2020-08-05 |
2023-08-28 |
シンセカイン インコーポレイテッド |
IL10Ra binding molecules and methods of use
|
EP4192489A2
(en)
|
2020-08-05 |
2023-06-14 |
Synthekine, Inc. |
Il2rb binding molecules and methods of use
|
AR123156A1
(en)
|
2020-08-06 |
2022-11-02 |
Qilu Regor Therapeutics Inc |
GLP-1R AGONISTS AND THEIR USES
|
CN116113689A
(en)
|
2020-08-14 |
2023-05-12 |
凯德药业股份有限公司 |
Improving immune cell function
|
JP2023541455A
(en)
|
2020-09-14 |
2023-10-02 |
ブイオーアール バイオファーマ インコーポレーテッド |
Single domain antibody against CD33
|
EP4213939A1
(en)
|
2020-09-21 |
2023-07-26 |
Boehringer Ingelheim International GmbH |
Use of anti-cd40 antibodies for treatment of inflammatory conditions
|
CA3194386A1
(en)
|
2020-10-06 |
2022-04-14 |
Ying Ding |
Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
|
US20230382899A1
(en)
|
2020-10-14 |
2023-11-30 |
Qilu Regor Therapeutics Inc. |
Crystal forms of glp-1r agonists and uses thereof
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
US11058637B1
(en)
*
|
2020-11-25 |
2021-07-13 |
King Abdulaziz University |
Surface-modified emulsomes for intranasal delivery of drugs
|
CA3200234A1
(en)
|
2020-11-25 |
2022-06-02 |
Daryl C. Drummond |
Lipid nanoparticles for delivery of nucleic acids, and related methods of use
|
AU2021400221A1
(en)
|
2020-12-18 |
2023-07-13 |
Momenta Pharmaceuticals, Inc. |
Antibodies against integrin alpha 11 beta 1
|
TW202241931A
(en)
|
2021-01-08 |
2022-11-01 |
美商斯特蘭德治療股份有限公司 |
Expression constructs and uses thereof
|
US11033495B1
(en)
|
2021-01-22 |
2021-06-15 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11278494B1
(en)
|
2021-01-22 |
2022-03-22 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11357727B1
(en)
|
2021-01-22 |
2022-06-14 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
EP4288457A2
(en)
|
2021-02-05 |
2023-12-13 |
Boehringer Ingelheim International GmbH |
Anti-il1rap antibodies
|
US11530197B2
(en)
|
2021-02-24 |
2022-12-20 |
Insilico Medicine Ip Limited |
Analogs for the treatment of disease
|
KR20230155521A
(en)
|
2021-03-11 |
2023-11-10 |
카이트 파마 인코포레이티드 |
Improved immune cell function
|
WO2022195504A1
(en)
|
2021-03-19 |
2022-09-22 |
Pfizer Inc. |
Method of treating osteoarthritis pain with an anti ngf antibody
|
WO2022200389A1
(en)
|
2021-03-22 |
2022-09-29 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
AU2022241935A1
(en)
|
2021-03-22 |
2023-09-28 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
US11952461B2
(en)
|
2021-03-22 |
2024-04-09 |
Sunbio, Inc. |
Siloxy polyethylene glycol and derivatives thereof
|
WO2022204581A2
(en)
|
2021-03-26 |
2022-09-29 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and use thereof
|
WO2022215054A1
(en)
|
2021-04-09 |
2022-10-13 |
Takeda Pharmaceutical Company Limited |
Antibodies targeting complement factor d and uses therof
|
EP4326873A1
(en)
|
2021-04-22 |
2024-02-28 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|
WO2022232035A1
(en)
|
2021-04-26 |
2022-11-03 |
Millennium Pharmaceuticals, Inc. |
Anti-adgre2 antibodies and uses thereof
|
EP4330284A2
(en)
|
2021-04-26 |
2024-03-06 |
Millennium Pharmaceuticals, Inc. |
Anti-clec12a antibodies and uses thereof
|
WO2022235940A1
(en)
|
2021-05-06 |
2022-11-10 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against alk and methods of use thereof
|
WO2022245859A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
US20230115257A1
(en)
|
2021-05-17 |
2023-04-13 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
WO2022256723A2
(en)
|
2021-06-03 |
2022-12-08 |
Scholar Rock, Inc. |
Tgf-beta inhibitors and therapeutic use thereof
|
IL309078A
(en)
|
2021-06-23 |
2024-02-01 |
Scholar Rock Inc |
A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
US20230048743A1
(en)
|
2021-07-12 |
2023-02-16 |
Genentech Inc. |
Structures for Reducing Antibody-Lipase Binding
|
WO2023288277A1
(en)
|
2021-07-14 |
2023-01-19 |
Scholar Rock, Inc. |
Ltbp complex-specific inhibitors of tgfb1 and uses thereof
|
WO2023007374A1
(en)
|
2021-07-27 |
2023-02-02 |
Pfizer Inc. |
Method of treatment of cancer pain with tanezumab
|
GB202111757D0
(en)
|
2021-08-17 |
2021-09-29 |
Cantab Biopharmaceuticals Patents Ltd |
Modified colloidal particles for use in the treatment of haemophilia A
|
GB202111759D0
(en)
|
2021-08-17 |
2021-09-29 |
Cantab Biopharmaceuticals Patents Ltd |
Modified colloidal particles
|
GB202111758D0
(en)
|
2021-08-17 |
2021-09-29 |
Cantab Biopharmaceuticals Patents Ltd |
Modified colloidal particles for use in the treatment of haemophilia A
|
AU2022336407A1
(en)
|
2021-08-31 |
2024-02-22 |
Pfizer Inc. |
Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
|
WO2023034901A1
(en)
|
2021-09-01 |
2023-03-09 |
The Broad Institute, Inc. |
Tumor avatar vaccine compositions and uses thereof
|
WO2023036982A1
(en)
|
2021-09-10 |
2023-03-16 |
Harbour Antibodies Bv |
Anti-sars2-s antibodies
|
GB202112935D0
(en)
|
2021-09-10 |
2021-10-27 |
Harbour Antibodies Bv |
Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
|
TW202330612A
(en)
|
2021-10-20 |
2023-08-01 |
日商武田藥品工業股份有限公司 |
Compositions targeting bcma and methods of use thereof
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
WO2023081471A1
(en)
|
2021-11-05 |
2023-05-11 |
Dana-Farber Cancer Institute, Inc. |
Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
|
WO2023097024A1
(en)
|
2021-11-24 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
WO2023100061A1
(en)
|
2021-12-01 |
2023-06-08 |
Pfizer Inc. |
3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
WO2023105371A1
(en)
|
2021-12-08 |
2023-06-15 |
Array Biopharma Inc. |
Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
WO2023111817A1
(en)
|
2021-12-17 |
2023-06-22 |
Pfizer Inc. |
Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
WO2023201238A1
(en)
|
2022-04-11 |
2023-10-19 |
Vor Biopharma Inc. |
Binding agents and methods of use thereof
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
WO2023212618A1
(en)
|
2022-04-26 |
2023-11-02 |
Strand Therapeutics Inc. |
Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023228023A1
(en)
|
2022-05-23 |
2023-11-30 |
Pfizer Inc. |
Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
|
WO2023235852A1
(en)
|
2022-06-03 |
2023-12-07 |
Zenas Biopharma, Inc. |
Methods and compositions for treating igg4- related diseases
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
WO2024030847A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030845A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030858A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
WO2024030850A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
WO2024030843A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024039672A2
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against msln and methods of use thereof
|
WO2024039670A1
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cldn4 and methods of use thereof
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024075051A1
(en)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|